Veradigm (MDRX) 10-K 2 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 24, 2015	Jun. 27, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	1124804
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		180,520,813
Entity Public Float			$2,858,836,224

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$53,173	$62,954
Accounts receivable, net of allowance of $36,047 and $54,252 as of December 31, 2014 and 2013, respectively	331,625	313,486
Deferred taxes, net	35,615	55,468
Prepaid expenses and other current assets	102,398	107,911
Total current assets	522,811	539,819
Long-term marketable securities	1,305	1,329
Fixed assets, net	145,830	174,013
Software development costs, net	86,153	88,244
Intangible assets, net	403,362	455,971
Goodwill	1,200,746	1,189,585
Deferred taxes, net	708	7,361
Other assets	147,249	163,341
Total assets	2,508,164	2,619,663
Current liabilities:
Accounts payable	70,824	72,956
Accrued expenses	78,967	96,499
Accrued compensation and benefits	51,062	80,196
Deferred revenue	293,022	251,038
Deferred taxes, net	21	0
Current maturities of long-term debt and capital lease obligations	27,504	16,350
Total current liabilities	521,400	517,039
Long-term debt	548,682	545,133
Deferred revenue	23,168	29,080
Deferred taxes, net	55,437	79,694
Other liabilities	75,257	130,572
Total liabilities	1,223,944	1,301,518
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of December 31, 2014 and 2013	0	0
Common stock: $0.01 par value, 350,000 shares authorized as of December 31, 2014 and 2013; 265,138 and 180,466 shares issued and outstanding as of December 31, 2014, respectively; 263,474 and 178,802 shares issued and outstanding as of December 31, 2013, respectively	2,651	2,635
Treasury stock: at cost, 84,672 as of December 31, 2014 and 2013	-278,036	-278,036
Additional paid-in capital	1,749,593	1,716,847
Accumulated deficit	-188,009	-121,556
Accumulated other comprehensive loss	-1,979	-1,745
Total stockholders' equity	1,284,220	1,318,145
Total liabilities and stockholders' equity	$2,508,164	$2,619,663

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$36,047	$54,252
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	265,138,000	263,474,000
Common stock, shares outstanding	180,466,000	178,802,000
Treasury stock at cost, shares	84,672,000	84,672,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue:
System sales	$92,241	$113,573	$145,274
Professional services	218,040	230,524	270,541
Maintenance	466,102	471,949	460,138
Transaction processing and other	601,490	557,015	570,372
Total revenue	1,377,873	1,373,061	1,446,325
Cost of revenue:
System sales (excluding amortization of software development and acquisition-related assets shown below)	35,095	54,252	62,884
Amortization of software development and acquisition-related assets	81,215	85,201	65,416
Professional services	191,915	215,136	234,869
Maintenance	146,712	143,957	145,352
Transaction processing and other	376,952	340,059	331,269
Total cost of revenue	831,889	838,605	839,790
Gross profit	545,984	534,456	606,535
Selling, general and administrative expenses	358,681	419,599	384,370
Research and development	192,821	199,751	162,158
Asset impairment charges	2,390	11,454	11,101
Amortization of intangible and acquisition-related assets	31,280	31,253	35,635
(Loss) income from operations	-39,188	-127,601	13,271
Interest expense	-29,297	-28,055	-16,187
Other income (expense), net	368	7,310	-14,544
Loss before income taxes	-68,117	-148,346	-17,460
Income tax benefit	1,664	44,320	16,307
Net loss	($66,453)	($104,026)	($1,153)
Loss per share - basic and diluted	($0.37)	($0.59)	($0.01)

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement Of Income And Comprehensive Income [Abstract]
Net loss	($66,453)	($104,026)	($1,153)
Other comprehensive income (loss), net of taxes:
Unrealized gain on marketable securities, net of tax	16	6	78
Derivatives qualifying as hedges:
Unrealized loss on interest rate swap	-38	-139	-1,563
Reclassification adjustment for loss included in net loss	496	1,215	1,783
Tax effect	-179	-421	-87
Unrealized gain on interest rate swap, net of tax	279	655	133
Change in foreign currency translation adjustments	-529	-2,482	407
Total other comprehensive (loss) income	-234	-1,821	618
Comprehensive loss	($66,687)	($105,847)	($535)

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]
In Thousands
Beginning Balance at Dec. 31, 2011		$2,547	($52,075)	$1,543,167	($16,377)	($542)
Beginning Balance, Shares at Dec. 31, 2011		254,691	-63,951
Stock-based compensation				39,985
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		2,396
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		24		-4,797
Purchases of treasury stock, Shares	-21,000		-20,721
Purchases of treasury stock	-225,961		-225,961
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation				-1,095
Net loss	-1,153				-1,153
Foreign currency translation adjustments, net	407					407
Unrecognized gain on interest rate swap, net of tax	133					133
Unrealized gain on marketable securities, net of tax	78					78
Ending Balance at Dec. 31, 2012	1,284,341	2,571	-278,036	1,577,260	-17,530	76
Ending Balance, Shares at Dec. 31, 2012		257,087	-84,672
Stock-based compensation				36,252
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		2,564
Issuance of common stock for acquisition of dbMotion, Shares		3,823
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		26		2,479
Issuance of common stock for acquisition of dbMotion		38		48,023
Purchases of treasury stock, Shares	0
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation				335
Warrants issued				52,498
Net loss	-104,026				-104,026
Foreign currency translation adjustments, net	-2,482					-2,482
Unrecognized gain on interest rate swap, net of tax	655					655
Unrealized gain on marketable securities, net of tax	6					6
Ending Balance at Dec. 31, 2013	1,318,145	2,635	-278,036	1,716,847	-121,556	-1,745
Ending Balance, Shares at Dec. 31, 2013		263,474	-84,672
Stock-based compensation				37,295
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,664
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		16		-6,969
Purchases of treasury stock, Shares	0
Excess tax benefit (deficiency) realized upon exercise of stock-based compensation				-123
Warrants issued				2,543
Net loss	-66,453				-66,453
Foreign currency translation adjustments, net	-529					-529
Unrecognized gain on interest rate swap, net of tax	279					279
Unrealized gain on marketable securities, net of tax	16					16
Ending Balance at Dec. 31, 2014	$1,284,220	$2,651	($278,036)	$1,749,593	($188,009)	($1,979)
Ending Balance, Shares at Dec. 31, 2014		265,138	-84,672

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	($66,453)	($104,026)	($1,153)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	174,263	178,815	150,234
Stock-based compensation expense	39,254	37,010	39,126
Excess tax benefits from stock-based compensation	0	-3,887	-3,516
Deferred taxes	-56	-43,880	-12,780
Asset impairment charges	2,390	11,454	11,101
Other losses, net	3,951	1,398	2,407
Changes in operating assets and liabilities, net of business combinations:
Accounts receivable, net	-14,644	-7,705	45,978
Prepaid expenses and other assets	-7,038	-23,481	-14,430
Accounts payable	-1,944	23,794	3,440
Accrued expenses	-22,767	-4,552	3,397
Accrued compensation and benefits	-29,544	33,482	13,101
Deferred revenue	33,109	-1,573	-16,591
Other liabilities	-7,025	-15,862	2,356
Net cash provided by operating activities	103,496	80,987	222,670
Cash flows from investing activities:
Capital expenditures	-26,438	-74,130	-80,166
Capitalized software	-40,661	-42,026	-42,965
Cash paid for business acquisitions, net of cash acquired	-20,180	-148,875	0
Purchases of marketable securities, other investments and related intangible assets	-21,544	0	0
Sales and maturities of marketable securities and other investments	50	12,891	94
Proceeds received from sale of fixed assets	85	0	0
Net cash used in investing activities	-108,688	-252,140	-123,037
Cash flows from financing activities:
Proceeds from issuance 1.25% senior cash convertible notes, net of issuance costs	0	336,662	0
Purchase of call option related to 1.25% senior cash convertible notes	0	-82,800	0
Proceeds from issuance of warrants, net of issuance costs	0	51,208	0
Proceeds from issuance of common stock	1,487	11,447	5,519
Excess tax benefits from stock-based compensation	0	3,887	3,516
Taxes paid related to net share settlement of equity awards	-10,400	-9,732	-10,292
Payments of capital lease obligations	-455	-458	-822
Payments of acquisition financing obligations	0	-29,671	0
Credit facility payments	-96,876	-609,593	-250,874
Credit facility borrowings, net of issuance costs	101,964	460,983	324,010
Repurchase of common stock	0	0	-225,961
Net cash (used in) provided by financing activities	-4,280	131,933	-154,904
Effect of exchange rate changes on cash and cash equivalents	-309	-1,782	1,474
Net decrease in cash and cash equivalents	-9,781	-41,002	-53,797
Cash and cash equivalents, beginning of period	62,954	103,956	157,753
Cash and cash equivalents, end of period	$53,173	$62,954	$103,956

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (Senior cash convertible notes [Member])	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Senior cash convertible notes [Member]
Debt instrument interest rate	1.25%	1.25%	1.25%

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” or “our” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries, unless otherwise stated.
	Use of Estimates
	The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.
	Revenue Recognition
	Revenue represents the fair value of consideration received or receivable from clients for goods and services provided by us. Revenue from system sales includes software and related hardware. Revenue from professional services includes implementation, training and consulting services. Revenue from maintenance includes post contract client support and maintenance services. Revenue from transaction processing and other includes electronic data interchange (“EDI”) services, software-as-a-service (“SaaS”) transactions, software hosting services, and IT outsourcing. For some clients, we remotely host the software applications licensed from us using our own or third-party servers, which saves these clients the cost of procuring and maintaining hardware and related facilities. For other clients, we offer an outsourced solution in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees.
	Revenue from software licensing arrangements where the service element is not considered essential to the functionality of the other elements of the arrangement is recognized upon delivery of the software or as services are performed, provided persuasive evidence of an arrangement exists, fees are considered fixed or determinable, and collection of the receivable is probable. The revenue recognized for each separate element of a multiple-element software contract is based upon vendor-specific objective evidence of fair value, which is based upon the price the client is required to pay when the element is sold separately or renewed. For arrangements in which vendor-specific objective evidence of fair value only exists for the undelivered elements, the delivered elements (generally software licenses) are accounted for using the residual method.
	Revenue from software licensing arrangements, where the service element is considered essential to the functionality of the other elements of the arrangement, is accounted for on an input basis under percentage of completion accounting using actual hours worked as a percentage of total expected hours required by the arrangement, provided that persuasive evidence of an arrangement exists, the fee is fixed or determinable and collection of the receivable is probable. Maintenance and support from these agreements is recognized over the term of the support agreement based on vendor-specific objective evidence of fair value of the maintenance revenue, which is based upon contractual renewal rates. For income statement presentation, consideration from agreements accounted for under percentage of completion accounting is allocated between system sales and professional services based on vendor specific evidence of our hourly services rate multiplied by the amount of hours performed with the residual amount allocated to software license fee.
	Revenue from certain value-added reseller (“VAR”) relationships in which software is directly sold to VARs is recognized upon delivery of the software assuming all other revenue recognition criteria have been met. Revenue recognition is deferred until the software is delivered to the ultimate end user if the arrangement terms do not satisfy the criteria for revenue recognition upon delivery of the software to the VAR.
	Fees related to SaaS arrangements are recognized as revenue ratably over the contract terms beginning on the date our solutions are made available to clients. These arrangements include professional services fees related to the implementation and set-up of our solutions and are billed upfront and recorded as deferred revenue until our solutions are made available to the client. The implementation and set-up fees are recognized as revenue ratably over the estimated client relationship period. The estimated length of a client relationship period is based on our experience with client contract renewals and consideration of the period over which such clients use our SaaS solutions.
	Software hosting services are provided to clients that have purchased a perpetual license to our software solutions and contracted with us to host the software. These arrangements provide the client with a contractual right to take possession of the software at any time during the hosting period without significant penalty and it is feasible for the client to either use the software on its own equipment or to contract with an unrelated third party to host the software. Hosting services are not deemed to be essential to the functionality of the software or other elements of the arrangement; accordingly, for these arrangements, we recognize software license revenues as system sales revenue upon delivery, assuming all other revenue recognition criteria have been met, and separately recognize fees for the hosting services as transaction processing and other revenue over the term of the hosting arrangement.
	We also enter into multiple-element arrangements that may include a combination of various software-related and non-software-related products and services. Management applies judgment to ensure appropriate accounting for multiple deliverables, including the allocation of arrangement consideration among multiple units of accounting, the determination of whether undelivered elements are essential to the functionality of delivered elements, and the timing of revenue recognition, among others. In such arrangements, we first allocate the total arrangement consideration based on a selling price hierarchy at the inception of the arrangement. The selling price for each element is based upon the following selling price hierarchy: vendor-specific objective evidence of fair value if available, third-party evidence of fair value if vendor-specific objective evidence of fair value is not available, or estimated selling price if neither vendor-specific objective evidence nor third-party evidence of fair value is available (discussion as to how we determine vendor-specific objective evidence of fair value, third-party evidence of fair value and estimated selling price is provided below). Upon allocation of the arrangement consideration to the software elements as a whole and individual non-software elements, we then further allocate consideration within the software group to the respective elements following higher-level, industry-specific guidance and our policies described above. After the arrangement consideration has been allocated to the various elements, we account for each respective element in the arrangement as described above.
	To determine the selling price in multiple-element arrangements, we establish vendor-specific objective evidence of fair value using the price charged for a deliverable when sold separately and contractual renewal rates for maintenance fees. For non-software multiple element arrangements, third-party evidence of fair value is established by evaluating similar and interchangeable competitor products or services in standalone arrangements with similarly situated clients. If we are unable to determine the selling price because vendor-specific objective evidence or third-party evidence of fair value does not exist, we determine an estimated selling price by considering several external and internal factors including, but not limited to, pricing practices, margin objectives, competition, client demand, internal costs and overall economic trends. The determination of an estimated selling price is made through consultation with and approval by our management, taking into consideration our go-to-market strategy. As our, or our competitors’, pricing and go-to-market strategies evolve, we may modify our pricing practices in the future. These events could result in changes to our determination of vendor-specific objective evidence of fair value, third-party evidence of fair value and estimated selling price. Selling prices are analyzed on an annual basis or more frequently if we experience significant changes in our selling prices.
	For those arrangements where the deliverables do not qualify as separate units of accounting, revenue recognition is evaluated for the combined deliverables as a single unit of accounting and the recognition pattern of the final deliverable will dictate the revenue recognition pattern for the single, combined unit of accounting. Changes in circumstances and client data may result in a requirement to either separate or combine deliverables, such that a delivered item could now meet the separation criteria and qualify as a separate unit of accounting which may lead to an upward or downward adjustment to the amount of revenue recognized under the arrangement on a prospective basis.
	We assess whether fees are fixed or determinable at the time of sale and recognize revenues if all other revenue recognition requirements are met. Our payment arrangements with clients typically include milestone-based software license fee payments and payments based upon delivery for services and hardware.
	While most of our arrangements include short-term payment terms, we periodically provide extended payment terms to clients from the date of contract signing. We do not recognize revenue under extended payment term arrangements until such payments become due. In certain circumstances, where all other revenue recognition criteria have been met, we occasionally offer discounts to clients with extended payment terms to accelerate the timing of when payments are made. Changes to extended payment term arrangements have not had a material impact on our consolidated results of operations.
	Maintenance fees are recognized ratably over the period of the contract based on vendor specific objective evidence of fair value based upon contractual renewal rates. Revenue from EDI services is recognized as services are provided and is determined based on the volume of transactions processed.
	We provide IT outsourcing services to our clients under arrangements that typically range from five to ten years in duration. Under these arrangements we assume full, partial or transitional responsibilities for a healthcare organization’s IT operations using our employees. Our outsourcing services include facilities management, network outsourcing and transition management. Revenue from these arrangements is recognized as services are performed.
	Revenue is recognized net of any taxes collected from clients and subsequently remitted to governmental authorities. We record as revenue any amounts billed to clients for shipping and handling costs and record as cost of revenue the actual shipping costs incurred.
	We record reimbursements for out-of-pocket expenses incurred as professional services revenue in our consolidated statements of operations. These amounts totaled:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Reimbursements for out-of-pocket expenses incurred as professional services	$	16,251			$	18,445			$	22,656
	revenue
	The following table summarizes revenue earned on contracts in excess of billings, both the current and non-current portions, which is included in the balance of accounts receivable and other assets, respectively. Billings are expected to occur according to the contract terms.
		December 31,
	(In thousands)	2014				2013
	Revenue earned on contracts in excess of billings
	Unbilled revenue (current)	$	42,818			$	37,271
	Unbilled revenue (long-term)		618				1,294
	Total revenue earned on contracts in excess of billings	$	43,436			$	38,565
	Fair Value Measurements
	Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories:
	Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Our Level 1 investments include money market funds valued daily by the fund companies, and the valuation is based on the publicly reported net asset value of each fund. There were no outstanding money market funds investments as of December 31, 2014.
	Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar instruments in active markets, and inputs other than quoted prices that are observable for the asset or liability. Our Level 2 non-derivative investments include marketable securities, which consist of mortgage and asset-backed bonds. Marketable securities are recorded at fair value determined using a market approach, based on prices and other relevant information generated by market transactions involving identical or comparable assets which are considered to be Level 2 inputs. Our Level 2 derivative financial instrument was an interest rate swap contract which expired in October 2014. Prior to expiration, the interest rate swap contract was valued based upon observable values for underlying interest rates and market determined risk premiums.
	Level 3: Inputs are unobservable for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option (as defined in Note 11, “Derivative Financial Instruments”) asset and the embedded conversion option liability. Refer to Note 6, “Debt,” and Note 11, “Derivative Financial Instruments,” for further information regarding our derivative financial instruments. These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine the fair value as of December 31, 2014 and 2013 included our common stock price, time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The 1.25% Call Option asset and the embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is substantially mitigated.
	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
		Balance Sheet		31-Dec-14														31-Dec-13
	(In thousands)	Classifications		Level 1				Level 2				Level 3			Total			Level 1		Level 2			Level 3			Total
	Money market	Cash		$	0			$	0			$	0		$	0		$	3,634	$	0		$	0		$	3,634
	funds	equivalents
	Marketable	Long-term marketable			0				1,305				0			1,305			0		1,329			0			1,329
	securities	securities
	1.25% Call	Other assets			0				0				57,091			57,091			0		0			104,656			104,656
	Option
	Cash conversion	Other liabilities			0				0				(57,839	)		(57,839	)		0		0			(105,637	)		(105,637	)
	option
	Interest rate	Other liabilities			0				0				0			0			0		(458	)		0			(458	)
	swap
	Total			$	0			$	1,305			$	(748	)	$	557		$	3,634	$	871		$	(981	)	$	3,524
	During 2014, we acquired certain non-marketable equity securities of four third parties and entered into new, or amended existing, commercial agreements with each of those third parties to license and distribute their products and services, for total consideration of approximately $21.1 million. The equity investments and the commercial agreements were valued at approximately $19.2 million and $1.9 million, respectively. Three of the equity investments acquired during 2014 are accounted for under the cost method, and one is accounted for under the equity method. The carrying values of the cost method investments and the equity method investment of approximately $17.8 million and $1.0 million, respectively, are included in other assets and the carrying value of the above-referenced commercial agreements is included in intangible assets, net, in the accompanying consolidated balance sheet as of December 31, 2014. As of December 31, 2013, our outstanding investments in non-marketable equity securities were not material.
	Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as defined below), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of the 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of December 31, 2014, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 6, “Debt,” for further information regarding our long-term financial liabilities.
	Financial Instruments
	We consider all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. The fair values of these investments approximate their carrying values.
	Other investments classified as long-term marketable securities include certain debt instruments. Debt securities are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Realized and unrealized gains and losses for all periods presented are immaterial. Changes in market value, excluding other-than-temporary impairments, are reflected in other comprehensive income. There were no other-than-temporary impairments for the years ended December 31, 2014, 2013 and 2012.
	Derivative instruments are recognized as either assets or liabilities and are measured at fair value. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the resulting designation.
	For derivative instruments designated as cash-flow hedges, the effective portion of the derivative’s gain (loss) is initially reported as a component of other comprehensive income and is subsequently recognized in earnings when the hedged exposure is recognized in earnings. Gains (losses) on derivatives representing either hedge components excluded from the assessment of effectiveness or hedge ineffectiveness are recognized in earnings. See Note 11, “Derivative Financial Instruments,” for information regarding gains and losses from derivative instruments during the years ended December 31, 2014, 2013 and 2012.
	Allowance for Doubtful Accounts Receivable
	Accounts receivable are recorded at the invoiced amounts and do not bear interest. An allowance for doubtful accounts is recorded to provide for estimated losses resulting from uncollectible accounts, and is based principally on specifically identified amounts where collection is deemed doubtful. Additional non-specific allowances are recorded based on historical experience and management’s assessment of a variety of factors related to the general financial condition of our clients, the industry in which we operate and general economic conditions. We review the collectability of individual accounts and assess the adequacy of the allowance for doubtful accounts. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. If the financial condition of our clients were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required.
	Contingent Liabilities
	A liability is contingent if the amount is not presently known, but may become known in the future as a result of the occurrence of some uncertain future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.
	The assessment of contingent liabilities, including legal and income tax contingencies, involves the use of estimates, assumptions and judgments. Our estimates are based on our belief that future events will validate the current assumptions regarding the ultimate outcome of these exposures. However, there can be no assurance that future events, such as court decisions or Internal Revenue Service (“IRS”) positions, will not differ from our assessments.
	Fixed Assets
Fixed assets are stated at cost. Depreciation and amortization is computed on the straight-line method over the estimated useful lives of the related assets. The depreciable life of leasehold improvements is the shorter of the lease term or the useful life. Upon asset retirement or other disposition, the fixed asset cost and the related accumulated depreciation or amortization are removed from the accounts, and any gain or loss is included in the consolidated statements of operations. Amounts incurred for repairs and maintenance are expensed as incurred.
Business Combinations
Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value the assets acquired, including intangible assets, and the liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair values of the assets acquired and the liabilities assumed, with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or the liabilities assumed, whichever comes first, any subsequent adjustments are reflected in our consolidated results of operations.
Goodwill and Intangible Assets
Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are tested for impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than its carrying value, we must determine the amount of implied goodwill that would be established if the reporting unit was hypothetically acquired on the impairment test date. If the carrying amount of a reporting unit’s goodwill exceeds the amount of implied goodwill, an impairment loss equal to the excess would be recorded. The recoverability of indefinite-lived intangible assets is assessed by comparison of the carrying value of the asset to its estimated fair value. If we determine that the carrying value of the asset exceeds its estimated fair value, an impairment loss equal to the excess would be recorded.
The determination of fair value of our reporting units is based on a combination of a market approach that considers benchmark company market multiples and an income approach that uses discounted cash flows for each reporting unit utilizing Level 3 inputs. Under the income approach, we determine fair value based on the present value of the most recent income projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions based on our historical experience, our expectations of future performance, and the expected economic environment. Our estimates are subject to change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. We also consider our market capitalization in assessing the reasonableness of the fair values estimated for our reporting units as part of our goodwill impairment testing.
Accounting guidance also requires that definite-lived intangible assets be amortized over their respective estimated useful lives and reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We estimate the useful lives of our intangible assets and ratably amortize the value over the estimated useful lives of those assets. If the estimates of the useful lives should change, we will amortize the remaining book value over the remaining useful lives or, if an asset is deemed to be impaired, a write-down of the value of the asset may be required at such time.
Long-Lived Assets and Long-Lived Assets to Be Disposed Of
We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Software Development Costs
We capitalize purchased software that is ready for service and software development costs incurred from the time technological feasibility of the software is established, or when the preliminary project phase is completed in the case of internal use software, until the software is available for general release. Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its value over that estimated life. If the actual useful life is shorter than our estimated useful life, we will amortize the remaining book value over the remaining useful life or the asset may be deemed to be impaired and, accordingly, a write-down of the value of the asset may be recorded as a charge to earnings. Upon the availability for general release, we commence amortization of the capitalized software costs on a product by product basis. Amortization of capitalized software is recorded using the greater of (i) the ratio of current revenues to total and anticipated future revenues for the applicable product or (ii) the straight-line method over the remaining estimated economic life, which is estimated to be three to five years.
At each balance sheet date, the unamortized capitalized costs of a software product are compared with the net realizable value of that product. The net realizable value is the estimated future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the costs of performing maintenance and client support required to satisfy our responsibility set forth at the time of sale. The amount by which the unamortized capitalized costs of a software product exceed the net realizable value of that asset is written off. If we determine in the future that the value of the capitalized software could not be recovered, a write-down of the value of the capitalized software to its recoverable value may be recorded as a charge to earnings.
The unamortized balances of capitalized software were as follows:
	December 31,
(In thousands)	2014				2013
Software development costs	$	213,601			$	170,486
Less: accumulated amortization		(127,448	)			(82,242	)
Software development costs, net	$	86,153			$	88,244
Capitalized software development costs, write-offs and amortization of capitalized software development costs included in system sales cost of revenue and asset impairment charges were as follows:
	Year Ended December 31,
(In thousands)	2014				2013				2012
Capitalized software development costs	$	45,461			$	42,026			$	42,965
Write-offs of capitalized software development costs	$	1,444			$	5,234			$	8,699
Amortization of capitalized software development costs	$	46,108			$	44,127			$	37,065
Income Taxes
We account for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of our assets and liabilities and for net operating loss and tax credit carryforwards. The objectives of accounting for income taxes are to recognize the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. Judgment is required in addressing the future tax consequences of events that have been recognized in our consolidated financial statements or tax returns. The deferred tax assets are recorded net of a valuation allowance when, based on the weight of available evidence, we believe it is more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience, expectations of future taxable income, the ability to carryback losses and other relevant factors.
In addition, we are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other tax authorities. A change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements.
The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes may be required. If we ultimately determine that payment of these amounts is unnecessary, then we reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We also recognize tax benefits to the extent that it is more likely than not that our positions will be sustained if challenged by the taxing authorities. To the extent we prevail in matters for which liabilities have been established, or are required to pay amounts in excess of our liabilities, our effective tax rate in a given period may be materially affected. An unfavorable tax settlement would require cash payments and may result in an increase in our effective tax rate in the year of resolution. A favorable tax settlement would be recognized as a reduction in our effective tax rate in the year of resolution. We report interest and penalties related to uncertain income tax positions in the income tax benefit (provision) line of our consolidated statements of operations.
We file income tax returns in the U.S. federal jurisdiction, numerous states in the U.S. and multiple countries outside of the U.S.
Earnings (Loss) Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.
The calculations of earnings (loss) per share are as follows:
	Year Ended December 31,
(In thousands, except per share amounts)	2014				2013				2012
Basic Loss per Common Share:
Net loss	$	(66,453	)		$	(104,026	)		$	(1,153	)
Net loss available to common stockholders	$	(66,453	)		$	(104,026	)		$	(1,153	)
Weighted-average common shares outstanding		179,849				177,026				178,699
Basic Loss per Common Share	$	(0.37	)		$	(0.59	)		$	(0.01	)
Diluted Loss per Common Share:
Net loss	$	(66,453	)		$	(104,026	)		$	(1,153	)
Net loss available to common stockholders	$	(66,453	)		$	(104,026	)		$	(1,153	)
Weighted-average common shares outstanding		179,849				177,026				178,699
Dilutive effect of stock options, restricted stock unit awards and warrants		0				0				0
Weighted-average common shares outstanding assuming dilution		179,849				177,026				178,699
Diluted Loss per Common Share	$	(0.37	)		$	(0.59	)		$	(0.01	)
As a result of our net loss available to common stockholders for the years ended December 31, 2014, 2013 and 2012, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for each of these years, since the inclusion of any stock equivalents would be anti-dilutive.
The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted (loss) earnings per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:
	Year Ended December 31,
(In thousands)	2014				2013				2012
Shares subject to anti-dilutive stock options, restricted stock unit awards and		24,254				14,926				2,878
warrants excluded from calculation
Stock-Based Compensation
We account for stock-based compensation in accordance with GAAP, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee directors based on their estimated fair value. We measure stock-based compensation cost at the grant date based on the fair value of the award and recognize the expense over the appropriate service period typically on a straight-line basis, net of estimated forfeitures. We recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at their underlying closing share price on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. The net proceeds from stock-based compensation activities are reflected as a financing activity within the accompanying consolidated statements of cash flows. We settle employee stock option exercises and stock awards with newly issued common shares.
Employee Benefit Plans
We provide employees with defined contribution savings plans.
We recognize expense for our contributions to the savings plans at the time employees make contributions to the plans and we contributed the following amounts to these plans:
	Year Ended December 31,
(In thousands)	2014				2013				2012
Company contributions to employee benefit plans	$	16,427			$	15,276			$	13,776
Foreign Currency
The determination of the functional currency is made based on the appropriate economic and management indicators. Our foreign subsidiaries use the local currency of their respective countries as the functional currency, with the exception of our subsidiaries in India and Israel which use the U.S. dollar as a functional currency. The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars at the exchange rates in effect at the consolidated balance sheet date, while revenues and expenses are translated at the average rates of exchange during the year. Translation gains and losses are not included in determining net income or loss but are included as a separate component of accumulated other comprehensive loss. Gains and losses resulting from foreign currency transactions are included in determining net income or loss and have not been material in any years presented in the accompanying consolidated statements of operations. We have not entered into any foreign currency hedging contracts during the years ended December 31, 2014, 2013 and 2012.
Concentrations of Credit Risk
Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and trade receivables. We primarily maintain our cash balances with one major commercial bank domestically and several commercial banks internationally. Our cash equivalents and marketable securities are comprised of interest-bearing, investment-grade securities.
We sell our products and services to healthcare providers. Credit risk with respect to trade receivables is generally diversified due to the large number of clients and their geographic dispersion. To reduce credit risk, we perform ongoing credit evaluations of significant clients and their payment histories. In general, we do not require collateral from our clients, but we do enter into advance deposit, if appropriate.
The majority of revenue is derived from clients located in the U.S. The majority of long-lived assets are located in the U.S. No single client accounted for more than 10% of our revenue in the years ended December 31, 2014, 2013 and 2012. No client represented more than 10% of accounts receivable as of December 31, 2014 or 2013.
Recently Adopted Accounting Pronouncements
In March 2013, the Financial Accounting Standards Board (“FASB”) issued updated authoritative guidance to resolve the diversity in practice about whether FASB Account Standards Codification (“ASC”) Subtopic 810-10, Consolidation—Overall, or ASC Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, this guidance resolves the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. This guidance is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013 and we adopted the new guidance in the first quarter of 2014. The adoption of this accounting guidance had no impact on our consolidated results.
In July 2013, the FASB issued Accounting Standards Update No. 2013-011, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-011”). ASU 2013-011 provides specific guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date and states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and we adopted the new guidance prospectively in the first quarter of 2014. The adoption of this accounting guidance resulted in the reclassification, for presentation purposes only, of approximately $4 million from other liabilities to deferred tax assets in our consolidated balance sheet as of December 31, 2014.
Accounting Pronouncements Not Yet Adopted
In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASU 2014-09”), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new standard permits the use of either the retrospective or cumulative effect transition methods. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently in the process of evaluating this new guidance.
In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting of a share-based award, and that could be achieved after the requisite service period, be treated as a performance condition. ASU 2014-12 is effective for reporting periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. In addition, entities will have the option of applying the guidance either prospectively (i.e. only to awards granted or modified on or after the effective date of ASU 2014-12) or retrospectively. We are currently evaluating the impact of this accounting guidance, but do not expect it to have any material impact on our consolidated financial statements.
In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which requires management of an entity to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about such entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable), and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the impact of this accounting guidance, but do not expect it to have any material impact on our consolidated financial statements.
We do not believe that any other recently issued, but not yet effective accounting standards, if currently adopted, would have a material impact on our consolidated financial statements.

Business_Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combinations	2. Business Combinations
	Acquisition of Oasis Medical Solutions Limited
	On July 8, 2014, we acquired the entire capital stock of Oasis Medical Solutions Limited (“Oasis”), a privately-held, Patient Administration System and health informatics solutions provider headquartered in London, United Kingdom, for approximately $20.6 million, in cash. The preliminary allocation of the fair value of the consideration transferred is as follows: approximately $0.4 million of acquired cash; approximately $5.4 million of accounts receivable and other current assets; approximately $5.6 million of intangible assets related to technology; approximately $0.3 million related to Oasis’ tradename; approximately $6.5 million of intangible assets related to customer relationships; goodwill of approximately $11.2 million; approximately $0.2 million of fixed assets; approximately $6.7 million of accounts payable, deferred revenue and accruals; and approximately $2.3 million of net deferred tax liabilities. Goodwill was determined based on the residual difference between the fair value of the consideration transferred and the value assigned to tangible and intangible assets and liabilities, and is not deductible for tax purposes. Among the factors that contributed to a purchase price resulting in the recognition of goodwill were the expected synergies that we believe will result from the integration of our product offerings with those of Oasis. The acquired intangible assets relating to technology, customer relationships and the Oasis’ tradename will be amortized on a straight-line basis over estimated lives of 10 years, 12 years and 2 years, respectively.
	The pro forma impact of the Oasis acquisition on current and prior quarters, as well as the net revenue and results of operations of Oasis subsequent to its acquisition for the six months ended December 31, 2014, were not material. The results of operations of Oasis have been included in our consolidated results from the date of acquisition. We did not incur any significant acquisition and integration-related costs related to the Oasis acquisition during the six months ended December 31, 2014.
	Acquisition of dbMotion
	On March 4, 2013, we acquired all of the issued and outstanding share capital of dbMotion Ltd. (“dbMotion”), a leading supplier of community health solutions, for aggregate consideration with a fair value of approximately $226 million. Immediately prior to the closing, we owned approximately 4.25% of the issued and outstanding share capital of dbMotion on a fully diluted basis. In addition, prior to the acquisition we had an ongoing strategic relationship with dbMotion in connection with the development and sale of software solutions to hospitals, physicians and other participants in the healthcare industry.
	The total fair value of consideration transferred for the acquisition is comprised of the following:
		(In thousands)
	Cash	$	140,079
	Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing		48,061
	$12.57 per share
	Deferred cash consideration payable on the 18-month anniversary of the closing		23,023
	Subordinated promissory note maturing 18 months following the closing		6,648
	Fair value of Allscripts' previous interest in dbMotion		8,367
	Total fair value of consideration transferred	$	226,178
	On March 5, 2013, we borrowed $130 million under our prior revolving credit facility to fund the cash component of the consideration transferred for the acquisition. On June 28, 2013, the liability for the deferred cash consideration payable was funded by placing the funds with an escrow agent, and the subordinated promissory note was paid off. Both the deferred cash consideration and subordinated promissory note had accrued interest at a 10% annual rate. These transactions were funded using proceeds from the initial draw down on our new revolving credit facility (see Note 6, “Debt”).
	The carrying value of our 4.25% interest in dbMotion prior to the acquisition was approximately $5 million, accounted for using the cost method. In connection with the acquisition, this investment was remeasured to a fair value of approximately $8.4 million resulting in a gain of approximately $3.4 million, which is included in other income (expense), net, in the accompanying consolidated statement of operations and other losses, net in the accompanying consolidated statement of cash flows for the year ended December 31, 2013. The remeasured fair value of our prior interest in dbMotion was estimated based on the fair value of consideration transferred to acquire the remaining 95.75% of dbMotion, less an estimated control premium of 15%. The inputs into this fair value estimate reflect our market assumptions based on premiums observed in similar transactions within our industry.
	Under the acquisition method of accounting, the fair value of consideration transferred was allocated to the tangible and intangible assets acquired and the liabilities assumed based on their estimated fair values as of the acquisition date with the remaining unallocated amount recorded as goodwill. During the three months ended March 31, 2014, we finalized the allocation of the fair value of the consideration transferred, which resulted in an increase of approximately $1.0 million in both the total fair value of consideration transferred and the residual allocation to goodwill. The allocation of the fair value of the consideration transferred, including all measurement period adjustments, is as follows:
		(In thousands)
	Acquired cash and cash equivalents, and restricted cash	$	14,188
	Accounts receivable, net		3,226
	Prepaid expenses and other current assets		574
	Fixed assets and other long-term assets		1,449
	Goodwill		137,649
	Intangible assets		85,450
	Accounts payable and accrued liabilities		(10,560	)
	Deferred taxes, net		(36	)
	Deferred revenue		(5,100	)
	Other liabilities		(662	)
	Net assets acquired	$	226,178
	Among the factors that contributed to a purchase price resulting in the recognition of goodwill were the expected synergies that we believe will result from the integration of ours and dbMotion’s product offerings. The goodwill is not deductible for tax purposes.
	The acquired intangible assets are being amortized on a straight-line basis over their useful lives and consist of the following amounts for each class of acquired intangible asset:
	(Dollar amounts in thousands)	Useful Life
	Description	in Years		Fair Value
	Core technology	10		$	80,100
	Maintenance agreements	12			2,500
	Services backlog	2			2,000
	Non-compete	3			500
	Trade name	2			350
				$	85,450
	Acquisition costs related to the dbMotion acquisition are included in selling, general and administrative expenses in the accompanying consolidated statement of operations and totaled approximately $3.7 million and $7.6 million, respectively, for the years ended December 31, 2014 and 2013. These costs include employee compensation costs of $3.7 million and $5.9 million, respectively, for the years ended December 31, 2014 and 2013, and $0.5 million of seller transaction costs for the year ended December 31, 2013. In addition, we incurred $5.5 million for the year ended December 31, 2013 related to product consolidation activities, which are included in asset impairment charges in the accompanying consolidated statement of operations.
	The following unaudited supplemental pro forma results were calculated after applying our accounting policies and adjusting the results of dbMotion to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had been applied on January 1, 2012, together with the consequential tax effects. Supplemental pro forma results for the year ended December 31, 2013 were also adjusted to exclude acquisition-related costs incurred during the period as well as the nonrecurring gain related to the fair value adjustment of our prior cost method investment in dbMotion. Supplemental pro forma results for the year ended December 31, 2012 were adjusted to include these items. The effects of transactions between us and dbMotion during the periods presented have been eliminated. The revenue and net loss of dbMotion since March 4, 2013 included in our consolidated statement of operations for the year ended December 31, 2013, and the unaudited supplemental pro forma revenue and net loss of the combined entity, are as follows:
		Year ended December 31,
	(In thousands, except per share amounts)	2013				2012
		(Unaudited)				(Unaudited)
	Actual from dbMotion since acquisition date of March 4, 2013:
	Revenue	$	18,609			$	0
	Net loss	$	(16,272	)		$	0
	Supplemental pro forma data for combined entity:
	Revenue	$	1,378,267			$	1,448,316
	Net loss	$	(105,119	)		$	(35,158	)
	Net loss per share, basic and diluted	$	(0.59	)		$	(0.19	)
	Amortization of software development and acquisition-related assets in our consolidated statement of operations for the year ended December 31, 2014 includes approximately ($0.8) million related to the acquisition of dbMotion, which is attributable to cost of revenue as follows: approximately ($0.6) million related to professional services, and approximately ($0.2) million related to system sales. Amortization of software development and acquisition-related assets in our consolidated statement of operations for the year ended December 31, 2013 includes approximately $7.1 million related to the acquisition of dbMotion, which is attributable to cost of revenue as follows: approximately $3.2 million related to system sales, approximately $1.3 million related to professional services, and approximately $2.6 million related to maintenance.
	Acquisition of Jardogs
	Also on March 4, 2013, we acquired substantially all of the assets of Jardogs LLC (“Jardogs”), the developer of FollowMyHealth, a highly-rated, cloud-based patient engagement solution provider, for $24.0 million in cash. The allocation of the fair value of the consideration transferred is as follows: approximately $4.2 million of intangible assets related to technology, including Jardogs’ portal software, approximately $2.4 million of intangible assets related to customer relationships, net deferred tax assets of approximately $0.4 million, and goodwill of approximately $17.0 million. Goodwill was determined based on the residual difference between the fair value of the consideration transferred and the value assigned to tangible and intangible assets and liabilities, and is deductible for tax purposes. Among the factors that contributed to a purchase price resulting in the recognition of goodwill were the expected synergies that we believe will result from the integration of ours and Jardogs’ product offerings. The acquired intangible assets, excluding goodwill, have estimated lives of 10 years and are being amortized on a straight-line basis.
	The pro forma impact of the Jardogs acquisition on current and prior periods, as well as the net revenues and operating losses generated by Jardogs subsequent to its acquisition for the year ended December 31, 2013, were not material.
	Acquisition costs related to the Jardogs acquisition are included in selling, general and administrative expenses and totaled approximately $0.7 million for the year ended December 31, 2013. We did not incur any significant acquisition and integration-related costs related to the Jardogs acquisition during the year ended December 31, 2014.

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Fixed Assets	3. Fixed Assets
	Fixed assets consist of the following:
		Estimated		December 31,				December 31,
	(Dollar amounts in thousands)	Useful Life		2014				2013
	Computer equipment and software	3 to 10 years		$	284,185			$	287,063
	Facility furniture, fixtures and equipment	5 to 7 years			19,846				24,700
	Leasehold improvements	7 to 8 years, or life of lease if shorter			30,795				30,816
	Assets under capital lease	3 to 5 years			2,873				9,419
	Fixed assets, gross				337,699				351,998
	Less: Accumulated depreciation and amortization				(191,869	)			(177,985	)
	Fixed assets, net			$	145,830			$	174,013
	Fixed assets depreciation and amortization expense were as follows:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Fixed assets depreciation and amortization expense	$	48,465			$	52,545			$	43,126

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	4. Goodwill and Intangible Assets
	Goodwill and intangible assets consist of the following:
		31-Dec-14								31-Dec-13
		Gross								Gross
		Carrying			Accumulated			Intangible		Carrying			Accumulated			Intangible
	(In thousands)	Amount			Amortization			Assets, Net		Amount			Amortization			Assets, Net
	Intangibles subject to amortization:
	Proprietary technology	$	451,087		$	(267,547	)	$	183,540	$	445,960		$	(231,634	)	$	214,326
	Customer contracts and relationships		550,287			(382,465	)		167,822		542,205			(352,560	)		189,645
	Total	$	1,001,374		$	(650,012	)	$	351,362	$	988,165		$	(584,194	)	$	403,971
	Intangibles not subject to amortization:
	Registered trademarks							$	52,000							$	52,000
	Goodwill								1,200,746								1,189,585
	Total							$	1,252,746							$	1,241,585
	During the fourth quarter of 2013, we revised our reportable segments in connection with changes to our organizational and management structure that were announced earlier in 2013. After the finalization of these changes and based upon the information used by our chief operating decision maker (“CODM”) for making operating decisions and assessing performance, we identified the following reportable segments: Clinical and Financial Solutions, Population Health, and Managed Services. Refer to Note 13, “Business Segments” for additional information.
	As a result of the changes to our reportable segments, we assessed our revised reporting units and allocated goodwill. Goodwill balances, which could be traced to specific products acquired as part of businesses we purchased within the past year, were allocated to the reporting unit where such products are currently managed and sold. Any remaining goodwill was then allocated to each reporting unit based on the unit’s relative fair value. The resulting allocation of goodwill to our reportable segments is shown below.
	In connection with our acquisition of Oasis, during the year ended December 31, 2014, we recognized additional goodwill of $11.2 million, which remains subject to future adjustments before the close of the measurement period. In addition, during the three months ended March 31, 2014, we finalized the allocation of the fair value of the consideration we paid in connection with our acquisitions of dbMotion and Jardogs, which resulted in the recognition of additional goodwill of approximately $1.0 million. Refer to Note 2, “Business Combinations,” for additional information regarding these acquisitions and the measurement period adjustment recorded during the three months ended March 31, 2014.
	There were no accumulated impairment losses associated with our goodwill as of December 31, 2013 or 2014, and no impairments were recorded during the years ended December 31, 2014, 2013 and 2012. Changes in the carrying amounts of goodwill by reportable segment for the years ended December 31, 2014 and 2013 were as follows:
		Clinical and			Population			Managed
	(In thousands)	Financial Solutions			Health			Services		Total
	Balance as of December 31, 2012	$	629,195		$	271,569		$	138,600	$	1,039,364
	Additions arising from business acquisitions:
	dbMotion		0			136,631			0		136,631
	Jardogs		0			17,016			0		17,016
	Total additions to goodwill		0			153,647			0		153,647
	Other adjustments to goodwill		(3,426	)		0			0		(3,426	)
	Balance as of December 31, 2013	$	625,769		$	425,216		$	138,600	$	1,189,585
	Additions arising from business acquisitions:
	Oasis		11,155			0			0		11,155
	dbMotion		0			1,018			0		1,018
	Total additions to goodwill		11,155			1,018			0		12,173
	Foreign exchange translation		(1,012	)		0			0		(1,012	)
	Balance as of December 31, 2014	$	635,912		$	426,234		$	138,600	$	1,200,746
	We performed our annual goodwill impairment test as of October 1, 2014, our annual testing date. The fair value of each reporting unit substantially exceeded its carrying value and no indicators of impairment were identified as a result of the test. We determined the fair value of each of our reporting units using a discounted cash flow analysis and a market approach considering benchmark company market multiples. A discount rate of 11% was applied to the cash flows used in the discounted cash flow analysis. We also considered our market capitalization as of the date of the test.
	Intangible assets are being amortized over their estimated useful lives and amortization expense related to intangible assets was as follows:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Proprietary technology amortization included in cost of revenue, system sales	$	35,924		$	33,970		$	27,226
	Intangible amortization included in operating expenses		31,280			31,253			35,635
	Total intangible amortization expense	$	67,204		$	65,223		$	62,861
	Estimated future amortization expense for the intangible assets that exist as of December 31, 2014, based on foreign currency exchange rates in effect as of such date, is as follows:
	Year Ended December 31,	(In thousands)
	2015	$	57,996
	2016		45,534
	2017		40,459
	2018		33,800
	2019		33,483
	Thereafter		140,090
	Total	$	351,362

Asset_Impairment_Charges

Asset Impairment Charges	12 Months Ended
	Dec. 31, 2014
Asset Impairment Charges [Abstract]
Asset Impairment Charges	5. Asset Impairment Charges
	In October of 2012, we initiated a MyWay convergence program. Since that time, we have been upgrading those MyWay clients who have elected to upgrade to Professional Suite, at no additional cost to these clients. As a result, during the years ended December 31, 2014, 2013 and 2012, we recorded non-cash charges to earnings of approximately $0.8 million, $5.0 million and $11.1 million, respectively, related to the impairment of previously capitalized software development costs for MyWay plus the net carrying value of a perpetual license for certain software code incorporated in MyWay and the write-off of certain MyWay deferred costs, which were determined to be unrealizable. We concluded the MyWay convergence program during the second quarter of 2014. During the year ended December 31, 2014, we also recorded $1.6 million of non-cash capitalized software impairment charges as a result of our decision to discontinue several software development projects, while during the year ended December 31, 2013, we also recorded approximately $6.5 million of software and fixed asset impairment non-cash charges primarily related to product consolidation activities associated with the dbMotion acquisition.
		Year Ended December 31,
	(In thousands)	2014		2013		2012
	Asset impairment charges	$	2,390	$	11,454	$	11,101

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	6. Debt
	Debt outstanding, excluding capital lease obligations, consisted of the following:
			31-Dec-14						31-Dec-13
			Principal		Unamortized		Net Carrying		Principal		Unamortized		Net Carrying
	(In thousands)		Balance		Discount		Amount		Balance		Discount		Amount
	1.25% Cash Convertible Senior Notes		$	345,000	$	67,276	$	277,724	$	345,000	$	77,529	$	267,471
	Senior Secured Credit Facility (long-term			272,410		1,452		270,958		280,000		2,338		277,662
	portion)
	Senior Secured Credit Facility (current			28,125		886		27,239		16,875		982		15,893
	portion)
	Total debt		$	645,535	$	69,614	$	575,921	$	641,875	$	80,849	$	561,026
	Interest expense consisted of the following:
			Year Ended December 31,
	(In thousands)		2014		2013		2012
	Interest expense		$	16,020	$	14,703	$	11,121
	Amortization of discounts			11,236		5,784		0
	Amortization of debt issuance costs			2,041		3,667		5,066
	Write off of unamortized deferred debt issuance costs			0		3,901		0
	Total interest expense		$	29,297	$	28,055	$	16,187
	1.25% Cash Convertible Senior Notes due 2020
	On June 18, 2013, we issued $345.0 million aggregate principal amount of the 1.25% Cash Convertible Senior Notes due 2020 (the “1.25% Notes”). The aggregate net proceeds of the 1.25% Notes were $305.1 million, after payment of the net cost of the 1.25% Notes Call Spread Overlay (as described below) and transaction costs. Additionally, we used $300 million of the net proceeds to repay a portion of the outstanding indebtedness under our prior credit facility.
	Interest on the 1.25% Notes is payable semiannually in arrears on January 1 and July 1 of each year, at a fixed annual rate of 1.25% commencing on January 1, 2014. The 1.25% Notes will mature on July 1, 2020 unless repurchased or converted in accordance with their terms prior to such date.
	The 1.25% Notes are convertible only into cash, and not into shares of our common stock or any other securities. Holders may convert their 1.25% Notes solely into cash at their option at any time prior to the close of business on the business day immediately preceding January 1, 2020 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2013 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period immediately after any five consecutive trading day period in which the trading price per $1,000 principal amount of the 1.25% Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or after January 1, 2020 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 1.25% Notes solely into cash at any time, regardless of the foregoing circumstances. Upon conversion, in lieu of receiving shares of our common stock, a holder will receive an amount in cash, per $1,000 principal amount of the 1.25% Notes, equal to the settlement amount, determined in the manner set forth in the Indenture.
	The initial conversion rate will be 58.1869 shares of our common stock per $1,000 principal amount of the 1.25% Notes (equivalent to an initial conversion price of approximately $17.19 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, we will pay a cash make-whole premium by increasing the conversion rate for a holder who elects to convert such holder’s 1.25% Notes in connection with such a corporate event in certain circumstances. We may not redeem the 1.25% Notes prior to the maturity date, and no sinking fund is provided for the 1.25% Notes.
	If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or part of their 1.25% Notes at a repurchase price equal to 100% of the principal amount of the 1.25% Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Indenture provides for customary events of default, including cross acceleration to certain other indebtedness of ours, and our subsidiaries.
	The 1.25% Notes are senior unsecured obligations, and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the 1.25% Notes; equal in right of payment to any of our unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of our secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries.
	The 1.25% Notes contain an embedded cash conversion option. We have determined that the embedded cash conversion option is a derivative financial instrument, required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the cash conversion option transaction settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). For further discussion of the derivative financial instruments relating to the 1.25% Notes, refer to Note 11, “Derivative Financial Instruments.”
	The reduced carrying value of the 1.25% Notes resulted in a debt discount that is amortized to the 1.25% Notes’ principal amount through the recognition of non-cash interest expense over the expected life of the 1.25% Notes, which extends through their maturity date of July 1, 2020. This has resulted in our recognition of interest expense on the 1.25% Notes at an effective rate approximating what we would have incurred had nonconvertible debt with otherwise similar terms been issued. The effective interest rate of the 1.25% Notes was 5.4%, which was imputed based on the amortization of the fair value of the embedded cash conversion option over the remaining term of the 1.25% Notes. As of December 31, 2014, we expect the 1.25% Notes to be outstanding until their July 1, 2020 maturity date, for a remaining amortization period of approximately five and a half years. The 1.25% Notes’ if-converted value did not exceed their principal amount as of December 31, 2014.
	In connection with the settlement of the 1.25% Notes, we paid approximately $8.4 million in transaction costs. Such costs have been allocated to the 1.25% Notes, the 1.25% Call Option (as defined below) and the 1.25% Warrants (as defined below). The amount allocated to the 1.25% Notes, or $8.3 million, was capitalized and will be amortized over the term of the 1.25% Notes. The remaining aggregate amounts allocated to the 1.25% Call Option and 1.25% Warrants were not significant. The outstanding capitalized amount of transaction costs related to the 1.25% Notes was $6.5 million and is included within other assets on our consolidated balance sheet as of December 31, 2014.
	Interest expense related to the 1.25% Notes was comprised of the following:
			Year Ended December 31,
	(In thousands)		2014		2013		2012
	Coupon interest at 1.25%		$	4,312	$	2,312	$	0
	Amortization of original issuance discount			10,253		5,271		0
	Amortization of debt issuance costs			1,180		639		0
	Total interest expense related to the 1.25% Notes		$	15,745	$	8,222	$	0
	Accrued and unpaid interest on the 1.25% Notes of approximately $2.2 million is included in accrued expenses in the accompanying consolidated balance sheet as of December 31, 2014.
	1.25% Notes Call Spread Overlay
	Also in June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions (collectively, the “1.25% Call Option”) and warrant transactions (collectively, the “1.25% Warrants”), with certain of the initial purchasers of the 1.25% Notes (collectively, the “Call Spread Overlay”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. We used $82.8 million of the proceeds from the settlement of the 1.25% Notes to pay for the 1.25% Call Option, and simultaneously received $51.2 million from the sale of the 1.25% Warrants, for a net cash outlay of $31.6 million for the Call Spread Overlay. The 1.25% Call Option is a derivative financial instruments and is discussed further in Note 11, “Derivative Financial Instruments.” The 1.25% Warrants are equity instruments and are further discussed in Note 9, “Stockholders’ Equity.”
	Credit Facility
	On June 28, 2013, we entered into a Credit Agreement (the “2013 Credit Agreement”) with a syndicate of financial institutions. The 2013 Credit Agreement provides for a $225 million senior secured term loan (the “Term Loan”) and a $425 million senior secured revolving facility (the “Revolving Facility”), each with a five year term (collectively, the “Senior Secured Credit Facility”). The Term Loan is repayable in quarterly installments, ending in June 2018. A total of up to $50 million of the Revolving Facility is available for the issuance of letters of credit, up to $10 million of the Revolving Facility is available for swingline loans, and up to $100 million of the Revolving Facility could be borrowed under certain foreign currencies.
	The proceeds of the Term Loan were used to repay the existing debt under the prior credit agreement, and to pay fees and expenses in connection with the refinancing. In conjunction with the closing of the 2013 Credit Agreement, we used a portion of the proceeds from the borrowings under the Revolving Facility to fund the payment of the seller notes and deferred purchase price obligations incurred in connection with our acquisition of dbMotion. The proceeds of the Revolving Facility can be used to finance our working capital needs and for general corporate purposes, including, without limitation, financing of permitted acquisitions, and for share repurchases. We may also request to add one or more incremental revolving and/or term loan facilities in an aggregate amount of up to $250 million, subject to certain conditions.
	Borrowings under the Senior Secured Credit Facility bear interest, at our option (except with respect to foreign currency loans), at a rate per annum equal to either (1) the rate (adjusted for statutory reserve requirements for eurocurrency liabilities and mandatory costs, if any) for deposits in the applicable currency for a period equal to one, two, three or six months or, with respect to loans under the Revolving Facility denominated in U.S. dollars, subject to availability to all affected lenders, 7 or 14 days (as selected by us), appearing on pages LIBOR01 or LIBOR02 or other page displaying such rate for such currency of the Reuters Screen (the “Eurocurrency Rate”) plus the applicable margin or (2) the highest of (a) the rate of interest publicly announced by JPMorgan Chase Bank, N.A. as its prime rate in effect at its principal office in New York City, (b) the federal funds effective rate from time to time plus 0.5%, and (c) the Eurocurrency Rate for U.S. dollars for a one month interest period plus 1.0%, plus, in each case, the applicable margin. Foreign currency loans bear interest according to clause (1) above with certain adjustments and fees applicable to fronted foreign currency loans. The applicable margin for borrowings under the Senior Secured Credit Facility was initially 1.25% for all loans except for loans based on the Eurocurrency Rate, for which the applicable margin was initially 2.25%.
	Subject to certain agreed upon exceptions, all obligations under the Senior Secured Credit Facility are guaranteed by the Guarantors pursuant to the Guarantee Agreement. Our obligations under the Senior Secured Credit Facility, any swap agreements and any cash management arrangements provided by any lender, are secured, subject to permitted liens and other agreed upon exceptions, by a perfected first priority security interest in all of the tangible and intangible assets (including, without limitation, intellectual property, material owned real property and all of the capital stock of each Guarantor and, in the case of foreign subsidiaries, up to 65% of the capital stock of first tier material foreign subsidiaries) of Allscripts Healthcare Solutions, Inc. and certain of our subsidiary guarantors.
	The Senior Secured Credit Facility requires us to maintain a minimum interest coverage ratio of 4.0 to 1.0, a maximum total leverage ratio of 4.0 to 1.0 and a maximum senior secured leverage ratio of 3.0 to 1.0. The minimum interest coverage ratio is calculated by dividing earnings before interest expense, income tax expense, depreciation and amortization expense by cash interest expense, subject to various agreed upon adjustments. The total leverage ratio is calculated by dividing total indebtedness by earnings before interest expense, income tax expense, depreciation and amortization expense, subject to various agreed upon adjustments. The senior secured leverage ratio is calculated by dividing senior secured indebtedness by earnings before interest expense, income tax expense, depreciation and amortization expense, subject to various agreed upon adjustments. In addition, the 2013 Credit Agreement requires mandatory prepayments of the debt outstanding under the facilities in certain specific circumstances and contains a number of covenants which, among other things, restrict our ability to incur additional indebtedness, engage in mergers, or declare dividends or other payments in respect of our capital stock.
	The Senior Secured Credit Facility also contains certain customary events of default, including relating to non-payment, breach of covenants, cross-default, bankruptcy and change of control.
	In connection with our entry into the 2013 Credit Agreement, we incurred fees and other costs aggregating to approximately $3.1 million. In addition, approximately $5.5 million of deferred costs associated with our prior credit facility carried over to the Senior Secured Credit Facility. Of those combined amounts, fees paid directly to the lending parties of approximately $3.8 million were recorded as an original issuance discount and fees and costs of approximately $4.3 million were recorded as deferred charges, both of which will be amortized to interest expense over the term of the new facilities. The outstanding capitalized amount of deferred charges was $3.0 million and is included within other assets on our consolidated balance sheet as of December 31, 2014. Also in connection with our entry into the 2013 Credit Agreement, approximately $3.4 million of deferred debt issuance costs associated with our prior credit facility and $0.5 million of fees incurred in connection with the new facility were written off to interest expense and are included in other losses, net in the accompanying consolidated statement of cash flows for the year ended December 31, 2013.
	As of December 31, 2014, $202.5 million under the Term Loan, $98.0 million under the Revolving Facility, and $0.9 million in letters of credit were outstanding under the 2013 Credit Agreement. Borrowings under the Revolving Facility as of such date consisted of $82.5 million denominated in US Dollars and $15.5 million, or the equivalent of 10.0 million British Pounds Sterling, denominated in foreign currency. As of December 31, 2014, the interest rate on the US Dollars-denominated borrowings under the Senior Secured Credit Facility was LIBOR plus 2.75%, which totaled 2.92%, and the interest rate on the British Pound Sterling-denominated borrowings was 2.87%. We were in compliance with all covenants under the 2013 Credit Agreement as of December 31, 2014. Unamortized deferred debt issuance costs totaled $9.5 million and are included within other assets on the consolidated balance sheet as of December 31, 2014.
	As of December 31, 2014, we had $325.6 million available, net of outstanding letters of credit, under our Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of our 2013 Credit Agreement if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings.
	The following table summarizes our future payments under the 1.25% Notes and the Senior Secured Credit Facility as of December 31, 2014:
	(In thousands)		Total		2015		2016		2017		2018		2019		Thereafter
	1.25% Cash Convertible Senior		$	345,000	$	0	$	0	$	0	$	0	$	0	$	345,000
	Notes (1)
	Senior Secured Term Loan			202,500		28,125		39,375		50,625		84,375		0		0
	Senior Secured Revolving Facility			98,035		0		0		0		98,035		0		0
	Total debt		$	645,535	$	28,125	$	39,375	$	50,625	$	182,410	$	0	$	345,000
	-1	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes
	The following is a geographic breakdown of (loss) income before income tax benefits:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	United States	$	(62,987	)	$	(137,468	)	$	(36,933	)
	Foreign		(5,130	)		(10,878	)		19,473
	Total loss before income taxes	$	(68,117	)	$	(148,346	)	$	(17,460	)
	The following is a summary of the components of the provision (benefit) for income taxes:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Current tax provision
	Federal	$	840		$	(448	)	$	1,610
	State		213			1,421			3,793
	Foreign		(399	)		45			5,184
			654			1,018			10,587
	Deferred tax provision
	Federal		(581	)		(43,542	)		(24,196	)
	State		(3,261	)		(7,929	)		(2,473	)
	Foreign		1,524			6,133			(225	)
			(2,318	)		(45,338	)		(26,894	)
	Income tax benefit	$	(1,664	)	$	(44,320	)	$	(16,307	)
	Taxes computed at the statutory federal income tax rate of 35% are reconciled to the provision for income taxes as follows:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	United States federal tax at statutory rate		35	%		35	%		35	%
	Items affecting federal income tax rate
	Non-deductible acquisition and reorganization expenses		0.1	%		(0.2	%)		0	%
	Research credits		4.6	%		5	%		14.5	%
	Change in unrecognized tax benefits		0.8	%		(1.1	%)		(6.6	%)
	State income taxes, net of federal benefit		3.1	%		3.3	%		5.8	%
	Compensation		(1.5	%)		(0.6	%)		(3.9	%)
	Meals and entertainment		(1.4	%)		(0.7	%)		(6.1	%)
	Impact of foreign operations		(3.7	%)		(1.1	%)		10.7	%
	Federal, state and local rate changes		0.4	%		0.7	%		(11.3	%)
	Change in unrecognized tax benefit, Coniston		0	%		0	%		91.4	%
	Indemnification asset settlement, Coniston		0	%		0	%		(28.2	%)
	Change in unrecognized tax benefits, Bilateral Advance Pricing Agreement		0	%		3	%		0	%
	Bilateral Advance Pricing Agreement impact		0.3	%		(3.2	%)		0	%
	Non-deductible items		(0.1	%)		(0.1	%)		(0.5	%)
	Valuation allowance		(36.2	%)		(9.2	%)		(4.0	%)
	True-up of capitalized software deferred tax		0	%		0	%		(2.3	%)
	Other		1.1	%		(0.9	%)		(1.1	%)
	Effective rate		2.5	%		29.9	%		93.4	%
	Significant components of our deferred tax assets and liabilities consist of the following:
		December 31,			December 31,
	(In thousands)	2014			2013
	Deferred tax assets
	Accruals and reserves, net	$	26,086		$	28,210
	Allowance for doubtful accounts		14,159			21,242
	Stock-based compensation, net		10,773			7,498
	Deferred revenue		17,422			12,636
	Net operating loss carryforwards		90,463			90,964
	Research and development tax credit		24,313			21,580
	AMT credits		5,606			5,250
	Other		3,617			4,962
	Less:  Valuation Allowance		(41,273	)		(14,241	)
	Total deferred tax assets		151,166			178,101
	Deferred tax liabilities
	Prepaid expense		(9,268	)		(11,395	)
	Property and equipment, net		(903	)		(852	)
	Acquired intangibles, net		(160,130	)		(182,719	)
	Total deferred tax liabilities		(170,301	)		(194,966	)
	Net deferred tax liabilities	$	(19,135	)	$	(16,865	)
	The deferred tax assets (liabilities) are classified in the consolidated balance sheets as follows:
	December 31,			December 31,
(In thousands)	2014			2013
Current deferred tax assets, net	$	35,615		$	55,468
Current deferred tax liabilities, net		(21	)		0
Current deferred tax assets (liabilities), net		35,594			55,468
Non-current deferred tax assets, net		708			7,361
Non-current deferred tax liabilities, net		(55,437	)		(79,694	)
Non-current deferred tax assets (liabilities), net		(54,729	)		(72,333	)
Net deferred tax liabilities	$	(19,135	)	$	(16,865	)
As of December 31, 2014 and 2013, we had federal net operating loss (“NOL”) carryforwards of $278 million and $276 million, respectively. Of the total federal NOL carryforwards, approximately $11 million relates to stock compensation tax deductions that will be tax-effected and the related benefit credited to additional paid-in capital when realized. As of December 31, 2014 and 2013, we had state NOL carryforwards of approximately $8 million and $8 million, respectively. The NOL carryforwards expire in various amounts starting in 2020 for both federal and state tax purposes. The utilization of the federal NOL carryforwards is subject to limitation under the rules regarding changes in stock ownership as determined by the Internal Revenue Code. Our historical federal NOLs are subject to annual limitation on usage of approximately $62 million per year. In connection with our merger with Eclipsys Corporation (the “Eclipsys Merger”) in 2010, we acquired federal NOLs totaling approximately $265 million. Due to the change in control in Eclipsys, these NOLs are subject to annual limitation on utilization of approximately $48 million per year. NOLs incurred subsequent to the Eclipsys Merger have no restrictions on utilization. We have Israeli NOL carryovers of approximately $84 million that do not expire.
We use the tax law ordering approach for determining when tax benefits derived from stock-based awards are utilized. Under this approach, the utilization of excess tax deductions associated with stock-based awards is dictated by provisions in the tax law that identify the sequence in which such benefits are utilized for tax purposes when net operating losses exist.
For federal purposes, 1993 to 2013 tax years remain subject to income tax examination by federal authorities. The IRS has commenced with an audit of all open years. Due to NOL carryforwards, in some cases the tax years continue to remain subject to examination with respect to such NOL carryforwards. For our state tax jurisdictions, 2004 to 2013 tax years remain open to income tax examination by state tax authorities. In Canada, the 2003 to 2013 tax years remain open for examination and in India the 2011 to 2013 tax years remain open.
We have a subsidiary in India that is entitled to a tax holiday that allows for tax-free operations during such holiday. The tax holiday for the subsidiary began to partially expire in 2012 and will fully expire in 2017. Tax savings realized from this holiday totaled $0.8 million, $0.6 million and $1 million for the years ended December 31, 2014, 2013 and 2012, respectively, which reduced our diluted loss per share by less than $0.01 in each of those years.
On June 1, 2007, we adopted the provisions of accounting guidance for uncertainty in income taxes recognized in our financial statements. These principles prescribe a threshold of more-likely-than-not to be sustained upon examination for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These principles also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
The following table reconciles unrecognized tax benefits:
	Year Ended December 31,
(In thousands)	2014			2013			2012
Beginning balance as of January 1	$	18,283		$	18,140		$	43,284
Increases for tax positions related to the current year		627			1,517			46
Decreases for tax positions related to prior years		(3,239	)		(23	)		(13,944	)
Increases for tax positions related to prior years		173			3,238			656
Decreases relating to settlements with taxing authorities		(384	)		(4,099	)		(11,925	)
Foreign currency translation		(26	)		(394	)		97
Reductions due to lapsed statute of limitations		(120	)		(96	)		(74	)
Ending balance as of December 31	$	15,314		$	18,283		$	18,140
As of December 31, 2011, we had accrued approximately $29 million related to uncertain tax positions resulting from the Framework Agreement with Misys dated June 9, 2010, which was subsequently amended on July 26, 2010. Pursuant to the Framework Agreement, we agreed to reduce Misys’ existing indirect ownership interest in our parent company, Allscripts Healthcare Solutions, Inc., through a series of transactions which are referred to as the Coniston Transactions. The acquired tax position related to the Coniston Transactions was indemnified by Misys in accordance with the Framework Agreement. Accordingly, we had an indemnification asset totaling $29 million, including related interest, as of December 31, 2011.
During 2012, we settled an IRS examination for the period May 2007 through May 2010 which primarily resulted in a tax assessment of $13 million that was indemnified by Misys pursuant to the Framework Agreement. The remaining tax liability related to the Coniston Transactions totaling $16 million was reversed, as reflected in the table above, and recognized as a tax benefit in our consolidated statement of operations for the year ended December 31, 2012.
Since the settlement amount with the IRS was less than the carrying value of the related indemnification asset, we recorded a write-off of the remaining indemnification asset, which is included in other income (expense), net within the accompanying consolidated statements of operations. The resulting charge of $16 million is substantially non-deductible for tax purposes and, therefore, increases the effective tax rate for the entire year.
During 2013, we completed a Bilateral Advance Pricing Agreement (BAPA) with the Canada Revenue Authority and the Internal Revenue Service covering the years 2003 through 2016. This BAPA provides certainty with respect to transactions between our Canadian entity and our US entity. Relating to these transactions, we had previously recorded $4.4 million in uncertain tax benefits, which we reversed in the quarter ended December 31, 2013 and recognized as a tax benefit. This benefit was offset by the reversal of an indirect tax benefit of the uncertain tax benefit of $6.3 million, recorded as a tax expense. We also recorded a $1.6 million tax benefit for the estimated impacts of amended returns required under the BAPA, resulting in a net impact of $0.3 million in tax expense recorded in the quarter ended December 31, 2013.
We had gross unrecognized tax benefits of approximately $15.3 million and $17.1 million as of December 31, 2014 and 2013, respectively. If the current gross unrecognized tax benefits were recognized, the result would be an increase in our income tax benefit of $2.3 million and $10.2 million, respectively. These amounts are net of accrued interest and penalties relating to unrecognized tax benefits of approximately $1.3 million and $2 million, respectively. We believe that it is reasonably possible that approximately $3.3 million of our currently remaining unrecognized tax benefits may be recognized by the end of 2015, as a result of audit settlements and/or a lapse of the applicable statute of limitations.
We recognized interest and penalties related to uncertain tax positions in our consolidated statements of operations as follows:
	Year Ended December 31,
(In thousands)	2014			2013			2012
Interest and penalties included in the provision for income taxes	$	(715	)	$	(188	)	$	(2,539	)
The amount of interest and penalties included in our consolidated balance sheets is as follows:
	December 31,			December 31,
(In thousands)	2014			2013
Interest and penalties included in the liability for uncertain tax positions	$	1,295		$	2,011
During the years ended December 31, 2014 and 2013, we recorded valuation allowances of $25.8 million and $13.6 million, respectively, for federal credit carryforwards, and foreign and state NOL carryforwards. In evaluating our ability to recover our deferred tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). Using all available evidence, we determined that it was uncertain that we will realize the deferred tax asset for certain of these carryforwards within the carryforward period.
Our effective rate is lower for the year ended December 31, 2014 as compared to the prior year, primarily due to the valuation allowance discussed above. On December 19, 2014, the Tax Increase Prevention Act of 2014 was enacted into law, reinstating the research and development credit retroactively to January 1, 2014. Our effective tax rate for 2014 includes the impact of the estimated 2014 credit of $3.1 million. As of the date of this Form 10-K, the research and development credit has not been reinstated for 2015 and future years.
We file income tax returns in the U.S. federal jurisdiction, numerous states in the U.S. and multiple countries outside of the U.S. We are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other tax authorities. A change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements.
We intend to indefinitely reinvest the undistributed earnings of our foreign subsidiaries. Accordingly, no deferred taxes have been recorded for the difference between the financial and tax basis investment in our foreign subsidiaries. If these earnings were distributed to the U.S. in the form of dividends or otherwise, we would have additional U.S. taxable income and, depending on our tax position in the year of repatriation, may have to pay additional U.S. income taxes. Withholding taxes may also apply to the repatriated earnings. Determination of the amount of unrecognized income tax liability related to these permanently reinvested and undistributed foreign subsidiary earnings is currently not practicable.
During 2014, we determined that approximately $44.3 million of these foreign subsidiaries’ undistributed earnings are now indefinitely reinvested outside the U.S. As we have determined that the earnings of these subsidiaries are not required as a source of funding for U.S. operations, such earnings are not planned to be distributed to the U.S. in the foreseeable future.

Stock_Award_Plans

Stock Award Plans	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Award Plans	8. Stock Award Plans
	Our Amended and Restated 2011 Stock Incentive Plan (“Plan”) provides for the granting of stock options, service-based share awards, performance-based share awards and market-based share awards, among other awards. As of December 31, 2014, there were 7.2 million shares of common stock reserved for issuance under future share-based awards to be granted to any of our employees, officers, directors or independent consultants at terms and prices to be determined by our Board, and subject to the terms of the Plan.
	We recorded stock-based compensation expense as follows:
		Year Ended December 31,
	(In thousands)	2014			2013		2012
	Cost of revenue:
	Professional services	$	2,679		$	2,598	$	2,437
	Maintenance		1,264			1,430		1,579
	Transaction processing and other		1,971			1,616		1,913
	Total cost of revenue		5,914			5,644		5,929
	Selling, general and administrative expenses		25,376			23,013		25,869
	Research and development		7,964			8,353		7,328
	Total stock-based compensation expense	$	39,254		$	37,010	$	39,126
	The estimated income tax benefit of stock-based compensation expense included in the provision for income taxes for the year ended December 31, 2014 is approximately $8 million. No stock-based compensation costs were capitalized during the years ended December 31, 2014, 2013 and 2012. The calculation of stock-based compensation expenses includes an estimate for forfeitures at the time of grant. This estimate can be revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. As of December 31, 2014, total unrecognized stock-based compensation expense related to non-vested awards and options was $59.5 million and this expense is expected to be recognized over a weighted-average period of 2.3 years.
	We issue service-based awards, performance-based, and market-based awards in the form of restricted stock units, stock options or shares. A description of each category of awards is presented below.
	Service-based Share Awards
	Service-based share awards include stock options, restricted stock units and shares, and typically vest over a four-year period commencing on the date of grant subject to continued service with us. Upon termination of an employee’s employment, any unvested service-based share awards are forfeited unless otherwise provided in an employee’s employment agreement. Deferred share units are awarded to directors and vest within one year, when issued in lieu of annual share awards, or immediately, when issued in lieu of cash.
	As of December 31, 2014, there was $50.0 million of total estimated unrecognized stock-based compensation expense related to the service-based share awards which is expected to be recognized through December 2018.
	Performance-based Share Awards
	Performance-based share awards include restricted stock units and shares. The purpose of such awards is to align management’s compensation with our financial performance and other operational objectives and, in certain cases, to retain key employees over a specified performance period. Awards granted under this category are based on the achievement of various targeted financial measures, including, but not limited to, non-GAAP EBITDA, revenue and bookings growth, as defined in the grant agreements. The awards are earned based on actual results achieved compared to targeted amounts. Stock-based compensation expense related to these awards is recognized over three-year and four-year vesting periods under the accelerated attribution method if and when we conclude that it is probable that the performance conditions will be achieved.
	As of December 31, 2014, there was $6.2 million of total estimated unrecognized stock-based compensation expense, assuming various target attainments related to the performance-based share awards, which is expected to be recognized through February 2018.
	Market-based Share Awards
	Market-based share awards include restricted stock units. The purpose of such awards is to align management’s compensation with the performance of our common stock relative to the market. Awards granted under this category are dependent on our total shareholder returns relative to a specified peer group of companies over three-year performance periods with vesting based on three annual performance segments from the grant dates. Fair values of the awards were estimated at the date of the grants using the Monte Carlo pricing model. Following completion of the three-year performance periods, the Compensation Committee of our Board will determine the number of awards that would vest considering overall performance over the three-year performance periods. If the numbers of shares that would vest under this scenario are greater than the amount vesting under the three annual performance segments, then such greater numbers of awards shall vest, reduced by the number of awards previously vested. Stock-based compensation expense related to these awards will be recognized over three-year vesting periods under the accelerated attribution method.
	As of December 31, 2014, there was $3.3 million of total estimated unrecognized stock-based compensation expense, assuming various target attainments related to the market-based share awards, which is expected to be recognized through December 2016.
	Restricted Stock Units and Awards
	The following table summarizes the activity for restricted stock units during the periods presented:
					Weighted-Average
	(In thousands, except per share amounts)	Shares			Grant Date Fair Value
	Unvested restricted stock units as of December 31, 2011		4,182		$	17.83
	Awarded		5,574		$	11.78
	Vested		(1,898	)	$	16.11
	Forfeited		(1,130	)	$	17.16
	Unvested restricted stock units as of December 31, 2012		6,728		$	13.43
	Awarded		2,511		$	15.06
	Vested		(2,023	)	$	13.77
	Forfeited		(1,482	)	$	13.74
	Unvested restricted stock units as of December 31, 2013		5,734		$	13.94
	Awarded		2,199		$	18.09
	Vested		(2,044	)	$	13.9
	Forfeited		(793	)	$	14.28
	Unvested restricted stock units as of December 31, 2014		5,096		$	15.69
	The following table summarizes the activity for restricted stock awards during the periods presented:
					Weighted-Average
	(In thousands, except per share amounts)	Shares			Grant Date Fair Value
	Unvested restricted stock awards as of December 31, 2011		411		$	16.95
	Vested		(254	)	$	16.27
	Forfeited		(137	)	$	16.72
	Unvested restricted stock awards as of December 31, 2012		20		$	15.94
	Vested		(17	)	$	15.92
	Forfeited		(3	)	$	16.05
	Unvested restricted stock awards as of December 31, 2013		0		$	0
	Vested		0		$	0
	Forfeited		0		$	0
	Unvested restricted stock awards as of December 31, 2014		0		$	0
	Net Share-settlements
	Beginning in 2011, upon vesting, restricted stock units and awards are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested in 2014 and 2013 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees’ minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld during the years ended December 31, 2014, 2013 and 2012 were 669 thousand, 693 thousand and 860 thousand, respectively, and were based on the value of the restricted stock units and awards on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.
	Stock Options
	The following table summarizes the status of stock options outstanding and the changes during the periods presented:
		Options			Weighted-Average		Options		Weighted-Average
	(In thousands, except per share amounts)	Outstanding			Exercise Price		Exercisable		Exercise Price
	Balance as of December 31, 2011		3,976		$	10.31		3,499	$	9.87
	Options exercised		(1,138	)	$	5.32
	Options forfeited		(171	)	$	16.62
	Balance as of December 31, 2012		2,667		$	12.04		2,548	$	11.88
Options granted		3,870		$	13.79
Options exercised		(1,442	)	$	8.47
Options forfeited		(773	)	$	14.94
Balance as of December 31, 2013		4,322		$	14.28		1,025	$	15.52
Options granted		0		$	0
Options exercised		(289	)	$	11.88
Options forfeited		(606	)	$	15.03
Balance as of December 31, 2014		3,427		$	14.35		1,393	$	14.97
We estimate the fair value of our service and performance-based stock option awards on the date of grant using the Black-Scholes-Merton option-pricing model. Option valuation models, including the Black-Scholes-Merton option-pricing model, require the input of certain assumptions that involve judgment. Changes in the input assumptions can materially affect the fair value estimates and, ultimately, how much we recognize as stock-based compensation expense.
The following table contains the stock option weighted-average grant date fair value information and related valuation assumptions for the year ended December 31, 2013. No stock option awards were granted for the years ended December 31, 2014 and 2012.
Stock options granted (in thousands)		3,870
Fair Value per option	$	6.25
Valuation assumptions:
Expected term ( in years)		4.8
Expected volatility		54	%
Expected dividend yield		0	%
Risk-free interest rate		0.9	%
The stock option grant prices equaled the closing prices of our common stock on the date of grant and the stock options have a contractual term of 7 years. The expected term is based on historical exercise patterns and post-vesting termination behavior, the risk-free interest rate input is based on U.S. Treasury instruments and the volatility input is calculated based on the implied volatility of our common stock.
The aggregate intrinsic value of stock options outstanding and exercisable as of December 31, 2014 was $0.6 million and $0.6 million, respectively, based on our closing stock price of $12.77 as of December 31, 2014. The intrinsic value of stock options outstanding represents the amount that would have been received by the option holders had all option holders exercised their stock options as of that date.
The following activity occurred under our plans:
	Year Ended December 31,
(In thousands)	2014			2013		2012
Total intrinsic value of stock options exercised	$	1,535		$	7,500	$	7,756
Total fair value of share awards vested	$	31,672		$	28,609	$	28,600
The following table summarizes information about stock options outstanding as of December 31, 2014:
	Number of					Number of
	Options			Weighted-Average		Options		Weighted-Average
Range of Exercise Prices	Outstanding			Exercise Price		Exercisable		Exercise Price
$6.65 to $12.72		513,202		$	11.57		239,025	$	10.26
$13.15 to $14.78		2,145,654		$	13.99		553,095	$	13.96
$14.94 to $16.80		465,943		$	16.02		298,879	$	16.48
$17.83 to $18.58		143,160		$	18.42		143,160	$	18.42
$18.74 to $20.94		159,100		$	19.63		159,100	$	19.63
		3,427,059					1,393,259
The weighted average remaining contractual life of the options outstanding and exercisable as of December 31, 2014 is 3.3 years.
Employee Stock Purchase Plan
Our Employee Stock Purchase Plan (the “ESPP”) allows eligible employees to authorize payroll deductions of up to 20% of their base salary to be applied toward the purchase of full shares of common stock on the last business day of each offering period. Offering periods under the ESPP are three months in duration and begin on each March 1st, June 1st, September 1st, and December 1st. Shares are purchased on the last day of each offering period at a discount of 15% to the fair market value of our common stock as reported on NASDAQ based on the lower of the closing price either on the first or last business day of each offering period. Employees are limited to purchasing shares under the ESPP having a collective fair market value no greater than $25 thousand in any one calendar year. The shares available for purchase under the ESPP may be drawn from either authorized but previously unissued shares of common stock or from reacquired shares of common stock, including shares purchased by us in the open market and held as treasury shares.
We treat the ESPP as a compensatory plan in accordance with GAAP. There were 644 thousand and 388 thousand shares purchased under the ESPP during the years ended December 31, 2014 and 2013, respectively.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity
	Stock Repurchases
	The stock repurchase program approved by the Board of Directors of Allscripts Healthcare Solutions, Inc. in April 2011 expired on May 9, 2014. No shares were repurchased under this program during the years ended December 31, 2014 and 2013. During the year ended December 31, 2012, we repurchased approximately 21 million shares of our common stock under this program at an aggregate purchase price of approximately $226 million. The average price paid per share during the year ended December 31, 2012 was $10.89.
	Issuance of Warrants
	During June 2013, in connection with the issuance of the 1.25% Notes, we issued the 1.25% Warrants for approximately 20.1 million shares of our common stock (subject to anti-dilution adjustments under certain circumstances) with an initial exercise price of $23.135 per share, subject to customary adjustments. The net proceeds from the sale of the 1.25% Warrants of approximately $51.2 million are included as additional paid in capital in the accompanying consolidated balance sheets as of December 31, 2014 and 2013. The 1.25% Warrants expire over a period of 70 trading days beginning on October 1, 2020 and are exercisable only upon expiration. Additionally, if the market value per share of our common stock exceeds the strike price of the 1.25% Warrants on any trading day during the 70 trading day measurement period, we will, for each such trading day, be obligated to issue to the counterparties a number of shares equal in value to the product of the amount by which such market value exceeds such strike price and 1/70th of the aggregate number of shares of our common stock underlying the 1.25% Warrants transactions, subject to a share delivery cap. For each 1.25% Warrant that is exercised, we will deliver to the option counterparties a number of shares of our common stock equal to the amount by which the settlement price exceeds the exercise price, divided by the settlement price, plus cash in lieu of fractional shares. We will not receive any additional proceeds if the 1.25% Warrants are exercised. The number of warrants and the strike price are subject to adjustment under certain circumstances. The 1.25% Warrants could separately have a dilutive effect to the extent that the market value per share of our common stock (as measured under the terms of the warrant transactions) exceeds the applicable strike price of the 1.25% Warrants.
	In June 2013, we agreed to issue a warrant to a commercial partner as part of an overall commercial relationship pursuant to which the warrant holder has the right to purchase 1.5 million shares of our common stock at a strike price of $12.94 per share. The warrant vests in four equal annual installments of 375 thousand shares (beginning in June 2014) and expires in June 2020. Our issuance of the warrant was a private placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. This warrant is not actively traded and is valued based on an option pricing model that uses observable and unobservable market data for inputs. During the years ended December 31, 2014 and 2013, we recognized approximately $2.5 million and $1.3 million of the warrant fair value as a reduction to transaction processing and other revenues.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Accumulated Other Comprehensive Loss	10. Accumulated Other Comprehensive Loss
	The following table summarizes, as of each balance sheet date, the components of our accumulated other comprehensive loss:
		December 31,			December 31,
	(In thousands)	2014			2013
	Unrealized gain on marketable securities	$	228		$	203
	Tax effect		(88	)		(79	)
	Unrealized gain on marketable securities, net of tax		140			124
	Unrealized loss on interest rate swap		0			(458	)
	Tax effect		0			179
	Unrealized loss on interest rate swap, net of tax		0			(279	)
	Foreign currency translation adjustment		(2,119	)		(1,590	)
	Total accumulated other comprehensive loss	$	(1,979	)	$	(1,745	)

Derivative_Financial_Instrumen

Derivative Financial Instruments	12 Months Ended
	Dec. 31, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	11. Derivative Financial Instruments
	1.25% Call Option
	In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into the 1.25% Call Option with certain of the initial purchasers of the 1.25% Notes (the “Option Counterparties”). We used $82.8 million of the proceeds from the issuance of the 1.25% Notes to pay for the 1.25% Call Option, and simultaneously received $51.2 million for the sale of the 1.25% Warrants, for a net cash outlay of $31.6 million for the Call Spread Overlay. Assuming full performance by the option counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes.
	Aside from the initial payment of a premium to the option counterparties of $82.8 million for the 1.25% Call Option, we will not be required to make any cash payments to the counterparties under the 1.25% Call Option, and, subject to the terms and conditions thereof, will be entitled to receive from the option counterparties an amount of cash, generally equal to the amount by which the market price per share of common stock exceeds the strike price of the 1.25% Call Options during the relevant valuation period. The strike price under the 1.25% Call Option is initially equal to the conversion price of the 1.25% Notes of $17.19 per share of common stock.
	The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to the cash settlement features until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to discussion of fair value measurements in Note 1, “Basis of Presentation and Significant Accounting Policies.” The fair value of the 1.25% Call Option as of December 31, 2014 and 2013 was approximately $57.1 million and $104.7 million, respectively.
	The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in other income (expense), net. For the years ended December 31, 2014 and 2013, the change in the fair value of the 1.25% Call Option resulted in a net loss of $47.6 million and a net gain of $21.9 million, respectively. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal.
	1.25% Notes Embedded Cash Conversion Option
	The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in other income (expense), net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to discussion of fair value measurements in Note 1, “Basis of Presentation and Significant Accounting Policies.” The fair value of the embedded cash conversion option as of December 31, 2014 and 2013 was approximately $57.8 million and $105.6 million, respectively. For the years ended December 31, 2014 and 2013, the change in the fair value of the embedded cash conversion option resulted in a net gain of $47.8 million and a net loss of $22.8 million, respectively. These amounts were slightly higher than the net loss and net gain recognized on the 1.25% Call Option over the same respective time periods.
	Interest Rate Swap Agreement
	We entered into an interest rate swap agreement with an effective date of October 29, 2010 that had the economic effect of modifying the variable rate component of the interest obligations associated with a portion of our variable rate debt. The initial notional amount of the interest rate swap agreement was $300 million, with scheduled step downs over time. The interest rate swap agreement expired on October 31, 2014. The interest rate swap agreement converted the one-month LIBOR rate on the corresponding notional amount of debt to an effective fixed rate of 0.896% (exclusive of the applicable margin currently charged under the Senior Secured Credit Facility). The critical terms of the interest rate swap agreement and the related debt agreement matched and allowed us to designate the interest rate swap agreement as a highly effective cash flow hedge under GAAP. The interest rate swap agreement was designed to protect us against changes in interest payments due to benchmark interest rate movements. The change in fair value of this interest rate swap agreement was recognized in other comprehensive income (loss) with the corresponding amounts included in other assets or other liabilities in our consolidated balance sheets. Amounts accumulated in other comprehensive (loss) income were indirectly recognized in earnings as periodic settlements of the swap occurred and the fair value of the swap declined to zero at expiration.
	The fair value of our interest rate swap was a liability of approximately $0.5 million as of December 31, 2013. We recognized the following activity related to our interest rate swap agreement:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Effective portion:
	Current period increase in fair value recognized in other comprehensive (loss)	$	458		$	1,076		$	220
	income, net
	Tax effect		(179	)		(421	)		(87	)
	Net	$	279		$	655		$	133
	Loss reclassified from accumulated other comprehensive loss to interest expense	$	496		$	1,215		$	1,783
	Amount excluded from effectiveness assessment and ineffective portion gain	$	0		$	0		$	0
	(loss) recognized in other income (expense), net
	No gains (losses) were reclassified from other comprehensive (loss) income into earnings as a result of forecasted transactions that failed to occur during the years ended December 31, 2014, 2013 and 2012.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Commitments	12. Commitments
	Operating and Capital Leases
	We conduct our operations from leased premises under a number of operating leases. We also lease office equipment and vehicles under operating leases. Certain office leases contain renewal options and rent escalation clauses calling for rent increases over the term of the lease. All leases which contain a rent escalation clause are accounted for on a straight-line basis. Total rent expense recognized, which consists of the base rental amount and other lessor charges when mandated in a lease agreement, was as follows:
		Year Ended December 31,
	(In thousands)	2014			2013		2012
	Rent expense	$	16,259		$	17,062	$	18,543
	The long-term portion of capital lease obligations is included on the consolidated balance sheet under other liabilities. Our future commitments under capital and operating leases are shown below. Future operating lease commitments are calculated using the base rental amount and foreign currency exchange rates in effect as of December 31, 2014.
		Capital			Operating
	(In thousands)	Leases			Leases
	2015	$	244		$	15,659
	2016		57			14,987
	2017		0			10,180
	2018		0			5,527
	2019		0			3,073
	Thereafter		0			1,248
			301		$	50,674
	Less amount representing interest		(17	)
			284
	Current maturities of capital lease obligations		228
	Capital lease obligations, net of current maturities	$	56
	Commitment with Strategic Partner
	We are currently in the fourth year of a ten-year agreement with Xerox Consultant Services, Inc. (“Xerox”) to provide services to support our remote hosting services for our Sunrise acute care clients. We maintain all client relationships and domain expertise with respect to the hosted applications. This agreement includes the payment of an initial base amount of approximately $50 million per year plus charges for services incremental to the base agreement. Expenses incurred under this agreement are included in cost of revenue in our consolidated statements of operations and were as follows:
		Year Ended December 31,
	(In thousands)	2014			2013		2012
	Expenses incurred under Xerox agreement	$	68,165		$	62,259	$	55,987

Business_Segments

Business Segments	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Business Segments	13. Business Segments
	We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a SaaS-delivery model), professional services, and IT outsourcing and remote hosting services. These sales are also the basis for our recurring service contracts for software maintenance and certain transaction processing services. We revised our reportable segments effective December 1, 2013, in connection with changes to our organizational and management structure that were announced earlier in 2013.
	The changes to our organizational and management structure were aimed at improving our operational effectiveness, enhancing our competitiveness and creating a greater focus on client needs. These changes, which involved the creation of strategic business units, were designed to transition us towards a flatter business unit model aligned with key products and services, and away from a functional organization. After the finalization of these changes and based upon the information used by our CODM for making operating decisions and assessing performance, we identified nine operating segments, which were aggregated into three reportable segments: Clinical and Financial Solutions, Population Health, and Managed Services.
	The Clinical and Financial Solutions segment includes our Acute, TouchWorks, Professional Practices, Payer and Life Sciences, and International strategic business units. This segment derives its revenue from the sale of integrated clinical software applications, financial and information solutions, and related installation and maintenance services, to physician practices, hospitals and health systems of various sizes. These solutions primarily include EHR-related software, financial and practice management software, related installation and training services, and electronic claims administration services. The Population Health segment includes our Performance and Care Logistics and Population Health strategic business units. This segment derives its revenue from the sale of health management solutions, which are mainly targeted at hospitals, health systems and ACOs, and which enable such organizations to connect, transition, analyze, and coordinate care across the entire care community. The Managed Services segment includes our Outsourcing and Remote Hosting strategic business units. It derives its revenue from the sale of outsourcing solutions, where we assume partial to total responsibility for a healthcare organization’s IT operations and remote hosting solutions. The revenues from this segment are primarily reflected as part of transaction processing and other in our consolidated statements of operations. Segment data for prior periods presented in the table below has been restated to conform to the current year’s presentation.
	Our CODM uses segment revenues, gross profit and income from operations as measures of performance and to allocate resources. In determining revenue, gross profit and income from operations for our segments, we do not include the amortization of acquisition-related deferred revenue adjustments in revenue and we exclude the amortization of intangible assets, stock-based compensation expense and one-time expenses from the operating segment data provided to our CODM. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), interest expense and the provision for income taxes, all of which are centrally managed. In addition, the “Unallocated Amounts” category includes revenue and the associated cost from the resale of certain ancillary products, primarily consisting of hardware. We do not track our assets by segment.
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Revenue:
	Clinical and Financial Solutions	$	827,926		$	871,819		$	947,011
	Population Health		284,836			257,738			244,153
	Managed Services		251,951			222,358			231,869
	Unallocated Amounts		13,160			21,146			23,292
	Total revenue	$	1,377,873		$	1,373,061		$	1,446,325
	Gross Profit:
	Clinical and Financial Solutions	$	398,774		$	407,624		$	458,930
	Population Health		192,445			175,591			157,007
	Managed Services		16,537			20,454			35,392
	Unallocated Amounts		(61,772	)		(69,213	)		(44,794	)
	Total gross profit	$	545,984		$	534,456		$	606,535
	Income (Loss) from operations:
	Clinical and Financial Solutions	$	175,318		$	166,500		$	239,712
	Population Health		115,732			108,733			101,457
	Managed Services		16,537			20,454			35,392
	Unallocated Amounts		(346,775	)		(423,288	)		(363,290	)
	Total loss from operations	$	(39,188	)	$	(127,601	)	$	13,271

Supplemental_Disclosures

Supplemental Disclosures	12 Months Ended
	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures	14. Supplemental Disclosures
		Year Ended December 31,
	(In thousands)	2014		2013		2012
	Cash paid during the period for:
	Interest	$	15,585	$	12,997	$	11,218
	Income taxes paid, net of tax refunds	$	7,104	$	7,944	$	7,040
	Non-cash transactions:
	Obligations incurred to purchase capitalized software	$	4,800	$	0	$	0
	Accrued expenses consist of the following:
		December 31,		December 31,
	(In thousands)	2014		2013
	Royalties, certain third party product costs and licenses	$	23,946	$	30,997
	Other		55,021		65,502
	Total accrued expenses	$	78,967	$	96,499
	Other consists of various accrued expenses and no individual item accounted for more than 5% of the current liabilities balance at the respective balance sheet dates.

Geographic_Information

Geographic Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Geographic Information	15. Geographic Information
	Revenues are attributed to geographic regions based on the location where the sale originated. Our revenues by geographic area are summarized below:
		Year Ended December 31,
	(In thousands)	2014		2013		2012
	United States	$	1,327,840	$	1,321,779	$	1,387,304
	Canada		20,727		24,999		23,909
	Other international		29,306		26,283		35,112
	Total	$	1,377,873	$	1,373,061	$	1,446,325
	A summary of our long-lived assets, comprised of fixed assets by geographic area, is presented below:
		December 31,		December 31,
	(In thousands)	2014		2013
	United States	$	133,485	$	160,237
	India		8,044		9,652
	Israel		2,142		2,180
	Canada		935		1,295
	Other international		1,224		649
	Total	$	145,830	$	174,013

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Contingencies	16. Contingencies
	In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated, certain of which are discussed below. We intend to vigorously defend ourselves in these matters.
	No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.
	The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. If one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results.
	In the opinion of our management, based on the information currently available, there was not at least a reasonable possibility that we may have incurred a material loss, or a material loss in excess of a recorded accrual, with respect to the following matter.
	On September 14, 2010, Pegasus Imaging Corporation filed a complaint against us in the Circuit Court of the Thirteenth Judicial Circuit of the State of Florida in and for Hillsborough County, Florida, which we transferred to the Special Superior Court for Complex Business Cases. The lawsuit also named former officers Jeffrey Amrein and John Reinhart as defendants. The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence. On June 27, 2013, we filed our First Amended Answer, Defenses, and Counterclaims to the plaintiff’s Second Amended Complaint, denying all material allegations, and asserting counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation. On July 7, 2014, the Court granted our motion for summary judgment on the plaintiff’s claim of unfair trade practices under Florida law and our motion for summary judgment as to the aforementioned defunct corporations, and granted the plaintiff’s motion for summary judgment on our counterclaims, for which the plaintiff has moved for reconsideration. No trial date has been scheduled.
	In the opinion of our management, based on the information currently available, there is a reasonable possibility that we may incur a material loss with respect to the following matters. However, it is not possible to estimate the possible loss or range of loss at this time. Our management will continue to evaluate the potential exposure related to these matters in future periods.
	On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in U.S. District Court for the Northern District of Illinois against us. The complaint alleges that on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA; treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Discovery is proceeding. The plaintiff must file a motion for class certification by June 22, 2015. No trial date has been scheduled.
	On May 2, 2012, a lawsuit was filed in the United States District Court for the Northern District of Illinois against us; Glen Tullman, our former Chief Executive Officer; and William Davis, our former Chief Financial Officer, by the Bristol County Retirement System for itself and on behalf of a purported class consisting of stockholders who purchased our common stock between November 18, 2010 and April 26, 2012. The plaintiffs later added Lee Shapiro, our former President, as a defendant. The plaintiffs allege that we, Mr. Tullman, Mr. Davis and Mr. Shapiro made materially false and misleading statements and/or omissions during the putative class period regarding our progress in integrating our business with the business of Eclipsys Corporation following the two companies’ August 24, 2010 merger, and that we lacked a reasonable basis for certain statements regarding those post-merger integration efforts as well as our operations and results and projections of future financial performance. A fully-briefed motion to dismiss is pending. No trial date has been scheduled.
	On June 27, 2012, a purported shareholder, Richard Devereaux, filed a shareholder derivative action in the Circuit Court of Cook County, Illinois against us; Glen Tullman, our former Chief Executive Officer; William Davis, our former Chief Financial Officer; Paul Black, our current Chief Executive Officer and a current member of the Board; and Dennis Chookaszian, Robert Cindrich, Marcel Gamache, Philip Green, and Michael Kluger, each of whom are or were members of the Board. The suit alleges breach of fiduciary duties and unjust enrichment against certain of our former and current executives who allegedly made misleading claims about our business and financial condition, which allegedly caused our stock price to be artificially inflated and then drop sharply when we reported earnings below expectations and disclosed a “leadership dispute” in a regulatory filing. The case is currently stayed by agreement of the parties.
	On July 11, 2012, RLIS, Inc. filed a complaint in the United States District Court for the Southern District of Texas against us. The complaint alleges, among other things, that our Enterprise EHR product (now Allscripts Touchworks) willfully infringes U.S. Patent No. 7,076,436. On September 28, 2012, the plaintiff filed an amended complaint that alleges, among other things, that certain of our products and services infringe both the foregoing patent as well as U.S. Patent No. 5,823,948. The amended complaint seeks an unspecified amount of damages and interest, as well as injunctive relief. The case is currently scheduled for trial in March 2015, although the Court has indicated it may potentially delay the trial date.
	On May 15, 2014, Medfusion, Inc. filed a complaint in the Superior Court of Wake County, North Carolina, against us. The complaint alleges, among other things, breach of contract, fraudulent inducement, fraud, and violation of North Carolina’s unfair methods of competition and unfair or deceptive trade practices statutes by us in connection with a previous commercial agreement between the parties. The complaint seeks an unspecified amount of damages and interest. The case is currently scheduled for trial in February 2016.
	Other Matters
	During 2014, we resolved a number of pending legal proceedings related to our offer to upgrade MyWay clients to Professional Suite. In August 2014, we concluded our arbitration with Etransmedia Technology, Inc. In October 2014, we entered into a settlement agreement with Pain Clinic of Northwest Florida, Inc., American Pain Care Specialists, LLC, Advanced Pain Specialists, Inc., and South Baldwin Family Practice, LLC. The court granted final approval of this settlement agreement in February 2015. In December 2014, we entered into a settlement agreement with Costco Wholesale Corporation, as well as a settlement agreement with Cardinal Health 200, LLC. During 2014, we paid approximately $14.0 million in connection with the resolution of these claims, including approximately $4.0 million in the fourth quarter of 2014.

North_American_Site_Consolidat

North American Site Consolidation Plan	12 Months Ended
	Dec. 31, 2014
Restructuring And Related Activities [Abstract]
North American Site Consolidation Plan	17. North American Site Consolidation Plan
	On February 18, 2013, we announced a North American site consolidation plan (the “Site Consolidation Plan”) designed to create a more simplified and efficient organization that is aligned more closely with our business priorities. The Site Consolidation Plan included the closing of twelve offices and one warehouse in conjunction with changes to our corporate operating models intended to reduce costs associated with product solutions development. The costs of implementing these changes primarily consist of employee severance and relocation costs.
	During the year ended December 31, 2014, we recognized benefits of approximately $2.2 million due to the release of previously accrued severance costs which we no longer expect to pay; while during the year ended December 31, 2013, we incurred approximately $20.1 million in severance, retention bonuses and relocation expenses costs resulting from the Site Consolidation Plan. These amounts are included in selling, general and administrative expenses in our consolidated statements of operations for the years ended December 31, 2014 and 2013, with the exception of $3.9 million for the year ended December 31, 2013, included in research and development. The portion of these amounts allocable to our reportable segments is not material.
	In the first quarter of 2013, we established a liability for approximately $11.2 million for severance costs resulting from the Site Consolidation Plan, of which approximately $4.2 million remained as of December 31, 2013 and was included in accrued compensation and benefits in our consolidated balance sheet as of December 31, 2013. During the year ended December 31, 2014, we paid approximately $2.0 million and released approximately $2.2 million of previously accrued severance costs, which we no longer expect to pay, resulting in no remaining liability as of December 31, 2014.
	As of December 31, 2014, the Site Consolidation Plan was substantially completed and additional estimated costs yet to be incurred in connection with the Site Consolidation Plan, which primarily consist of lease-related costs, are not expected to be material.

Quarterly_Financial_Informatio

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	18. Quarterly Financial Information (Unaudited)
	The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters.
			Quarter Ended
			December 31,				September 30,				June 30,				March 31,
	(In thousands, except per share amounts)		2014				2014				2014				2014
	Revenue		$	340,903			$	345,389			$	351,296			$	340,285
	Cost of revenue			204,549				213,933				211,308				202,099
	Gross profit			136,354				131,456				139,988				138,186
	Selling, general and administrative expenses			85,038				97,034				86,663				89,946
	Research and development			41,538				45,962				53,016				52,305
	Asset impairment charges			256				188				1,751				195
	Amortization of intangible and acquisition-related			8,866				7,112				7,651				7,651
	assets
	Loss income from operations			656				(18,840	)			(9,093	)			(11,911	)
	Interest expense			(7,292	)			(7,542	)			(7,230	)			(7,233	)
	Other (expense) income, net			(1	)			171				230				(32	)
	Loss before income taxes			(6,637	)			(26,211	)			(16,093	)			(19,176	)
	Income tax benefit (provision)			4,459				448		-3		(1,677	)			(1,566	)
	Net loss		$	(2,178	)		$	(25,763	)		$	(17,770	)		$	(20,742	)
	Loss per share - basic and diluted		$	(0.01	)		$	(0.15	)		$	(0.09	)		$	(0.12	)
			Quarter Ended
			December 31,				September 30,				June 30,				March 31,
	(In thousands, except per share amounts)		2013 (1)				2013 (1)				2013 (1)				2013 (1)
	Revenue		$	350,977			$	330,191			$	344,827			$	347,066
	Cost of revenue			212,778				204,644				208,545				212,638
	Gross profit			138,199				125,547				136,282				134,428
	Selling, general and administrative expenses			109,273				104,506				101,588				104,232
	Research and development			47,870				49,400				51,822				50,659
	Asset impairment charges			950				7,371		-2		2,814		-2		319
	Amortization of intangible and acquisition-related			7,651				7,722				8,379				7,501
	assets
	Loss income from operations			(27,545	)			(43,452	)			(28,321	)			(28,283	)
	Interest expense			(7,024	)			(6,895	)			(9,499	)	-4		(4,637	)
	Other (expense) income, net			(213	)			(826	)			218				8,131		-5
	Loss before income taxes			(34,782	)			(51,173	)			(37,602	)			(24,789	)
	Income tax benefit			14,164		-3		2,233		-3		14,726				13,197
	Net loss		$	(20,618	)		$	(48,940	)		$	(22,876	)		$	(11,592	)
	Loss per share - basic and diluted		$	(0.12	)		$	(0.27	)		$	(0.13	)		$	(0.07	)
	-1	Results of operations for the quarter include the results of operations of dbMotion and Jardogs for the period subsequent to the date of each acquisition, which was, in each case, March 4, 2013.
	-2	Asset impairment charges reflect non-cash charges to earnings primarily related to the impairment of previously capitalized software development and other deferred costs related to our MyWay convergence program. In addition, the quarters ended June 30, 2013 and September 30, 2013 also include the impairment of software and fixed assets related to product consolidation activities associated with the dbMotion acquisition.
	-3	Income tax benefit (provision) reflects the recognition of a valuation allowance of $5.2 million and $16.3 million for federal credit carryforwards, and foreign and state net operating loss carryforwards in the quarters ended September 30, 2014 and 2013, respectively, and a reduction of the valuation allowance of $2.7 million in the quarter ended December 31, 2013.
	-4	Interest expense includes the write-off of $3.9 million of deferred debt issuance costs associated with our prior credit facility, which was replaced in June 2013.
	-5	Other (expense) income, net includes a gain of $4.7 million resulting from the sale of our investment in Humedica, Inc., as well as a gain of $3.3 million from the remeasurement to fair value of our prior interest in dbMotion in connection with our acquisition of dbMotion.

Schedule_IIValuation_and_Quali

Schedule II-Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation And Qualifying Accounts [Abstract]
Schedule II-Valuation and Qualifying Accounts	Schedule II—Valuation and Qualifying Accounts
				Charged to
		Balance at		Expenses/		Deferred			Write-Offs,			Balance at
		Beginning of		Against		Revenue			Net of			End of
	(In thousands)	Year		Revenue		Reclassification			Recoveries			Year
	Allowance for doubtful accounts and sales
	credits
	Year ended December 31, 2014	$	54,252		9,592		(5,340	)		(22,457	)	$	36,047
	Year ended December 31, 2013	$	45,320		20,095		1,116			(12,279	)	$	54,252
	Year ended December 31, 2012	$	27,627		37,447		(7,640	)		(12,114	)	$	45,320
	In 2013, we changed our presentation of accounts receivable by reclassifying to the related allowance the deferred revenue directly associated with account balances that were deemed to be uncollectible. Prior periods were revised to conform to the current year presentation.
	All other schedules are omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” or “our” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries, unless otherwise stated.
Use of Estimates	Use of Estimates
	The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Revenue Recognition	Revenue Recognition
	Revenue represents the fair value of consideration received or receivable from clients for goods and services provided by us. Revenue from system sales includes software and related hardware. Revenue from professional services includes implementation, training and consulting services. Revenue from maintenance includes post contract client support and maintenance services. Revenue from transaction processing and other includes electronic data interchange (“EDI”) services, software-as-a-service (“SaaS”) transactions, software hosting services, and IT outsourcing. For some clients, we remotely host the software applications licensed from us using our own or third-party servers, which saves these clients the cost of procuring and maintaining hardware and related facilities. For other clients, we offer an outsourced solution in which we assume partial to total responsibility for a healthcare organization’s IT operations using our employees.
	Revenue from software licensing arrangements where the service element is not considered essential to the functionality of the other elements of the arrangement is recognized upon delivery of the software or as services are performed, provided persuasive evidence of an arrangement exists, fees are considered fixed or determinable, and collection of the receivable is probable. The revenue recognized for each separate element of a multiple-element software contract is based upon vendor-specific objective evidence of fair value, which is based upon the price the client is required to pay when the element is sold separately or renewed. For arrangements in which vendor-specific objective evidence of fair value only exists for the undelivered elements, the delivered elements (generally software licenses) are accounted for using the residual method.
	Revenue from software licensing arrangements, where the service element is considered essential to the functionality of the other elements of the arrangement, is accounted for on an input basis under percentage of completion accounting using actual hours worked as a percentage of total expected hours required by the arrangement, provided that persuasive evidence of an arrangement exists, the fee is fixed or determinable and collection of the receivable is probable. Maintenance and support from these agreements is recognized over the term of the support agreement based on vendor-specific objective evidence of fair value of the maintenance revenue, which is based upon contractual renewal rates. For income statement presentation, consideration from agreements accounted for under percentage of completion accounting is allocated between system sales and professional services based on vendor specific evidence of our hourly services rate multiplied by the amount of hours performed with the residual amount allocated to software license fee.
	Revenue from certain value-added reseller (“VAR”) relationships in which software is directly sold to VARs is recognized upon delivery of the software assuming all other revenue recognition criteria have been met. Revenue recognition is deferred until the software is delivered to the ultimate end user if the arrangement terms do not satisfy the criteria for revenue recognition upon delivery of the software to the VAR.
	Fees related to SaaS arrangements are recognized as revenue ratably over the contract terms beginning on the date our solutions are made available to clients. These arrangements include professional services fees related to the implementation and set-up of our solutions and are billed upfront and recorded as deferred revenue until our solutions are made available to the client. The implementation and set-up fees are recognized as revenue ratably over the estimated client relationship period. The estimated length of a client relationship period is based on our experience with client contract renewals and consideration of the period over which such clients use our SaaS solutions.
	Software hosting services are provided to clients that have purchased a perpetual license to our software solutions and contracted with us to host the software. These arrangements provide the client with a contractual right to take possession of the software at any time during the hosting period without significant penalty and it is feasible for the client to either use the software on its own equipment or to contract with an unrelated third party to host the software. Hosting services are not deemed to be essential to the functionality of the software or other elements of the arrangement; accordingly, for these arrangements, we recognize software license revenues as system sales revenue upon delivery, assuming all other revenue recognition criteria have been met, and separately recognize fees for the hosting services as transaction processing and other revenue over the term of the hosting arrangement.
	We also enter into multiple-element arrangements that may include a combination of various software-related and non-software-related products and services. Management applies judgment to ensure appropriate accounting for multiple deliverables, including the allocation of arrangement consideration among multiple units of accounting, the determination of whether undelivered elements are essential to the functionality of delivered elements, and the timing of revenue recognition, among others. In such arrangements, we first allocate the total arrangement consideration based on a selling price hierarchy at the inception of the arrangement. The selling price for each element is based upon the following selling price hierarchy: vendor-specific objective evidence of fair value if available, third-party evidence of fair value if vendor-specific objective evidence of fair value is not available, or estimated selling price if neither vendor-specific objective evidence nor third-party evidence of fair value is available (discussion as to how we determine vendor-specific objective evidence of fair value, third-party evidence of fair value and estimated selling price is provided below). Upon allocation of the arrangement consideration to the software elements as a whole and individual non-software elements, we then further allocate consideration within the software group to the respective elements following higher-level, industry-specific guidance and our policies described above. After the arrangement consideration has been allocated to the various elements, we account for each respective element in the arrangement as described above.
	To determine the selling price in multiple-element arrangements, we establish vendor-specific objective evidence of fair value using the price charged for a deliverable when sold separately and contractual renewal rates for maintenance fees. For non-software multiple element arrangements, third-party evidence of fair value is established by evaluating similar and interchangeable competitor products or services in standalone arrangements with similarly situated clients. If we are unable to determine the selling price because vendor-specific objective evidence or third-party evidence of fair value does not exist, we determine an estimated selling price by considering several external and internal factors including, but not limited to, pricing practices, margin objectives, competition, client demand, internal costs and overall economic trends. The determination of an estimated selling price is made through consultation with and approval by our management, taking into consideration our go-to-market strategy. As our, or our competitors’, pricing and go-to-market strategies evolve, we may modify our pricing practices in the future. These events could result in changes to our determination of vendor-specific objective evidence of fair value, third-party evidence of fair value and estimated selling price. Selling prices are analyzed on an annual basis or more frequently if we experience significant changes in our selling prices.
	For those arrangements where the deliverables do not qualify as separate units of accounting, revenue recognition is evaluated for the combined deliverables as a single unit of accounting and the recognition pattern of the final deliverable will dictate the revenue recognition pattern for the single, combined unit of accounting. Changes in circumstances and client data may result in a requirement to either separate or combine deliverables, such that a delivered item could now meet the separation criteria and qualify as a separate unit of accounting which may lead to an upward or downward adjustment to the amount of revenue recognized under the arrangement on a prospective basis.
	We assess whether fees are fixed or determinable at the time of sale and recognize revenues if all other revenue recognition requirements are met. Our payment arrangements with clients typically include milestone-based software license fee payments and payments based upon delivery for services and hardware.
	While most of our arrangements include short-term payment terms, we periodically provide extended payment terms to clients from the date of contract signing. We do not recognize revenue under extended payment term arrangements until such payments become due. In certain circumstances, where all other revenue recognition criteria have been met, we occasionally offer discounts to clients with extended payment terms to accelerate the timing of when payments are made. Changes to extended payment term arrangements have not had a material impact on our consolidated results of operations.
	Maintenance fees are recognized ratably over the period of the contract based on vendor specific objective evidence of fair value based upon contractual renewal rates. Revenue from EDI services is recognized as services are provided and is determined based on the volume of transactions processed.
	We provide IT outsourcing services to our clients under arrangements that typically range from five to ten years in duration. Under these arrangements we assume full, partial or transitional responsibilities for a healthcare organization’s IT operations using our employees. Our outsourcing services include facilities management, network outsourcing and transition management. Revenue from these arrangements is recognized as services are performed.
	Revenue is recognized net of any taxes collected from clients and subsequently remitted to governmental authorities. We record as revenue any amounts billed to clients for shipping and handling costs and record as cost of revenue the actual shipping costs incurred.
	We record reimbursements for out-of-pocket expenses incurred as professional services revenue in our consolidated statements of operations. These amounts totaled:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Reimbursements for out-of-pocket expenses incurred as professional services	$	16,251			$	18,445			$	22,656
	revenue
	The following table summarizes revenue earned on contracts in excess of billings, both the current and non-current portions, which is included in the balance of accounts receivable and other assets, respectively. Billings are expected to occur according to the contract terms.
		December 31,
	(In thousands)	2014				2013
	Revenue earned on contracts in excess of billings
	Unbilled revenue (current)	$	42,818			$	37,271
	Unbilled revenue (long-term)		618				1,294
	Total revenue earned on contracts in excess of billings	$	43,436			$	38,565
Fair Value Measurements	Fair Value Measurements
	Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories:
	Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Our Level 1 investments include money market funds valued daily by the fund companies, and the valuation is based on the publicly reported net asset value of each fund. There were no outstanding money market funds investments as of December 31, 2014.
	Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar instruments in active markets, and inputs other than quoted prices that are observable for the asset or liability. Our Level 2 non-derivative investments include marketable securities, which consist of mortgage and asset-backed bonds. Marketable securities are recorded at fair value determined using a market approach, based on prices and other relevant information generated by market transactions involving identical or comparable assets which are considered to be Level 2 inputs. Our Level 2 derivative financial instrument was an interest rate swap contract which expired in October 2014. Prior to expiration, the interest rate swap contract was valued based upon observable values for underlying interest rates and market determined risk premiums.
	Level 3: Inputs are unobservable for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option (as defined in Note 11, “Derivative Financial Instruments”) asset and the embedded conversion option liability. Refer to Note 6, “Debt,” and Note 11, “Derivative Financial Instruments,” for further information regarding our derivative financial instruments. These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine the fair value as of December 31, 2014 and 2013 included our common stock price, time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The 1.25% Call Option asset and the embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is substantially mitigated.
	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
		Balance Sheet		31-Dec-14														31-Dec-13
	(In thousands)	Classifications		Level 1				Level 2				Level 3			Total			Level 1		Level 2			Level 3			Total
	Money market	Cash		$	0			$	0			$	0		$	0		$	3,634	$	0		$	0		$	3,634
	funds	equivalents
	Marketable	Long-term marketable			0				1,305				0			1,305			0		1,329			0			1,329
	securities	securities
	1.25% Call	Other assets			0				0				57,091			57,091			0		0			104,656			104,656
	Option
	Cash conversion	Other liabilities			0				0				(57,839	)		(57,839	)		0		0			(105,637	)		(105,637	)
	option
	Interest rate	Other liabilities			0				0				0			0			0		(458	)		0			(458	)
	swap
	Total			$	0			$	1,305			$	(748	)	$	557		$	3,634	$	871		$	(981	)	$	3,524
	During 2014, we acquired certain non-marketable equity securities of four third parties and entered into new, or amended existing, commercial agreements with each of those third parties to license and distribute their products and services, for total consideration of approximately $21.1 million. The equity investments and the commercial agreements were valued at approximately $19.2 million and $1.9 million, respectively. Three of the equity investments acquired during 2014 are accounted for under the cost method, and one is accounted for under the equity method. The carrying values of the cost method investments and the equity method investment of approximately $17.8 million and $1.0 million, respectively, are included in other assets and the carrying value of the above-referenced commercial agreements is included in intangible assets, net, in the accompanying consolidated balance sheet as of December 31, 2014. As of December 31, 2013, our outstanding investments in non-marketable equity securities were not material.
	Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as defined below), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of the 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of December 31, 2014, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 6, “Debt,” for further information regarding our long-term financial liabilities.
Financial Instruments	Financial Instruments
	We consider all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. The fair values of these investments approximate their carrying values.
	Other investments classified as long-term marketable securities include certain debt instruments. Debt securities are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Realized and unrealized gains and losses for all periods presented are immaterial. Changes in market value, excluding other-than-temporary impairments, are reflected in other comprehensive income. There were no other-than-temporary impairments for the years ended December 31, 2014, 2013 and 2012.
	Derivative instruments are recognized as either assets or liabilities and are measured at fair value. The accounting for changes in the fair value of a derivative depends on the intended use of the derivative and the resulting designation.
	For derivative instruments designated as cash-flow hedges, the effective portion of the derivative’s gain (loss) is initially reported as a component of other comprehensive income and is subsequently recognized in earnings when the hedged exposure is recognized in earnings. Gains (losses) on derivatives representing either hedge components excluded from the assessment of effectiveness or hedge ineffectiveness are recognized in earnings. See Note 11, “Derivative Financial Instruments,” for information regarding gains and losses from derivative instruments during the years ended December 31, 2014, 2013 and 2012.
Allowance for Doubtful Accounts Receivable	Allowance for Doubtful Accounts Receivable
	Accounts receivable are recorded at the invoiced amounts and do not bear interest. An allowance for doubtful accounts is recorded to provide for estimated losses resulting from uncollectible accounts, and is based principally on specifically identified amounts where collection is deemed doubtful. Additional non-specific allowances are recorded based on historical experience and management’s assessment of a variety of factors related to the general financial condition of our clients, the industry in which we operate and general economic conditions. We review the collectability of individual accounts and assess the adequacy of the allowance for doubtful accounts. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. If the financial condition of our clients were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances and related bad debt expense may be required.
Contingent Liabilities	Contingent Liabilities
	A liability is contingent if the amount is not presently known, but may become known in the future as a result of the occurrence of some uncertain future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.
	The assessment of contingent liabilities, including legal and income tax contingencies, involves the use of estimates, assumptions and judgments. Our estimates are based on our belief that future events will validate the current assumptions regarding the ultimate outcome of these exposures. However, there can be no assurance that future events, such as court decisions or Internal Revenue Service (“IRS”) positions, will not differ from our assessments.
Fixed Assets	Fixed Assets
	Fixed assets are stated at cost. Depreciation and amortization is computed on the straight-line method over the estimated useful lives of the related assets. The depreciable life of leasehold improvements is the shorter of the lease term or the useful life. Upon asset retirement or other disposition, the fixed asset cost and the related accumulated depreciation or amortization are removed from the accounts, and any gain or loss is included in the consolidated statements of operations. Amounts incurred for repairs and maintenance are expensed as incurred.
Business Combinations	Business Combinations
	Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value the assets acquired, including intangible assets, and the liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the fair values of the assets acquired and the liabilities assumed, with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or the liabilities assumed, whichever comes first, any subsequent adjustments are reflected in our consolidated results of operations.
Goodwill and Intangible Assets	Goodwill and Intangible Assets
	Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized but are tested for impairment annually or between annual tests when an impairment indicator exists. If an optional qualitative goodwill impairment assessment is not performed, we are required to determine the fair value of each reporting unit. If a reporting unit’s fair value is lower than its carrying value, we must determine the amount of implied goodwill that would be established if the reporting unit was hypothetically acquired on the impairment test date. If the carrying amount of a reporting unit’s goodwill exceeds the amount of implied goodwill, an impairment loss equal to the excess would be recorded. The recoverability of indefinite-lived intangible assets is assessed by comparison of the carrying value of the asset to its estimated fair value. If we determine that the carrying value of the asset exceeds its estimated fair value, an impairment loss equal to the excess would be recorded.
	The determination of fair value of our reporting units is based on a combination of a market approach that considers benchmark company market multiples and an income approach that uses discounted cash flows for each reporting unit utilizing Level 3 inputs. Under the income approach, we determine fair value based on the present value of the most recent income projections for each reporting unit as of the date of the analysis and calculate a terminal value utilizing a terminal growth rate. The significant assumptions under this approach include, among others: income projections, which are dependent on sales to new and existing clients, new product introductions, client behavior, competitor pricing, operating expenses, the discount rate, and the terminal growth rate. The cash flows used to determine fair value are dependent on a number of significant management assumptions based on our historical experience, our expectations of future performance, and the expected economic environment. Our estimates are subject to change given the inherent uncertainty in predicting future results. Additionally, the discount rate and the terminal growth rate are based on our judgment of the rates that would be utilized by a hypothetical market participant. We also consider our market capitalization in assessing the reasonableness of the fair values estimated for our reporting units as part of our goodwill impairment testing.
	Accounting guidance also requires that definite-lived intangible assets be amortized over their respective estimated useful lives and reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We estimate the useful lives of our intangible assets and ratably amortize the value over the estimated useful lives of those assets. If the estimates of the useful lives should change, we will amortize the remaining book value over the remaining useful lives or, if an asset is deemed to be impaired, a write-down of the value of the asset may be required at such time.
Long-Lived Assets and Long-Lived Assets to Be Disposed Of	Long-Lived Assets and Long-Lived Assets to Be Disposed Of
	We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.
Software Development Costs	Software Development Costs
	We capitalize purchased software that is ready for service and software development costs incurred from the time technological feasibility of the software is established, or when the preliminary project phase is completed in the case of internal use software, until the software is available for general release. Research and development costs and other computer software maintenance costs related to software development are expensed as incurred. We estimate the useful life of our capitalized software and amortize its value over that estimated life. If the actual useful life is shorter than our estimated useful life, we will amortize the remaining book value over the remaining useful life or the asset may be deemed to be impaired and, accordingly, a write-down of the value of the asset may be recorded as a charge to earnings. Upon the availability for general release, we commence amortization of the capitalized software costs on a product by product basis. Amortization of capitalized software is recorded using the greater of (i) the ratio of current revenues to total and anticipated future revenues for the applicable product or (ii) the straight-line method over the remaining estimated economic life, which is estimated to be three to five years.
	At each balance sheet date, the unamortized capitalized costs of a software product are compared with the net realizable value of that product. The net realizable value is the estimated future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the costs of performing maintenance and client support required to satisfy our responsibility set forth at the time of sale. The amount by which the unamortized capitalized costs of a software product exceed the net realizable value of that asset is written off. If we determine in the future that the value of the capitalized software could not be recovered, a write-down of the value of the capitalized software to its recoverable value may be recorded as a charge to earnings.
	The unamortized balances of capitalized software were as follows:
		December 31,
	(In thousands)	2014				2013
	Software development costs	$	213,601			$	170,486
	Less: accumulated amortization		(127,448	)			(82,242	)
	Software development costs, net	$	86,153			$	88,244
	Capitalized software development costs, write-offs and amortization of capitalized software development costs included in system sales cost of revenue and asset impairment charges were as follows:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Capitalized software development costs	$	45,461			$	42,026			$	42,965
	Write-offs of capitalized software development costs	$	1,444			$	5,234			$	8,699
	Amortization of capitalized software development costs	$	46,108			$	44,127			$	37,065
Income Taxes	Income Taxes
	We account for income taxes using the liability method, which requires the recognition of deferred tax assets or liabilities for the tax-effected temporary differences between the financial reporting and tax bases of our assets and liabilities and for net operating loss and tax credit carryforwards. The objectives of accounting for income taxes are to recognize the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. Judgment is required in addressing the future tax consequences of events that have been recognized in our consolidated financial statements or tax returns. The deferred tax assets are recorded net of a valuation allowance when, based on the weight of available evidence, we believe it is more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience, expectations of future taxable income, the ability to carryback losses and other relevant factors.
	In addition, we are subject to the continuous examination of our income tax returns by the Internal Revenue Service and other tax authorities. A change in the assessment of the outcomes of such matters could materially impact our consolidated financial statements.
	The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for anticipated tax audit issues based on our estimate of whether, and the extent to which, additional taxes may be required. If we ultimately determine that payment of these amounts is unnecessary, then we reverse the liability and recognize a tax benefit during the period in which we determine that the liability is no longer necessary. We also recognize tax benefits to the extent that it is more likely than not that our positions will be sustained if challenged by the taxing authorities. To the extent we prevail in matters for which liabilities have been established, or are required to pay amounts in excess of our liabilities, our effective tax rate in a given period may be materially affected. An unfavorable tax settlement would require cash payments and may result in an increase in our effective tax rate in the year of resolution. A favorable tax settlement would be recognized as a reduction in our effective tax rate in the year of resolution. We report interest and penalties related to uncertain income tax positions in the income tax benefit (provision) line of our consolidated statements of operations.
	We file income tax returns in the U.S. federal jurisdiction, numerous states in the U.S. and multiple countries outside of the U.S.
Earnings (Loss) Per Share	Earnings (Loss) Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.
	The calculations of earnings (loss) per share are as follows:
		Year Ended December 31,
	(In thousands, except per share amounts)	2014				2013				2012
	Basic Loss per Common Share:
	Net loss	$	(66,453	)		$	(104,026	)		$	(1,153	)
	Net loss available to common stockholders	$	(66,453	)		$	(104,026	)		$	(1,153	)
	Weighted-average common shares outstanding		179,849				177,026				178,699
	Basic Loss per Common Share	$	(0.37	)		$	(0.59	)		$	(0.01	)
	Diluted Loss per Common Share:
	Net loss	$	(66,453	)		$	(104,026	)		$	(1,153	)
	Net loss available to common stockholders	$	(66,453	)		$	(104,026	)		$	(1,153	)
	Weighted-average common shares outstanding		179,849				177,026				178,699
	Dilutive effect of stock options, restricted stock unit awards and warrants		0				0				0
	Weighted-average common shares outstanding assuming dilution		179,849				177,026				178,699
	Diluted Loss per Common Share	$	(0.37	)		$	(0.59	)		$	(0.01	)
	As a result of our net loss available to common stockholders for the years ended December 31, 2014, 2013 and 2012, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for each of these years, since the inclusion of any stock equivalents would be anti-dilutive.
	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted (loss) earnings per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Shares subject to anti-dilutive stock options, restricted stock unit awards and		24,254				14,926				2,878
	warrants excluded from calculation
Stock-Based Compensation	Stock-Based Compensation
	We account for stock-based compensation in accordance with GAAP, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and non-employee directors based on their estimated fair value. We measure stock-based compensation cost at the grant date based on the fair value of the award and recognize the expense over the appropriate service period typically on a straight-line basis, net of estimated forfeitures. We recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at their underlying closing share price on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. The net proceeds from stock-based compensation activities are reflected as a financing activity within the accompanying consolidated statements of cash flows. We settle employee stock option exercises and stock awards with newly issued common shares.
Employee Benefit Plans	Employee Benefit Plans
	We provide employees with defined contribution savings plans.
	We recognize expense for our contributions to the savings plans at the time employees make contributions to the plans and we contributed the following amounts to these plans:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Company contributions to employee benefit plans	$	16,427			$	15,276			$	13,776
Foreign Currency	Foreign Currency
	The determination of the functional currency is made based on the appropriate economic and management indicators. Our foreign subsidiaries use the local currency of their respective countries as the functional currency, with the exception of our subsidiaries in India and Israel which use the U.S. dollar as a functional currency. The assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars at the exchange rates in effect at the consolidated balance sheet date, while revenues and expenses are translated at the average rates of exchange during the year. Translation gains and losses are not included in determining net income or loss but are included as a separate component of accumulated other comprehensive loss. Gains and losses resulting from foreign currency transactions are included in determining net income or loss and have not been material in any years presented in the accompanying consolidated statements of operations. We have not entered into any foreign currency hedging contracts during the years ended December 31, 2014, 2013 and 2012.
Concentrations of Credit Risk	Concentrations of Credit Risk
	Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and trade receivables. We primarily maintain our cash balances with one major commercial bank domestically and several commercial banks internationally. Our cash equivalents and marketable securities are comprised of interest-bearing, investment-grade securities.
	We sell our products and services to healthcare providers. Credit risk with respect to trade receivables is generally diversified due to the large number of clients and their geographic dispersion. To reduce credit risk, we perform ongoing credit evaluations of significant clients and their payment histories. In general, we do not require collateral from our clients, but we do enter into advance deposit, if appropriate.
	The majority of revenue is derived from clients located in the U.S. The majority of long-lived assets are located in the U.S. No single client accounted for more than 10% of our revenue in the years ended December 31, 2014, 2013 and 2012. No client represented more than 10% of accounts receivable as of December 31, 2014 or 2013.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued updated authoritative guidance to resolve the diversity in practice about whether FASB Account Standards Codification (“ASC”) Subtopic 810-10, Consolidation—Overall, or ASC Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, this guidance resolves the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. This guidance is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013 and we adopted the new guidance in the first quarter of 2014. The adoption of this accounting guidance had no impact on our consolidated results.
	In July 2013, the FASB issued Accounting Standards Update No. 2013-011, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-011”). ASU 2013-011 provides specific guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date and states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and we adopted the new guidance prospectively in the first quarter of 2014. The adoption of this accounting guidance resulted in the reclassification, for presentation purposes only, of approximately $4 million from other liabilities to deferred tax assets in our consolidated balance sheet as of December 31, 2014.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASU 2014-09”), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new standard permits the use of either the retrospective or cumulative effect transition methods. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently in the process of evaluating this new guidance.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting of a share-based award, and that could be achieved after the requisite service period, be treated as a performance condition. ASU 2014-12 is effective for reporting periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. In addition, entities will have the option of applying the guidance either prospectively (i.e. only to awards granted or modified on or after the effective date of ASU 2014-12) or retrospectively. We are currently evaluating the impact of this accounting guidance, but do not expect it to have any material impact on our consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which requires management of an entity to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about such entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable), and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the impact of this accounting guidance, but do not expect it to have any material impact on our consolidated financial statements.
	We do not believe that any other recently issued, but not yet effective accounting standards, if currently adopted, would have a material impact on our consolidated financial statements.

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Reimbursements for Out-of-Pocket Expenses Incurred as Professional Services Revenue	We record reimbursements for out-of-pocket expenses incurred as professional services revenue in our consolidated statements of operations. These amounts totaled:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Reimbursements for out-of-pocket expenses incurred as professional services	$	16,251			$	18,445			$	22,656
	revenue
Revenue Earned on Contracts in Excess of Billings Included in Accounts Receivable and Other Assets	The following table summarizes revenue earned on contracts in excess of billings, both the current and non-current portions, which is included in the balance of accounts receivable and other assets, respectively. Billings are expected to occur according to the contract terms.
		December 31,
	(In thousands)	2014				2013
	Revenue earned on contracts in excess of billings
	Unbilled revenue (current)	$	42,818			$	37,271
	Unbilled revenue (long-term)		618				1,294
	Total revenue earned on contracts in excess of billings	$	43,436			$	38,565
Summary of Financial Assets and Liabilities Measured at Fair value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
		Balance Sheet		31-Dec-14														31-Dec-13
	(In thousands)	Classifications		Level 1				Level 2				Level 3			Total			Level 1		Level 2			Level 3			Total
	Money market	Cash		$	0			$	0			$	0		$	0		$	3,634	$	0		$	0		$	3,634
	funds	equivalents
	Marketable	Long-term marketable			0				1,305				0			1,305			0		1,329			0			1,329
	securities	securities
	1.25% Call	Other assets			0				0				57,091			57,091			0		0			104,656			104,656
	Option
	Cash conversion	Other liabilities			0				0				(57,839	)		(57,839	)		0		0			(105,637	)		(105,637	)
	option
	Interest rate	Other liabilities			0				0				0			0			0		(458	)		0			(458	)
	swap
	Total			$	0			$	1,305			$	(748	)	$	557		$	3,634	$	871		$	(981	)	$	3,524
Unamortized Balances of Capitalized Software	The unamortized balances of capitalized software were as follows:
		December 31,
	(In thousands)	2014				2013
	Software development costs	$	213,601			$	170,486
	Less: accumulated amortization		(127,448	)			(82,242	)
	Software development costs, net	$	86,153			$	88,244
Capitalized Software Development Costs, Write Offs and Amortization of Capitalized Software Development Costs Included in System Sales Cost of Revenue	Capitalized software development costs, write-offs and amortization of capitalized software development costs included in system sales cost of revenue and asset impairment charges were as follows:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Capitalized software development costs	$	45,461			$	42,026			$	42,965
	Write-offs of capitalized software development costs	$	1,444			$	5,234			$	8,699
	Amortization of capitalized software development costs	$	46,108			$	44,127			$	37,065
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows:
		Year Ended December 31,
	(In thousands, except per share amounts)	2014				2013				2012
	Basic Loss per Common Share:
	Net loss	$	(66,453	)		$	(104,026	)		$	(1,153	)
	Net loss available to common stockholders	$	(66,453	)		$	(104,026	)		$	(1,153	)
	Weighted-average common shares outstanding		179,849				177,026				178,699
	Basic Loss per Common Share	$	(0.37	)		$	(0.59	)		$	(0.01	)
	Diluted Loss per Common Share:
	Net loss	$	(66,453	)		$	(104,026	)		$	(1,153	)
	Net loss available to common stockholders	$	(66,453	)		$	(104,026	)		$	(1,153	)
	Weighted-average common shares outstanding		179,849				177,026				178,699
	Dilutive effect of stock options, restricted stock unit awards and warrants		0				0				0
	Weighted-average common shares outstanding assuming dilution		179,849				177,026				178,699
	Diluted Loss per Common Share	$	(0.37	)		$	(0.59	)		$	(0.01	)
Anti-Dilutive Stock Options and Share Awards Excluded from Computation of Diluted Earnings Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted (loss) earnings per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Shares subject to anti-dilutive stock options, restricted stock unit awards and		24,254				14,926				2,878
	warrants excluded from calculation
Company Contributions to Employee Benefit Plan	We recognize expense for our contributions to the savings plans at the time employees make contributions to the plans and we contributed the following amounts to these plans:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Company contributions to employee benefit plans	$	16,427			$	15,276			$	13,776

Business_Combinations_Tables

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Final Fair Value of Consideration Transferred for Acquisition	The total fair value of consideration transferred for the acquisition is comprised of the following:
		(In thousands)
	Cash	$	140,079
	Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing		48,061
	$12.57 per share
	Deferred cash consideration payable on the 18-month anniversary of the closing		23,023
	Subordinated promissory note maturing 18 months following the closing		6,648
	Fair value of Allscripts' previous interest in dbMotion		8,367
	Total fair value of consideration transferred	$	226,178
Assets Acquired and Liabilities Assumed	The allocation of the fair value of the consideration transferred, including all measurement period adjustments, is as follows:
		(In thousands)
	Acquired cash and cash equivalents, and restricted cash	$	14,188
	Accounts receivable, net		3,226
	Prepaid expenses and other current assets		574
	Fixed assets and other long-term assets		1,449
	Goodwill		137,649
	Intangible assets		85,450
	Accounts payable and accrued liabilities		(10,560	)
	Deferred taxes, net		(36	)
	Deferred revenue		(5,100	)
	Other liabilities		(662	)
	Net assets acquired	$	226,178
Acquired Intangible Assets Amortization	The acquired intangible assets are being amortized on a straight-line basis over their useful lives and consist of the following amounts for each class of acquired intangible asset:
	(Dollar amounts in thousands)	Useful Life
	Description	in Years		Fair Value
	Core technology	10		$	80,100
	Maintenance agreements	12			2,500
	Services backlog	2			2,000
	Non-compete	3			500
	Trade name	2			350
				$	85,450
Proforma Results	The revenue and net loss of dbMotion since March 4, 2013 included in our consolidated statement of operations for the year ended December 31, 2013, and the unaudited supplemental pro forma revenue and net loss of the combined entity, are as follows:
		Year ended December 31,
	(In thousands, except per share amounts)	2013				2012
		(Unaudited)				(Unaudited)
	Actual from dbMotion since acquisition date of March 4, 2013:
	Revenue	$	18,609			$	0
	Net loss	$	(16,272	)		$	0
	Supplemental pro forma data for combined entity:
	Revenue	$	1,378,267			$	1,448,316
	Net loss	$	(105,119	)		$	(35,158	)
	Net loss per share, basic and diluted	$	(0.59	)		$	(0.19	)

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Fixed Assets	Fixed assets consist of the following:
		Estimated		December 31,				December 31,
	(Dollar amounts in thousands)	Useful Life		2014				2013
	Computer equipment and software	3 to 10 years		$	284,185			$	287,063
	Facility furniture, fixtures and equipment	5 to 7 years			19,846				24,700
	Leasehold improvements	7 to 8 years, or life of lease if shorter			30,795				30,816
	Assets under capital lease	3 to 5 years			2,873				9,419
	Fixed assets, gross				337,699				351,998
	Less: Accumulated depreciation and amortization				(191,869	)			(177,985	)
	Fixed assets, net			$	145,830			$	174,013
Depreciation and Amortization Expense
	Fixed assets depreciation and amortization expense were as follows:
		Year Ended December 31,
	(In thousands)	2014				2013				2012
	Fixed assets depreciation and amortization expense	$	48,465			$	52,545			$	43,126

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following:
		31-Dec-14								31-Dec-13
		Gross								Gross
		Carrying			Accumulated			Intangible		Carrying			Accumulated			Intangible
	(In thousands)	Amount			Amortization			Assets, Net		Amount			Amortization			Assets, Net
	Intangibles subject to amortization:
	Proprietary technology	$	451,087		$	(267,547	)	$	183,540	$	445,960		$	(231,634	)	$	214,326
	Customer contracts and relationships		550,287			(382,465	)		167,822		542,205			(352,560	)		189,645
	Total	$	1,001,374		$	(650,012	)	$	351,362	$	988,165		$	(584,194	)	$	403,971
	Intangibles not subject to amortization:
	Registered trademarks							$	52,000							$	52,000
	Goodwill								1,200,746								1,189,585
	Total							$	1,252,746							$	1,241,585
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the years ended December 31, 2014 and 2013 were as follows:
		Clinical and			Population			Managed
	(In thousands)	Financial Solutions			Health			Services		Total
	Balance as of December 31, 2012	$	629,195		$	271,569		$	138,600	$	1,039,364
	Additions arising from business acquisitions:
	dbMotion		0			136,631			0		136,631
	Jardogs		0			17,016			0		17,016
	Total additions to goodwill		0			153,647			0		153,647
	Other adjustments to goodwill		(3,426	)		0			0		(3,426	)
	Balance as of December 31, 2013	$	625,769		$	425,216		$	138,600	$	1,189,585
	Additions arising from business acquisitions:
	Oasis		11,155			0			0		11,155
	dbMotion		0			1,018			0		1,018
	Total additions to goodwill		11,155			1,018			0		12,173
	Foreign exchange translation		(1,012	)		0			0		(1,012	)
	Balance as of December 31, 2014	$	635,912		$	426,234		$	138,600	$	1,200,746
Amortization Expense Related to Intangible Assets	Intangible assets are being amortized over their estimated useful lives and amortization expense related to intangible assets was as follows:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Proprietary technology amortization included in cost of revenue, system sales	$	35,924		$	33,970		$	27,226
	Intangible amortization included in operating expenses		31,280			31,253			35,635
	Total intangible amortization expense	$	67,204		$	65,223		$	62,861
Estimated Future Amortization Expense for Intangible Assets	Estimated future amortization expense for the intangible assets that exist as of December 31, 2014, based on foreign currency exchange rates in effect as of such date, is as follows:
	Year Ended December 31,	(In thousands)
	2015	$	57,996
	2016		45,534
	2017		40,459
	2018		33,800
	2019		33,483
	Thereafter		140,090
	Total	$	351,362

Asset_Impairment_Charges_Table

Asset Impairment Charges (Tables)	12 Months Ended
	Dec. 31, 2014
Asset Impairment Charges [Abstract]
Asset Impairment Charges		Year Ended December 31,
	(In thousands)	2014		2013		2012
	Asset impairment charges	$	2,390	$	11,454	$	11,101

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Outstanding Excluding Capital Lease Obligations	Debt outstanding, excluding capital lease obligations, consisted of the following:
			31-Dec-14						31-Dec-13
			Principal		Unamortized		Net Carrying		Principal		Unamortized		Net Carrying
	(In thousands)		Balance		Discount		Amount		Balance		Discount		Amount
	1.25% Cash Convertible Senior Notes		$	345,000	$	67,276	$	277,724	$	345,000	$	77,529	$	267,471
	Senior Secured Credit Facility (long-term			272,410		1,452		270,958		280,000		2,338		277,662
	portion)
	Senior Secured Credit Facility (current			28,125		886		27,239		16,875		982		15,893
	portion)
	Total debt		$	645,535	$	69,614	$	575,921	$	641,875	$	80,849	$	561,026
Interest Expense
	Interest expense consisted of the following:
			Year Ended December 31,
	(In thousands)		2014		2013		2012
	Interest expense		$	16,020	$	14,703	$	11,121
	Amortization of discounts			11,236		5,784		0
	Amortization of debt issuance costs			2,041		3,667		5,066
	Write off of unamortized deferred debt issuance costs			0		3,901		0
	Total interest expense		$	29,297	$	28,055	$	16,187
Interest Expense Related to Notes	Interest expense related to the 1.25% Notes was comprised of the following:
			Year Ended December 31,
	(In thousands)		2014		2013		2012
	Coupon interest at 1.25%		$	4,312	$	2,312	$	0
	Amortization of original issuance discount			10,253		5,271		0
	Amortization of debt issuance costs			1,180		639		0
	Total interest expense related to the 1.25% Notes		$	15,745	$	8,222	$	0
Summary of Future Payments under Notes and Senior Secured Credit Facilities	The following table summarizes our future payments under the 1.25% Notes and the Senior Secured Credit Facility as of December 31, 2014:
	(In thousands)		Total		2015		2016		2017		2018		2019		Thereafter
	1.25% Cash Convertible Senior		$	345,000	$	0	$	0	$	0	$	0	$	0	$	345,000
	Notes (1)
	Senior Secured Term Loan			202,500		28,125		39,375		50,625		84,375		0		0
	Senior Secured Revolving Facility			98,035		0		0		0		98,035		0		0
	Total debt		$	645,535	$	28,125	$	39,375	$	50,625	$	182,410	$	0	$	345,000
	-1	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Geographic Breakdown of (Loss) Income Before Income Tax Benefits	The following is a geographic breakdown of (loss) income before income tax benefits:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	United States	$	(62,987	)	$	(137,468	)	$	(36,933	)
	Foreign		(5,130	)		(10,878	)		19,473
	Total loss before income taxes	$	(68,117	)	$	(148,346	)	$	(17,460	)
Components of Provision (Benefit) for Income Taxes	The following is a summary of the components of the provision (benefit) for income taxes:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Current tax provision
	Federal	$	840		$	(448	)	$	1,610
	State		213			1,421			3,793
	Foreign		(399	)		45			5,184
			654			1,018			10,587
	Deferred tax provision
	Federal		(581	)		(43,542	)		(24,196	)
	State		(3,261	)		(7,929	)		(2,473	)
	Foreign		1,524			6,133			(225	)
			(2,318	)		(45,338	)		(26,894	)
	Income tax benefit	$	(1,664	)	$	(44,320	)	$	(16,307	)
Taxes Computed at Statutory Federal Income Tax Rate Reconciled to Provision for Income Taxes	Taxes computed at the statutory federal income tax rate of 35% are reconciled to the provision for income taxes as follows:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	United States federal tax at statutory rate		35	%		35	%		35	%
	Items affecting federal income tax rate
	Non-deductible acquisition and reorganization expenses		0.1	%		(0.2	%)		0	%
	Research credits		4.6	%		5	%		14.5	%
	Change in unrecognized tax benefits		0.8	%		(1.1	%)		(6.6	%)
	State income taxes, net of federal benefit		3.1	%		3.3	%		5.8	%
	Compensation		(1.5	%)		(0.6	%)		(3.9	%)
	Meals and entertainment		(1.4	%)		(0.7	%)		(6.1	%)
	Impact of foreign operations		(3.7	%)		(1.1	%)		10.7	%
	Federal, state and local rate changes		0.4	%		0.7	%		(11.3	%)
	Change in unrecognized tax benefit, Coniston		0	%		0	%		91.4	%
	Indemnification asset settlement, Coniston		0	%		0	%		(28.2	%)
	Change in unrecognized tax benefits, Bilateral Advance Pricing Agreement		0	%		3	%		0	%
	Bilateral Advance Pricing Agreement impact		0.3	%		(3.2	%)		0	%
	Non-deductible items		(0.1	%)		(0.1	%)		(0.5	%)
	Valuation allowance		(36.2	%)		(9.2	%)		(4.0	%)
	True-up of capitalized software deferred tax		0	%		0	%		(2.3	%)
	Other		1.1	%		(0.9	%)		(1.1	%)
	Effective rate		2.5	%		29.9	%		93.4	%
Components of Deferred Tax Assets and Liabilities	Significant components of our deferred tax assets and liabilities consist of the following:
		December 31,			December 31,
	(In thousands)	2014			2013
	Deferred tax assets
	Accruals and reserves, net	$	26,086		$	28,210
	Allowance for doubtful accounts		14,159			21,242
	Stock-based compensation, net		10,773			7,498
	Deferred revenue		17,422			12,636
	Net operating loss carryforwards		90,463			90,964
	Research and development tax credit		24,313			21,580
	AMT credits		5,606			5,250
	Other		3,617			4,962
	Less:  Valuation Allowance		(41,273	)		(14,241	)
	Total deferred tax assets		151,166			178,101
	Deferred tax liabilities
	Prepaid expense		(9,268	)		(11,395	)
	Property and equipment, net		(903	)		(852	)
	Acquired intangibles, net		(160,130	)		(182,719	)
	Total deferred tax liabilities		(170,301	)		(194,966	)
	Net deferred tax liabilities	$	(19,135	)	$	(16,865	)
Deferred Tax Assets (Liabilities) Classified in Consolidated Balance Sheets	The deferred tax assets (liabilities) are classified in the consolidated balance sheets as follows:
		December 31,			December 31,
	(In thousands)	2014			2013
	Current deferred tax assets, net	$	35,615		$	55,468
	Current deferred tax liabilities, net		(21	)		0
	Current deferred tax assets (liabilities), net		35,594			55,468
	Non-current deferred tax assets, net		708			7,361
	Non-current deferred tax liabilities, net		(55,437	)		(79,694	)
	Non-current deferred tax assets (liabilities), net		(54,729	)		(72,333	)
	Net deferred tax liabilities	$	(19,135	)	$	(16,865	)
Reconciliation of Unrecognized Tax Benefits	The following table reconciles unrecognized tax benefits:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Beginning balance as of January 1	$	18,283		$	18,140		$	43,284
	Increases for tax positions related to the current year		627			1,517			46
	Decreases for tax positions related to prior years		(3,239	)		(23	)		(13,944	)
	Increases for tax positions related to prior years		173			3,238			656
	Decreases relating to settlements with taxing authorities		(384	)		(4,099	)		(11,925	)
	Foreign currency translation		(26	)		(394	)		97
	Reductions due to lapsed statute of limitations		(120	)		(96	)		(74	)
	Ending balance as of December 31	$	15,314		$	18,283		$	18,140
Recognized Interest and Penalties Related to Uncertain Tax Positions
	We recognized interest and penalties related to uncertain tax positions in our consolidated statements of operations as follows:
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Interest and penalties included in the provision for income taxes	$	(715	)	$	(188	)	$	(2,539	)
Amount of Interest and Penalties Included in Consolidated Balance Sheets	The amount of interest and penalties included in our consolidated balance sheets is as follows:
		December 31,			December 31,
	(In thousands)	2014			2013
	Interest and penalties included in the liability for uncertain tax positions	$	1,295		$	2,011

Stock_Award_Plans_Tables

Stock Award Plans (Tables)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-Based Compensation Expense	We recorded stock-based compensation expense as follows:
		Year Ended December 31,
	(In thousands)	2014			2013		2012
	Cost of revenue:
	Professional services	$	2,679		$	2,598	$	2,437
	Maintenance		1,264			1,430		1,579
	Transaction processing and other		1,971			1,616		1,913
	Total cost of revenue		5,914			5,644		5,929
	Selling, general and administrative expenses		25,376			23,013		25,869
	Research and development		7,964			8,353		7,328
	Total stock-based compensation expense	$	39,254		$	37,010	$	39,126
Stock Options Outstanding	The following table summarizes the status of stock options outstanding and the changes during the periods presented:
		Options			Weighted-Average		Options		Weighted-Average
	(In thousands, except per share amounts)	Outstanding			Exercise Price		Exercisable		Exercise Price
	Balance as of December 31, 2011		3,976		$	10.31		3,499	$	9.87
	Options exercised		(1,138	)	$	5.32
	Options forfeited		(171	)	$	16.62
	Balance as of December 31, 2012		2,667		$	12.04		2,548	$	11.88
	Options granted		3,870		$	13.79
	Options exercised		(1,442	)	$	8.47
	Options forfeited		(773	)	$	14.94
	Balance as of December 31, 2013		4,322		$	14.28		1,025	$	15.52
	Options granted		0		$	0
	Options exercised		(289	)	$	11.88
	Options forfeited		(606	)	$	15.03
	Balance as of December 31, 2014		3,427		$	14.35		1,393	$	14.97
Weighted Average Grant Date Fair Value Information and Related Valuation Assumptions	The following table contains the stock option weighted-average grant date fair value information and related valuation assumptions for the year ended December 31, 2013. No stock option awards were granted for the years ended December 31, 2014 and 2012.
	Stock options granted (in thousands)		3,870
	Fair Value per option	$	6.25
	Valuation assumptions:
	Expected term ( in years)		4.8
	Expected volatility		54	%
	Expected dividend yield		0	%
	Risk-free interest rate		0.9	%
Stock Option Activity	The following activity occurred under our plans:
		Year Ended December 31,
	(In thousands)	2014			2013		2012
	Total intrinsic value of stock options exercised	$	1,535		$	7,500	$	7,756
	Total fair value of share awards vested	$	31,672		$	28,609	$	28,600
Stock Option Awards	The following table summarizes information about stock options outstanding as of December 31, 2014:
		Number of					Number of
		Options			Weighted-Average		Options		Weighted-Average
	Range of Exercise Prices	Outstanding			Exercise Price		Exercisable		Exercise Price
	$6.65 to $12.72		513,202		$	11.57		239,025	$	10.26
	$13.15 to $14.78		2,145,654		$	13.99		553,095	$	13.96
	$14.94 to $16.80		465,943		$	16.02		298,879	$	16.48
	$17.83 to $18.58		143,160		$	18.42		143,160	$	18.42
	$18.74 to $20.94		159,100		$	19.63		159,100	$	19.63
			3,427,059					1,393,259
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Activity for Restricted Stock Awards	The following table summarizes the activity for restricted stock units during the periods presented:
					Weighted-Average
	(In thousands, except per share amounts)	Shares			Grant Date Fair Value
	Unvested restricted stock units as of December 31, 2011		4,182		$	17.83
	Awarded		5,574		$	11.78
	Vested		(1,898	)	$	16.11
	Forfeited		(1,130	)	$	17.16
	Unvested restricted stock units as of December 31, 2012		6,728		$	13.43
	Awarded		2,511		$	15.06
	Vested		(2,023	)	$	13.77
	Forfeited		(1,482	)	$	13.74
	Unvested restricted stock units as of December 31, 2013		5,734		$	13.94
	Awarded		2,199		$	18.09
	Vested		(2,044	)	$	13.9
	Forfeited		(793	)	$	14.28
	Unvested restricted stock units as of December 31, 2014		5,096		$	15.69
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Activity for Restricted Stock Awards	The following table summarizes the activity for restricted stock awards during the periods presented:
					Weighted-Average
	(In thousands, except per share amounts)	Shares			Grant Date Fair Value
	Unvested restricted stock awards as of December 31, 2011		411		$	16.95
	Vested		(254	)	$	16.27
	Forfeited		(137	)	$	16.72
	Unvested restricted stock awards as of December 31, 2012		20		$	15.94
	Vested		(17	)	$	15.92
	Forfeited		(3	)	$	16.05
	Unvested restricted stock awards as of December 31, 2013		0		$	0
	Vested		0		$	0
	Forfeited		0		$	0
	Unvested restricted stock awards as of December 31, 2014		0		$	0

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	The following table summarizes, as of each balance sheet date, the components of our accumulated other comprehensive loss:
		December 31,			December 31,
	(In thousands)	2014			2013
	Unrealized gain on marketable securities	$	228		$	203
	Tax effect		(88	)		(79	)
	Unrealized gain on marketable securities, net of tax		140			124
	Unrealized loss on interest rate swap		0			(458	)
	Tax effect		0			179
	Unrealized loss on interest rate swap, net of tax		0			(279	)
	Foreign currency translation adjustment		(2,119	)		(1,590	)
	Total accumulated other comprehensive loss	$	(1,979	)	$	(1,745	)

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Activity Related to Interest Rate Swap Agreement	We recognized the following activity related to our interest rate swap agreement
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Effective portion:
	Current period increase in fair value recognized in other comprehensive (loss)	$	458		$	1,076		$	220
	income, net
	Tax effect		(179	)		(421	)		(87	)
	Net	$	279		$	655		$	133
	Loss reclassified from accumulated other comprehensive loss to interest expense	$	496		$	1,215		$	1,783
	Amount excluded from effectiveness assessment and ineffective portion gain	$	0		$	0		$	0
	(loss) recognized in other income (expense), net

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Rent Expense	Total rent expense recognized, which consists of the base rental amount and other lessor charges when mandated in a lease agreement, was as follows:
		Year Ended December 31,
	(In thousands)	2014			2013		2012
	Rent expense	$	16,259		$	17,062	$	18,543
Future Commitments under Capital and Operating Leases	The long-term portion of capital lease obligations is included on the consolidated balance sheet under other liabilities. Our future commitments under capital and operating leases are shown below. Future operating lease commitments are calculated using the base rental amount and foreign currency exchange rates in effect as of December 31, 2014.
		Capital			Operating
	(In thousands)	Leases			Leases
	2015	$	244		$	15,659
	2016		57			14,987
	2017		0			10,180
	2018		0			5,527
	2019		0			3,073
	Thereafter		0			1,248
			301		$	50,674
	Less amount representing interest		(17	)
			284
	Current maturities of capital lease obligations		228
	Capital lease obligations, net of current maturities	$	56
Expense Incurred under Acs Agreement	Expenses incurred under this agreement are included in cost of revenue in our consolidated statements of operations and were as follows:
		Year Ended December 31,
	(In thousands)	2014			2013		2012
	Expenses incurred under Xerox agreement	$	68,165		$	62,259	$	55,987

Business_Segments_Tables

Business Segments (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts
		Year Ended December 31,
	(In thousands)	2014			2013			2012
	Revenue:
	Clinical and Financial Solutions	$	827,926		$	871,819		$	947,011
	Population Health		284,836			257,738			244,153
	Managed Services		251,951			222,358			231,869
	Unallocated Amounts		13,160			21,146			23,292
	Total revenue	$	1,377,873		$	1,373,061		$	1,446,325
	Gross Profit:
	Clinical and Financial Solutions	$	398,774		$	407,624		$	458,930
	Population Health		192,445			175,591			157,007
	Managed Services		16,537			20,454			35,392
	Unallocated Amounts		(61,772	)		(69,213	)		(44,794	)
	Total gross profit	$	545,984		$	534,456		$	606,535
	Income (Loss) from operations:
	Clinical and Financial Solutions	$	175,318		$	166,500		$	239,712
	Population Health		115,732			108,733			101,457
	Managed Services		16,537			20,454			35,392
	Unallocated Amounts		(346,775	)		(423,288	)		(363,290	)
	Total loss from operations	$	(39,188	)	$	(127,601	)	$	13,271

Supplemental_Disclosures_Table

Supplemental Disclosures (Tables)	12 Months Ended
	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Disclosures
		Year Ended December 31,
	(In thousands)	2014		2013		2012
	Cash paid during the period for:
	Interest	$	15,585	$	12,997	$	11,218
	Income taxes paid, net of tax refunds	$	7,104	$	7,944	$	7,040
	Non-cash transactions:
	Obligations incurred to purchase capitalized software	$	4,800	$	0	$	0
Accrued Expenses	Accrued expenses consist of the following:
		December 31,		December 31,
	(In thousands)	2014		2013
	Royalties, certain third party product costs and licenses	$	23,946	$	30,997
	Other		55,021		65,502
	Total accrued expenses	$	78,967	$	96,499

Geographic_Information_Tables

Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Revenues by Geographic Area	Revenues are attributed to geographic regions based on the location where the sale originated. Our revenues by geographic area are summarized below:
		Year Ended December 31,
	(In thousands)	2014		2013		2012
	United States	$	1,327,840	$	1,321,779	$	1,387,304
	Canada		20,727		24,999		23,909
	Other international		29,306		26,283		35,112
	Total	$	1,377,873	$	1,373,061	$	1,446,325
Long-Lived Assets by Geographic Area	A summary of our long-lived assets, comprised of fixed assets by geographic area, is presented below:
		December 31,		December 31,
	(In thousands)	2014		2013
	United States	$	133,485	$	160,237
	India		8,044		9,652
	Israel		2,142		2,180
	Canada		935		1,295
	Other international		1,224		649
	Total	$	145,830	$	174,013

Quarterly_Financial_Informatio1

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Financial Information	The following tables contain a summary of our unaudited quarterly consolidated results of operations for our last eight fiscal quarters.
			Quarter Ended
			December 31,				September 30,				June 30,				March 31,
	(In thousands, except per share amounts)		2014				2014				2014				2014
	Revenue		$	340,903			$	345,389			$	351,296			$	340,285
	Cost of revenue			204,549				213,933				211,308				202,099
	Gross profit			136,354				131,456				139,988				138,186
	Selling, general and administrative expenses			85,038				97,034				86,663				89,946
	Research and development			41,538				45,962				53,016				52,305
	Asset impairment charges			256				188				1,751				195
	Amortization of intangible and acquisition-related			8,866				7,112				7,651				7,651
	assets
	Loss income from operations			656				(18,840	)			(9,093	)			(11,911	)
	Interest expense			(7,292	)			(7,542	)			(7,230	)			(7,233	)
	Other (expense) income, net			(1	)			171				230				(32	)
	Loss before income taxes			(6,637	)			(26,211	)			(16,093	)			(19,176	)
	Income tax benefit (provision)			4,459				448		-3		(1,677	)			(1,566	)
	Net loss		$	(2,178	)		$	(25,763	)		$	(17,770	)		$	(20,742	)
	Loss per share - basic and diluted		$	(0.01	)		$	(0.15	)		$	(0.09	)		$	(0.12	)
			Quarter Ended
			December 31,				September 30,				June 30,				March 31,
	(In thousands, except per share amounts)		2013 (1)				2013 (1)				2013 (1)				2013 (1)
	Revenue		$	350,977			$	330,191			$	344,827			$	347,066
	Cost of revenue			212,778				204,644				208,545				212,638
	Gross profit			138,199				125,547				136,282				134,428
	Selling, general and administrative expenses			109,273				104,506				101,588				104,232
	Research and development			47,870				49,400				51,822				50,659
	Asset impairment charges			950				7,371		-2		2,814		-2		319
	Amortization of intangible and acquisition-related			7,651				7,722				8,379				7,501
	assets
	Loss income from operations			(27,545	)			(43,452	)			(28,321	)			(28,283	)
	Interest expense			(7,024	)			(6,895	)			(9,499	)	-4		(4,637	)
	Other (expense) income, net			(213	)			(826	)			218				8,131		-5
	Loss before income taxes			(34,782	)			(51,173	)			(37,602	)			(24,789	)
	Income tax benefit			14,164		-3		2,233		-3		14,726				13,197
	Net loss		$	(20,618	)		$	(48,940	)		$	(22,876	)		$	(11,592	)
	Loss per share - basic and diluted		$	(0.12	)		$	(0.27	)		$	(0.13	)		$	(0.07	)
	-1	Results of operations for the quarter include the results of operations of dbMotion and Jardogs for the period subsequent to the date of each acquisition, which was, in each case, March 4, 2013.
	-2	Asset impairment charges reflect non-cash charges to earnings primarily related to the impairment of previously capitalized software development and other deferred costs related to our MyWay convergence program. In addition, the quarters ended June 30, 2013 and September 30, 2013 also include the impairment of software and fixed assets related to product consolidation activities associated with the dbMotion acquisition.
	-3	Income tax benefit (provision) reflects the recognition of a valuation allowance of $5.2 million and $16.3 million for federal credit carryforwards, and foreign and state net operating loss carryforwards in the quarters ended September 30, 2014 and 2013, respectively, and a reduction of the valuation allowance of $2.7 million in the quarter ended December 31, 2013.
	-4	Interest expense includes the write-off of $3.9 million of deferred debt issuance costs associated with our prior credit facility, which was replaced in June 2013.
	-5	Other (expense) income, net includes a gain of $4.7 million resulting from the sale of our investment in Humedica, Inc., as well as a gain of $3.3 million from the remeasurement to fair value of our prior interest in dbMotion in connection with our acquisition of dbMotion.

Basis_of_Presentation_and_Sign3

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies [Line Items]
Outstanding money market funds investments	$0
Total consideration for non marketable equity securities	21,100,000
Value of equity investments	19,200,000
Value of commercial agreement	1,900,000
Carrying values of cost method investments	17,800,000
Carrying values of equity method investment	1,000,000
Percentage of revenues	No single client accounted for more than 10% of our revenue in the years ended December 31, 2014, 2013 and 2012.
Customer concentration	No client represented more than 10% of accounts receivable as of December 31, 2014 or 2013.
Unrecognized tax benefit presented as a reduction to deferred tax asset	$4,000,000
Senior cash convertible notes [Member]
Summary Of Significant Accounting Policies [Line Items]
Interest rate	1.25%	1.25%	1.25%
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Outsourcing services arrangements period	5 years
Capitalized software estimated economic life	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Outsourcing services arrangements period	10 years
Capitalized software estimated economic life	5 years

Reimbursements_for_OutofPocket

Reimbursements for Out-of-Pocket Expenses Incurred as Professional Services Revenue (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Reimbursements for out-of-pocket expenses incurred as professional services revenue	$16,251	$18,445	$22,656

Revenue_Earned_on_Contracts_in

Revenue Earned on Contracts in Excess of Billings Included in Accounts Receivable and Other Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounting Policies [Abstract]
Unbilled revenue (current)	$42,818	$37,271
Unbilled revenue (long-term)	618	1,294
Total revenue earned on contracts in excess of billings	$43,436	$38,565

Summary_of_Financial_Assets_an

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$557	$3,524
Interest Rate Swap [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	-458
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	57,091	104,656
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	0	3,634
Level 1 [Member] | Interest Rate Swap [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	1,305	871
Level 2 [Member] | Interest Rate Swap [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	-458
Level 2 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	-748	-981
Level 3 [Member] | Interest Rate Swap [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 3 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	57,091	104,656
Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	3,634
Money market funds [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	3,634
Money market funds [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Money market funds [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Marketable securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	1,305	1,329
Marketable securities [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	0	0
Marketable securities [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	1,305	1,329
Marketable securities [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	0	0
Cash conversion option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	-57,839	-105,637
Cash conversion option [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Cash conversion option [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Cash conversion option [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	($57,839)	($105,637)

Unamortized_Balances_of_Capita

Unamortized Balances of Capitalized Software (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounting Policies [Abstract]
Software development costs	$213,601	$170,486
Less: accumulated amortization	-127,448	-82,242
Software development costs, net	$86,153	$88,244

Capitalized_Software_Developme

Capitalized Software Development Costs, Write Offs and Amortization of Capitalized Software Development Costs Included in System Sales Cost of Revenue (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Capitalized software development costs	$45,461	$42,026	$42,965
Write-offs of capitalized software development costs	1,444	5,234	8,699
Amortization of capitalized software development costs	$46,108	$44,127	$37,065

Calculations_of_Earnings_Loss_

Calculations of Earnings (Loss) Per Share (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Net loss	($2,178)	($25,763)	($17,770)	($20,742)	($20,618)	($48,940)	($22,876)	($11,592)	($66,453)	($104,026)	($1,153)
Net loss available to common stockholders									-66,453	-104,026	-1,153
Weighted-average common shares outstanding									179,849	177,026	178,699
Basic Loss per Common Share									($0.37)	($0.59)	($0.01)
Net loss	-2,178	-25,763	-17,770	-20,742	-20,618	-48,940	-22,876	-11,592	-66,453	-104,026	-1,153
Net loss available to common stockholders									($66,453)	($104,026)	($1,153)
Weighted-average common shares outstanding									179,849	177,026	178,699
Dilutive effect of stock options, restricted stock unit awards and warrants									0	0	0
Weighted-average common shares outstanding assuming dilution									179,849	177,026	178,699
Diluted Loss per Common Share									($0.37)	($0.59)	($0.01)

AntiDilutive_Stock_Options_Res

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted (Loss) Earnings Per Share (Detail)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	24,254	14,926	2,878

Company_Contributions_to_Emplo

Company Contributions to Employee Benefit Plan (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Company contributions to employee benefit plans	$16,427	$15,276	$13,776

Business_Combinations_Acquisit

Business Combinations - Acquisition of Oasis Medical Solutions Limited - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jul. 08, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Goodwill		1,200,746,000	$1,189,585,000	$1,039,364,000
Oasis Medical Solutions Limited [Member]
Business Acquisition [Line Items]
Aggregate consideration with a fair value	20,600,000
Date of acquisition		8-Jul-14
Acquired cash and cash equivalents, and restricted cash	400,000
Assets acquired ,accounts receivable and other current assets	5,400,000
Goodwill	11,200,000
Assets acquired, fixed assets	200,000
Liabilities assumed, accounts payable, deferred revenue and accruals	6,700,000
Liabilities assumed, deferred tax liabilities net	2,300,000
Oasis Medical Solutions Limited [Member] | Technology [Member]
Business Acquisition [Line Items]
Assets acquired, intangible assets	5,600,000
Intangible assets, useful life (in years)		10 years
Oasis Medical Solutions Limited [Member] | Trade Name [Member]
Business Acquisition [Line Items]
Assets acquired, intangible assets	300,000
Intangible assets, useful life (in years)		2 years
Oasis Medical Solutions Limited [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Assets acquired, intangible assets	$6,500,000
Intangible assets, useful life (in years)		12 years

Business_Combinations_Acquisit1

Business Combinations - Acquisition of dbMotion - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended			0 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 04, 2013
Business Acquisition [Line Items]
Product consolidation activities	$256,000	$188,000	$1,751,000	$195,000	$950,000	$7,371,000	$2,814,000	$319,000	$2,390,000	$11,454,000	$11,101,000
dbMotion [Member]
Business Acquisition [Line Items]
Date of acquisition									4-Mar-13
Aggregate consideration with a fair value												226,000,000
Cash borrowed to settle purchase consideration	130,000,000								130,000,000
Interest rate on subordinated promissory note and deferred cash consideration	10.00%								10.00%
Acquisition, percentage of interest in dbMotion	4.25%								4.25%
Carrying value of interest in dbMotion prior to the acquisition	5,000,000								5,000,000
Remeasurement of interest in dbMotion in connection with the acquisition									8,367,000
Business combination, remeasurement gain									3,400,000
Percentage of non-marketable equity securities	95.75%								95.75%
Percentage of estimated control premium									15.00%
Increase in fair value of the consideration transferred				1,000,000
Product consolidation activities										6,500,000
dbMotion [Member] | Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition-related costs									3,700,000	7,600,000
Product consolidation activities										5,500,000
dbMotion [Member] | Selling, General and Administrative Expenses [Member] | Acquisition-related Costs [Member] | Employee Compensation Costs [Member]
Business Acquisition [Line Items]
Acquisition-related costs									3,700,000	5,900,000
dbMotion [Member] | Selling, General and Administrative Expenses [Member] | Acquisition-related Costs [Member] | Seller Transaction Costs [Member]
Business Acquisition [Line Items]
Acquisition-related costs										500,000
dbMotion [Member] | Cost of revenue [Member]
Business Acquisition [Line Items]
Amortization of software development costs and acquisition-related assets									-800,000	7,100,000
dbMotion [Member] | Cost of revenue [Member] | System Sales [Member]
Business Acquisition [Line Items]
Amortization of software development costs and acquisition-related assets									-200,000	3,200,000
dbMotion [Member] | Cost of revenue [Member] | Professional Services [Member]
Business Acquisition [Line Items]
Amortization of software development costs and acquisition-related assets									-600,000	1,300,000
dbMotion [Member] | Cost of revenue [Member] | Maintenance [Member]
Business Acquisition [Line Items]
Amortization of software development costs and acquisition-related assets										$2,600,000

Final_Fair_Value_of_Considerat

Final Fair Value of Consideration Transferred for Acquisition (Detail) (dbMotion [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Business Acquisition [Line Items]
Cash	$140,079
Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share	48,061
Fair value of Allscripts' previous interest in dbMotion	8,367
Total fair value of consideration transferred	226,178
Deferred Cash Consideration [Member]
Business Acquisition [Line Items]
Liabilities incurred on total consideration transferred	23,023
Subordinated Promissory Note [Member]
Business Acquisition [Line Items]
Liabilities incurred on total consideration transferred	$6,648

Final_Fair_Value_of_Considerat1

Final Fair Value of Consideration Transferred for Acquisition (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Common stock, par value	$0.01	$0.01
dbMotion [Member]
Business Acquisition [Line Items]
Common stock, shares	3,823,453
Common stock, par value	$0.01
Common stock, fair value	$12.57
dbMotion [Member] | Deferred Cash Consideration [Member]
Business Acquisition [Line Items]
Period of acquisition liability incurred	18 months
dbMotion [Member] | Subordinated Promissory Note [Member]
Business Acquisition [Line Items]
Period of acquisition liability incurred	18 months

Assets_Acquired_and_Liabilitie

Assets Acquired and Liabilities Assumed (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Business Acquisition [Line Items]
Goodwill	$1,200,746	$1,189,585	$1,039,364
dbMotion [Member]
Business Acquisition [Line Items]
Acquired cash and cash equivalents, and restricted cash	14,188
Assets acquired ,accounts receivable and other current assets	3,226
Prepaid expenses and other current assets	574
Fixed assets and other long-term assets	1,449
Goodwill	137,649
Intangible assets	85,450
Accounts payable and accrued liabilities	-10,560
Deferred taxes, net	-36
Deferred revenue	-5,100
Other liabilities	-662
Net assets acquired	$226,178

Acquired_Intangible_Assets_Amo

Acquired Intangible Assets Amortization (Detail) (dbMotion [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Business Acquisition [Line Items]
Intangible assets, fair value	$85,450
Core Technology [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	10 years
Intangible assets, fair value	80,100
Maintenance Agreements [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	12 years
Intangible assets, fair value	2,500
Services Backlog [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	2 years
Intangible assets, fair value	2,000
Non-compete [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	3 years
Intangible assets, fair value	500
Trade Name [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	2 years
Intangible assets, fair value	$350

Proforma_Results_Detail

Proforma Results (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
dbMotion [Member]
Business Acquisition [Line Items]
Revenue	$18,609	$0
Net loss	-16,272	0
Combined Entity [Member]
Business Acquisition [Line Items]
Revenue	1,378,267	1,448,316
Net loss	($105,119)	($35,158)
Net loss per share, basic and diluted	($0.59)	($0.19)

Business_Combinations_Acquisit2

Business Combinations - Acquisition of Jardogs - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Mar. 04, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Business Acquisition [Line Items]
Goodwill		1,200,746,000	$1,189,585,000	$1,039,364,000
Jardogs [Member]
Business Acquisition [Line Items]
Date of acquisition		4-Mar-13
Aggregate consideration with a fair value	24,000,000
Assets Acquired, deferred tax assets	400,000
Goodwill	17,000,000
Intangible assets, useful life (in years)	10 years
Acquisition-related costs			700,000
Jardogs [Member] | Technology [Member]
Business Acquisition [Line Items]
Assets acquired, intangible assets	4,200,000
Jardogs [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Assets acquired, intangible assets	$2,400,000

Fixed_Assets_Detail

Fixed Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]
Fixed assets, gross	$337,699	$351,998
Less: Accumulated depreciation and amortization	-191,869	-177,985
Fixed assets, net	145,830	174,013
Computer Equipment and Software [Member]
Property Plant And Equipment [Line Items]
Fixed assets, gross	284,185	287,063
Computer Equipment and Software [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	10 years
Facility Furniture, Fixtures and Equipment [Member]
Property Plant And Equipment [Line Items]
Fixed assets, gross	19,846	24,700
Facility Furniture, Fixtures and Equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	5 years
Facility Furniture, Fixtures and Equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	7 years
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Fixed assets, gross	30,795	30,816
Estimated useful life, description	7 to 8 years, or life of lease if shorter
Leasehold Improvements [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	7 years
Leasehold Improvements [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	8 years
Assets Under Capital Lease [Member]
Property Plant And Equipment [Line Items]
Fixed assets, gross	$2,873	$9,419
Assets Under Capital Lease [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	3 years
Assets Under Capital Lease [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Estimated useful life (in years)	5 years

Depreciation_and_Amortization_

Depreciation and Amortization Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment [Abstract]
Fixed assets depreciation and amortization expense	$48,465	$52,545	$43,126

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$1,001,374	$988,165
Accumulated Amortization	-650,012	-584,194
Intangible Assets, Net	351,362	403,971
Registered trademarks	52,000	52,000
Goodwill	1,200,746	1,189,585	1,039,364
Total	1,252,746	1,241,585
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	451,087	445,960
Accumulated Amortization	-267,547	-231,634
Intangible Assets, Net	183,540	214,326
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	550,287	542,205
Accumulated Amortization	-382,465	-352,560
Intangible Assets, Net	$167,822	$189,645

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended			3 Months Ended
	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014
Schedule Of Goodwill And Intangible Assets [Line Items]
Additional goodwill recognized		$12,173,000	$153,647,000
Accumulated impairment losses associated with goodwill		0	0
Goodwill, impairments recorded		0	0	0
Cash flow discount rate	11.00%
Oasis Medical Solutions Limited [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additional goodwill recognized		11,200,000
dbMotion [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Additional goodwill recognized		$1,018,000	$136,631,000		$1,000,000

Changes_in_Carrying_Amount_of_

Changes in Carrying Amount of Goodwill (Detail) (USD $)	12 Months Ended		3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 04, 2013	Jul. 08, 2014
Goodwill [Line Items]
Goodwill	$1,189,585	$1,039,364	$1,189,585
Additions arising from business acquisitions	12,173	153,647
Other adjustments to goodwill		-3,426
Foreign exchange translation	-1,012
Goodwill, net	1,200,746	1,189,585
dbMotion [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	1,018	136,631	1,000
Goodwill, net	137,649
Jardogs [Member]
Goodwill [Line Items]
Goodwill				17,000
Additions arising from business acquisitions		17,016
Goodwill, net				17,000
Oasis Medical Solutions Limited [Member]
Goodwill [Line Items]
Goodwill					11,200
Additions arising from business acquisitions	11,155
Goodwill, net					11,200
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	625,769	629,195	625,769
Additions arising from business acquisitions	11,155	0
Other adjustments to goodwill		-3,426
Foreign exchange translation	-1,012
Goodwill, net	635,912	625,769
Clinical and Financial Solutions [Member] | dbMotion [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0	0
Clinical and Financial Solutions [Member] | Jardogs [Member]
Goodwill [Line Items]
Additions arising from business acquisitions		0
Clinical and Financial Solutions [Member] | Oasis Medical Solutions Limited [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	11,155
Population Health [Member]
Goodwill [Line Items]
Goodwill	425,216	271,569	425,216
Additions arising from business acquisitions	1,018	153,647
Other adjustments to goodwill		0
Foreign exchange translation	0
Goodwill, net	426,234	425,216
Population Health [Member] | dbMotion [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	1,018	136,631
Population Health [Member] | Jardogs [Member]
Goodwill [Line Items]
Additions arising from business acquisitions		17,016
Population Health [Member] | Oasis Medical Solutions Limited [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0
Managed Services [Member]
Goodwill [Line Items]
Goodwill	138,600	138,600	138,600
Additions arising from business acquisitions	0	0
Other adjustments to goodwill		0
Foreign exchange translation	0
Goodwill, net	138,600	138,600
Managed Services [Member] | dbMotion [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	0	0
Managed Services [Member] | Jardogs [Member]
Goodwill [Line Items]
Additions arising from business acquisitions		0
Managed Services [Member] | Oasis Medical Solutions Limited [Member]
Goodwill [Line Items]
Additions arising from business acquisitions	$0

Amortization_Expense_Related_t

Amortization Expense Related to Intangible Assets (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill And Intangible Assets [Line Items]
Proprietary technology amortization included in cost of revenue, system sales									$81,215	$85,201	$65,416
Intangible amortization included in operating expenses	8,866	7,112	7,651	7,651	7,651	7,722	8,379	7,501	31,280	31,253	35,635
Total intangible amortization expense	67,204				65,223				67,204	65,223	62,861
Proprietary Technology [Member]
Goodwill And Intangible Assets [Line Items]
Proprietary technology amortization included in cost of revenue, system sales									$35,924	$33,970	$27,226

Estimated_Future_Amortization_

Estimated Future Amortization Expense for Intangible Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]
2015	$57,996
2016	45,534
2017	40,459
2018	33,800
2019	33,483
Thereafter	140,090
Intangible Assets, Net	$351,362	$403,971

Asset_Impairment_Charges_Addit

Asset Impairment Charges - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Asset Impairment Charges [Line Items]
Non-cash charges recorded to earnings	$256	$188	$1,751	$195	$950	$7,371	$2,814	$319	$2,390	$11,454	$11,101
MyWay [Member]
Asset Impairment Charges [Line Items]
Non-cash charges recorded to earnings									800	5,000	11,100
Capitalized Software Development Projects [Member]
Asset Impairment Charges [Line Items]
Non-cash charges recorded to earnings									1,600
dbMotion [Member]
Asset Impairment Charges [Line Items]
Non-cash charges recorded to earnings										$6,500

Asset_Impairment_Charges_Detai

Asset Impairment Charges (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Asset Impairment Charges [Abstract]
Asset impairment charges	$256	$188	$1,751	$195	$950	$7,371	$2,814	$319	$2,390	$11,454	$11,101

Debt_Outstanding_Excluding_Cap

Debt Outstanding Excluding Capital Lease Obligations (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Jun. 18, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Principal Balance	$645,535	$641,875
Unamortized Discount	69,614	80,849
Net Carrying Amount	575,921	561,026
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	345,000	345,000
Unamortized Discount	67,276	77,529
Net Carrying Amount	277,724	267,471
Senior Secured Credit Facility (long-term portion) [Member]
Debt Instrument [Line Items]
Principal Balance	272,410	280,000
Unamortized Discount	1,452	2,338
Net Carrying Amount	270,958	277,662
Senior Secured Credit Facility (current portion) [Member]
Debt Instrument [Line Items]
Principal Balance	28,125	16,875
Unamortized Discount	886	982
Net Carrying Amount	$27,239	$15,893

Interest_Expense_Detail

Interest Expense (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]
Interest expense									$16,020	$14,703	$11,121
Amortization of discounts									11,236	5,784	0
Amortization of debt issuance costs									2,041	3,667	5,066
Write off of unamortized deferred debt issuance costs									0	3,901	0
Total interest expense	$7,292	$7,542	$7,230	$7,233	$7,024	$6,895	$9,499	$4,637	$29,297	$28,055	$16,187

Debt_Additional_Information_De

Debt - Additional Information (Detail)

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Jun. 30, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Jun. 28, 2013

Jun. 28, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 18, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Jun. 28, 2013

Jun. 28, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

USD ($)

USD ($)

USD ($)

USD ($)

Prior Credit Facility [Member]

Letter of Credit [Member]

Line of Credit [Member]

Senior Secured Revolving Facility And / Or Term Loan Facility [Member]

Senior Secured Revolving Facility And / Or Term Loan Facility [Member]

Senior Secured Revolving Facility And / Or Term Loan Facility [Member]

Credit Agreement On Two Thousand And Thirteen [Member]

1.25% Cash Convertible Senior Notes [Member]

1.25% Cash Convertible Senior Notes [Member]

1.25% Cash Convertible Senior Notes [Member]

1.25% Cash Convertible Senior Notes [Member]

1.25% Cash Convertible Senior Notes [Member]

1.25% Cash Convertible Senior Notes [Member]

1.25% Cash Convertible Senior Notes [Member]

1.25% Cash Convertible Senior Notes [Member]

Term Loan Facility [Member]

Senior Secured Revolving Facility [Member]

Senior Secured Revolving Facility [Member]

Senior Secured Revolving Facility [Member]

Senior Secured Revolving Facility [Member]

Senior Secured Revolving Facility [Member]

Senior Secured Revolving Facility [Member]

Senior Secured Revolving Facility [Member]

Senior Secured Term Loan [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Maximum [Member]

Minimum [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Maximum [Member]

Minimum [Member]

Condition One [Member]

Condition Two [Member]

USD ($)

USD ($)

USD ($)

US Dollars [Member]

British Pounds Sterling [member]

British Pounds Sterling [member]

Eurocurrency Rate for U.S. Dollars [Member]

LIBOR [Member]

USD ($)

USD ($)

USD ($)

USD ($)

GBP (£)

US Dollars [Member]

Debt Instrument [Line Items]

Debt instrument principal amount

$645,535,000

$641,875,000

$345,000,000

$345,000,000

$345,000,000

$98,035,000

$202,500,000

Proceeds from debt

305,100,000

Repayment of outstanding prior credit facility

300,000,000

Interest payment, terms

Interest on the 1.25% Notes is payable semiannually in arrears on January 1 and July 1 of each year

Debt, Maturity date

1-Jul-20

1-Jul-20

Threshold trading days

20 days

5 days

Threshold consecutive trading days

30 days

5 days

Debt instrument conversion price percentage

130.00%

98.00%

Debt instrument convertible, principal amount

1,000

1,000

Convertible number of equity instrument

58.1869

Conversion price per common stock

$17.19

$17.19

Repurchase percentage on principal

100.00%

Fair value liability of embedded cash conversion option

82,800,000

Convertible debt instrument remaining discount amortization period

5 years 6 months

Debt instrument, interest rate, effective percentage

5.40%

2.92%

2.87%

2.87%

Debt Instrument, fees and aggregate cost

3,100,000

8,400,000

Debt instrument capitalized amount

5,500,000

4,300,000

8,300,000

Deferred charges capitalized amount outstanding

3,000,000

6,500,000

Accrued and unpaid interest

2,200,000

Payments for 1.25% Call Option

82,800,000

0

82,800,000

0

Proceeds from issuance of warrants, net of issuance costs

51,200,000

0

51,208,000

0

Net cash payment for 1.25% Notes call spread overlay

31,600,000

Credit facility, maximum borrowing capacity

225,000,000

425,000,000

Senior secured credit facilities term, years

5 years

5 years

Term Loan repayment, end date

2018-06

Portion of facility available for issuance of letters of credit

50,000,000

Portion of facility available for issuance of swingline loans

10,000,000

Credit facility, maximum borrowing capacity, foreign currencies

100,000,000

Aggregate amount of additional credit facilities authorized

250,000,000

Applicable margin for borrowings based on federal funds rate

0.50%

Senior secured credit facility interest rate spread

1.00%

2.75%

Initial margin for borrowings based on non-Eurocurrency rate

1.25%

Initial margin for borrowings based on Eurocurrency rate

2.25%

Maximum percentage of foreign subsidiary capital stock guaranteeing credit facility

65.00%

Leverage ratio

400.00%

400.00%

Interest coverage ratio

400.00%

400.00%

Secured leverage ratio

300.00%

Debt issue discount, amortized to interest expense

69,614,000

80,849,000

3,800,000

67,276,000

77,529,000

Deferred debt issuance cost written off with previous credit facility

0

3,901,000

0

3,400,000

Amortization of debt issuance costs

2,041,000

3,667,000

5,066,000

500,000

1,180,000

639,000

0

Credit facility, amount borrowed

98,000,000

82,500,000

15,500,000

10,000,000

Borrowings outstanding in term loan

202,500,000

Letters of credit outstanding

900,000

Unamortized deferred debt issuance costs

9,500,000

Credit facility, amount available

$325,600,000

Interest_Expense_Related_to_No

Interest Expense Related to Notes (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Coupon interest at 1.25%									$16,020	$14,703	$11,121
Amortization of original issuance discount									11,236	5,784	0
Amortization of debt issuance costs									2,041	3,667	5,066
Total interest expense	7,292	7,542	7,230	7,233	7,024	6,895	9,499	4,637	29,297	28,055	16,187
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Coupon interest at 1.25%									4,312	2,312	0
Amortization of original issuance discount									10,253	5,271	0
Amortization of debt issuance costs									1,180	639	0
Total interest expense									$15,745	$8,222	$0

Summary_of_Future_Payments_und

Summary of Future Payments under Notes and Senior Secured Credit Facilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Jun. 18, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Total	$645,535	$641,875
2015	28,125
2016	39,375
2017	50,625
2018	182,410
2019	0
Thereafter	345,000
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total	345,000	345,000	345,000
2015	0
2016	0
2017	0
2018	0
2019	0
Thereafter	345,000
Senior Secured Term Loan [Member]
Debt Instrument [Line Items]
Total	202,500
2015	28,125
2016	39,375
2017	50,625
2018	84,375
2019	0
Thereafter	0
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Total	98,035
2015	0
2016	0
2017	0
2018	98,035
2019	0
Thereafter	$0

Summary_of_Future_Payments_und1

Summary of Future Payments under Notes and Senior Secured Credit Facilities (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
1.25% notes maturity period	1-Jul-20

Geographic_Breakdown_of_Loss_I

Geographic Breakdown of (Loss) Income Before Income Tax Benefits (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
United States									($62,987)	($137,468)	($36,933)
Foreign									-5,130	-10,878	19,473
Loss before income taxes	($6,637)	($26,211)	($16,093)	($19,176)	($34,782)	($51,173)	($37,602)	($24,789)	($68,117)	($148,346)	($17,460)

Components_of_Provision_Benefi

Components of Provision (Benefit) for Income Taxes (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Current tax provision, Federal									$840	($448)	$1,610
Current tax provision, State									213	1,421	3,793
Current tax provision, Foreign									-399	45	5,184
Current tax provision									654	1,018	10,587
Deferred tax provision, Federal									-581	-43,542	-24,196
Deferred tax provision, State									-3,261	-7,929	-2,473
Deferred tax provision, Foreign									1,524	6,133	-225
Deferred tax provision									-2,318	-45,338	-26,894
Income tax benefit	($4,459)	($448)	$1,677	$1,566	($14,164)	($2,233)	($14,726)	($13,197)	($1,664)	($44,320)	($16,307)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended			12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 30, 2014	Dec. 31, 2011	Dec. 31, 2010
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Statutory rate				35.00%	35.00%	35.00%
Net operating loss carryforwards expiry beginning period				2020
Tax holiday savings				$800,000	$600,000	$1,000,000
Diluted earnings per share, increase				$0.01	$0.01	$0.01
Accrued uncertain tax positions								29,000,000
Indemnification asset								29,000,000
Settlement with IRS for the period May 2007 through May 2010						13,000,000
Remaining tax liability related to the Coniston Transactions, reversed and recognized as a tax benefit						16,000,000
Write-off of the remaining tax indemnification asset						16,000,000
Unrecognized Tax Benefits		18,283,000		15,314,000	18,283,000	18,140,000		43,284,000
Unrecognized Tax Benefits		17,100,000		15,300,000	17,100,000
Estimated increase in income tax benefit				2,300,000	10,200,000
Unrecognized tax benefits, accrued interest and penalties		2,011,000		1,295,000	2,011,000		1,295,000
Other Tax Expense (Benefit)				3,300,000
Tax Credit Carryforward, Valuation Allowance	5,200,000	-2,700,000	16,300,000	25,800,000	13,600,000
Research and development tax credit				3,100,000
Undistributed earnings indefinitely reinvested outside the United States				44,300,000
Bilateral Advance Pricing Agreement
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Unrecognized Tax Benefits		4,400,000			4,400,000
Reversal Of Unrecognized Tax Benefits					6,300,000
Impact Of Unrecognized Tax		300,000			300,000
Bilateral Advance Pricing Agreement | Amended Returns[Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Unrecognized Tax Benefits		1,600,000			1,600,000
India [Member] | Partially Expire [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Tax holiday expiration date				2012
India [Member] | Fully Expire [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Tax holiday expiration date				2017
Eclipsys [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating losses subject to annual limitation on usage per year									48,000,000
Related To Stock Compensation [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating loss carryforwards				11,000,000
State [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating loss carryforwards		8,000,000		8,000,000	8,000,000
State [Member] | Minimum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years				2004
State [Member] | Maximum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years				2013
Israeli [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating loss carryforwards									84,000,000
Canadian [Member] | Minimum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years				2003
Canadian [Member] | Maximum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years				2013
Foreign Country [Member] | Minimum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years				2011
Foreign Country [Member] | Maximum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years				2013
Federal [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Net operating loss carryforwards		276,000,000		278,000,000	276,000,000
Net operating losses subject to annual limitation on usage per year				62,000,000
Federal [Member] | Minimum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years				1993
Federal [Member] | Maximum [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Income tax examination, remaining tax years				2013
Federal [Member] | Eclipsys [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Acquired net operating losses									$265,000,000

Taxes_Computed_at_Statutory_Fe

Taxes Computed at Statutory Federal Income Tax Rate Reconciled to Provision for Income Taxes (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
United States federal tax at statutory rate	35.00%	35.00%	35.00%
Non-deductible acquisition and reorganization expenses	0.10%	-0.20%	0.00%
Research credits	4.60%	5.00%	14.50%
Change in unrecognized tax benefits	0.80%	-1.10%	-6.60%
State income taxes, net of federal benefit	3.10%	3.30%	5.80%
Compensation	-1.50%	-0.60%	-3.90%
Meals and entertainment	-1.40%	-0.70%	-6.10%
Impact of foreign operations	-3.70%	-1.10%	10.70%
Federal, state and local rate changes	0.40%	0.70%	-11.30%
Non-deductible items	-0.10%	-0.10%	-0.50%
Valuation allowance	-36.20%	-9.20%	-4.00%
True-up of capitalized software deferred tax	0.00%	0.00%	-2.30%
Other	1.10%	-0.90%	-1.10%
Effective rate	2.50%	29.90%	93.40%
Bilateral Advance Pricing Agreement
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Change in unrecognized tax benefit	0.30%	-3.20%	0.00%
Change in unrecognized tax benefits, Bilateral Advance Pricing Agreement	0.00%	3.00%	0.00%
Coniston [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Change in unrecognized tax benefit	0.00%	0.00%	91.40%
Indemnification asset settlement, Coniston	0.00%	0.00%	-28.20%

Components_of_Deferred_Tax_Ass

Components of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets
Accruals and reserves, net	$26,086	$28,210
Allowance for doubtful accounts	14,159	21,242
Stock-based compensation, net	10,773	7,498
Deferred revenue	17,422	12,636
Net operating loss carryforwards	90,463	90,964
Research and development tax credit	24,313	21,580
AMT credits	5,606	5,250
Other	3,617	4,962
Less: Valuation Allowance	-41,273	-14,241
Total deferred tax assets	151,166	178,101
Deferred tax liabilities
Prepaid expense	-9,268	-11,395
Property and equipment, net	-903	-852
Acquired intangibles, net	-160,130	-182,719
Total deferred tax liabilities	-170,301	-194,966
Net deferred tax liabilities	($19,135)	($16,865)

Deferred_Tax_Assets_Liabilitie

Deferred Tax Assets (Liabilities) Classified in Consolidated Balance Sheets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]
Current deferred tax assets, net	$35,615	$55,468
Current deferred tax liabilities, net	-21	0
Current deferred tax assets (liabilities), net	35,594	55,468
Non-current deferred tax assets, net	708	7,361
Non-current deferred tax liabilities, net	-55,437	-79,694
Non-current deferred tax assets (liabilities), net	-54,729	-72,333
Net deferred tax liabilities	($19,135)	($16,865)

Reconciliation_of_Unrecognized

Reconciliation of Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Unrecognized tax benefit, beginning balance	$18,283	$18,140	$43,284
Increases for tax positions related to the current year	627	1,517	46
Decreases for tax positions related to prior years	-3,239	-23	-13,944
Increases for tax positions related to prior years	173	3,238	656
Decreases relating to settlements with taxing authorities	-384	-4,099	-11,925
Foreign currency translation	-26	-394
Foreign currency translation			97
Reductions due to lapsed statute of limitations	-120	-96	-74
Unrecognized tax benefit, ending balance	$15,314	$18,283	$18,140

Recognized_Interest_and_Penalt

Recognized Interest and Penalties Related to Uncertain Tax Positions (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Interest and penalties included in the provision for income taxes	($715)	($188)	($2,539)

Amount_of_Interest_and_Penalti

Amount of Interest and Penalties Included in Consolidated Balance Sheets (Detail) (USD $)	Dec. 31, 2014	Dec. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]
Interest and penalties included in the liability for uncertain tax positions	$1,295	$1,295	$2,011

Stock_Award_Plans_Additional_I

Stock Award Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares reserved for issuance under future share-based awards	7,200,000
Stock-based compensation expense included in provision for income taxes	$8,000,000
Capitalized stock-based compensation costs	0	0	0
Unrecognized compensation cost	59,500,000
Unrecognized compensation expense expected to recognized over weighted-average period, in years	2 years 3 months 18 days
Shares settled for tax withholding	669,000	693,000	860,000
Stock options granted	0	3,870,000	0
Stock options, contractual terms	7 years
Aggregate intrinsic value of stock options outstanding	600,000
Aggregate intrinsic value of stock options exercisable	600,000
Aggregate intrinsic value of stock options exercisable, Weighted-Average	$12.77
Weighted average remaining contractual life of options outstanding, in years	3 years 3 months 18 days
Weighted average remaining contractual life of options exercisable, in years	3 years 3 months 18 days
Payroll deductions	20.00%
Offering price percentage	15.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual fair value limit on shares purchased	25,000
Plan Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchased under the ESPP	644,000	388,000
Service-based share awards include restricted stock units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award vesting period	4 years
Deferred share units awarded to directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award vesting period	1 year
Service-Based Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	50,000,000
Period target attainment expected to be recognized	Dec-18
Awards Granted Under Financial Performance [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award vesting period	3 years
Awards Granted Under Financial Performance [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award vesting period	4 years
Performance-Based Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	6,200,000
Period target attainment expected to be recognized	Feb-18
Market-Based Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$3,300,000
Share based compensation award vesting period	3 years
Period target attainment expected to be recognized	Dec-16

StockBased_Compensation_Expens

Stock-Based Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$39,254	$37,010	$39,126
Cost of revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	5,914	5,644	5,929
Cost of revenue [Member] | Professional Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	2,679	2,598	2,437
Cost of revenue [Member] | Maintenance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	1,264	1,430	1,579
Cost of revenue [Member] | Transaction Processing and Other [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	1,971	1,616	1,913
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	25,376	23,013	25,869
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$7,964	$8,353	$7,328

Activity_for_Restricted_Stock_

Activity for Restricted Stock Units (Detail) (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock Units (RSUs) [Member]
Shares
Shares, Unvested service-based/performance-based share awards as of beginning balance	5,734	6,728	4,182
Shares, Awarded	2,199	2,511	5,574
Shares, Vested	-2,044	-2,023	-1,898
Shares, Forfeited	-793	-1,482	-1,130
Shares, Unvested service-based/performance-based share awards as of ending balance	5,096	5,734	6,728
Weighted-Average Grant Date Fair Value
Weighted-Average Grant Date Fair Value, Unvested Service-based/Performance-based share awards as of beginning balance	$13.94	$13.43	$17.83
Weighted-Average Grant Date Fair Value, Awarded	$18.09	$15.06	$11.78
Weighted-Average Grant Date Fair Value, Vested	$13.90	$13.77	$16.11
Weighted-Average Grant Date Fair Value, Forfeited	$14.28	$13.74	$17.16
Weighted-Average Grant Date Fair Value, Unvested Service-based/Performance-based share awards as of ending balance	$15.69	$13.94	$13.43

Activity_for_Restricted_Stock_1

Activity for Restricted Stock Awards (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock [Member]
Shares
Shares, Unvested service-based/performance-based share awards as of beginning balance	0	20	411
Shares, Vested	0	-17	-254
Shares, Forfeited	0	-3	-137
Shares, Unvested service-based/performance-based share awards as of ending balance	0	0	20
Restricted Stock Award [Member]
Weighted-Average Grant Date Fair Value
Weighted-Average Grant Date Fair Value, Unvested Service-based/Performance-based share awards as of beginning balance	0	15.94	16.95
Weighted-Average Grant Date Fair Value, Vested	0	15.92	16.27
Weighted-Average Grant Date Fair Value, Forfeited	0	16.05	16.72
Weighted-Average Grant Date Fair Value, Unvested Service-based/Performance-based share awards as of ending balance	0	0	15.94

Stock_Options_Outstanding_Deta

Stock Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Options Outstanding
Options Outstanding, beginning balance	4,322,000	2,667,000	3,976,000
Options Outstanding, options granted	0	3,870,000	0
Options Outstanding, options exercised	-289,000	-1,442,000	-1,138,000
Options Outstanding, options forfeited	-606,000	-773,000	-171,000
Options Outstanding, ending balance	3,427,059	4,322,000	2,667,000
Weighted-Average Exercise Price
Weighted-average exercise price, beginning balance	$14.28	$12.04	$10.31
Weighted-average exercise price, Options granted	$0	$13.79
Weighted-average exercise price, options exercised	$11.88	$8.47	$5.32
Weighted-average exercise price, options forfeited	$15.03	$14.94	$16.62
Weighted-average exercise price, ending balance	$14.35	$14.28	$12.04
Options Exercisable
Options Exercisable	1,393,259	1,025,000	2,548,000	3,499,000
Weighted-average exercise price, exercisable	$14.97	$15.52	$11.88	$9.87

Weighted_Average_Grant_Date_Fa

Weighted Average Grant Date Fair Value Information and Related Valuation Assumptions (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock options granted	0	3,870	0
Fair Value per option		$6.25
Expected term ( in years)		4 years 9 months 18 days
Expected volatility		54.00%
Expected dividend yield		0.00%
Risk-free interest rate		0.90%

Stock_Option_Activity_Detail

Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Total intrinsic value of stock options exercised	$1,535	$7,500	$7,756
Total fair value of share awards vested	$31,672	$28,609	$28,600

Stock_Option_Awards_Detail

Stock Option Awards (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule Of Stock Options [Line Items]
Number of options Outstanding	3,427,059	4,322,000	2,667,000	3,976,000
Weighted-average exercise price, outstanding	$14.35	$14.28	$12.04	$10.31
Number of options exercisable	1,393,259	1,025,000	2,548,000	3,499,000
Weighted-average exercise price, exercisable	$14.97	$15.52	$11.88	$9.87
$6.65 to $12.72 [Member]
Schedule Of Stock Options [Line Items]
Range of exercise prices, lower limit	$6.65
Range of exercise prices, upper limit	$12.72
Number of options Outstanding	513,202
Weighted-average exercise price, outstanding	$11.57
Number of options exercisable	239,025
Weighted-average exercise price, exercisable	$10.26
$13.15 to $14.78 [Member]
Schedule Of Stock Options [Line Items]
Range of exercise prices, lower limit	$13.15
Range of exercise prices, upper limit	$14.78
Number of options Outstanding	2,145,654
Weighted-average exercise price, outstanding	$13.99
Number of options exercisable	553,095
Weighted-average exercise price, exercisable	$13.96
$14.94 to $16.80 [Member]
Schedule Of Stock Options [Line Items]
Range of exercise prices, lower limit	$14.94
Range of exercise prices, upper limit	$16.80
Number of options Outstanding	465,943
Weighted-average exercise price, outstanding	$16.02
Number of options exercisable	298,879
Weighted-average exercise price, exercisable	$16.48
$17.83 to $18.58 [Member]
Schedule Of Stock Options [Line Items]
Range of exercise prices, lower limit	$17.83
Range of exercise prices, upper limit	$18.58
Number of options Outstanding	143,160
Weighted-average exercise price, outstanding	$18.42
Number of options exercisable	143,160
Weighted-average exercise price, exercisable	$18.42
$18.74 to $20.94 [Member]
Schedule Of Stock Options [Line Items]
Range of exercise prices, lower limit	$18.74
Range of exercise prices, upper limit	$20.94
Number of options Outstanding	159,100
Weighted-average exercise price, outstanding	$19.63
Number of options exercisable	159,100
Weighted-average exercise price, exercisable	$19.63

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Apr. 30, 2011	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Capital Unit [Line Items]
Stock repurchase program, expiring date	9-May-14
Common stock repurchased, shares		0	0	21,000,000
Common stock repurchased, value				$225,961,000
Common stock repurchased, average price per share				$10.89
Warrant [Member] | Commercial partner [Member]
Capital Unit [Line Items]
Number of warrants issued		1,500,000
Initial exercise price of warrant per share		12.94
Number of installments		4
Number of warrants vested during period		375,000
Warrant expiration period		2020-06
Fair value recognized as reduction to transaction processing and other revenue		2,500,000	1,300,000
1.25% Warrants [Member]
Capital Unit [Line Items]
Number of warrants issued		20,100,000
Initial exercise price of warrant per share		23.135
Warrants issued		51,200,000
Warrant expiration term		The 1.25% Warrants expire over a period of 70 trading days beginning on October 1, 2020 and are exercisable only upon expiration. Additionally, if the market value per share of our common stock exceeds the strike price of the 1.25% Warrants on any trading day during the 70 trading day measurement period, we will, for each such trading day, be obligated to issue to the counterparties a number of shares equal in value to the product of the amount by which such market value exceeds such strike price and 1/70th of the aggregate number of shares of our common stock underlying the 1.25% Warrants transactions, subject to a share delivery cap.
Warrant expiration period		70 days
Warrant expiration beginning period		1-Oct-20

Components_of_Accumulated_Othe

Components of Accumulated Other Comprehensive Income (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Equity [Abstract]
Unrealized gain on marketable securities	$228	$203
Tax effect	-88	-79
Unrealized gain on marketable securities, net of tax	140	124
Unrealized loss on interest rate swap	0	-458
Tax effect	0	179
Unrealized loss on interest rate swap, net of tax	0	-279
Foreign currency translation adjustment	-2,119	-1,590
Total accumulated other comprehensive loss	($1,979)	($1,745)

Derivative_Financial_Instrumen2

Derivative Financial Instruments - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended			0 Months Ended
	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 29, 2010	Jun. 18, 2013
Derivative [Line Items]
Purchase of call option related to 1.25% senior cash convertible notes	$82,800,000	$0	$82,800,000	$0
Proceeds from issuance of warrants	51,200,000	0	51,208,000	0
Conversion price per common stock		$17.19
1.25% Notes Embedded Cash Conversion Options [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option		57,800,000	105,600,000			82,800,000
1.25% Call Option [Member] | Short [Member]
Derivative [Line Items]
Gain (Loss) on call options		-47,600,000	21,900,000
1.25% Call Option [Member] | Short [Member] | 1.25% Notes Embedded Cash Conversion Options [Member]
Derivative [Line Items]
Gain (Loss) on call options		47,800,000	-22,800,000
1.25% Call Option [Member] | Level 3 [Member] | Fair Value Measurements [Member]
Derivative [Line Items]
Fair value of option		57,100,000	104,700,000
Call Spread Overlay
Derivative [Line Items]
Net cash outflow for call spread overlay	31,600,000
Interest Rate Swap [Member]
Derivative [Line Items]
Interest rate swap agreement effective date					29-Oct-10
Notional amount of interest rate swap agreement					300,000,000
Interest rate swap agreement termination date					31-Oct-14
Effective fixed interest rate for swap agreement		0.90%
Fair value of interest rate swap agreement		0	500,000
Gains (losses) reclassified from OCI into earnings due to forecasted transactions that failed to occur		$0	$0	$0

Activity_Related_to_Interest_R

Activity Related to Interest Rate Swap Agreement (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Current period increase in fair value recognized in other comprehensive (loss) income, net	$458	$1,076	$220
Tax effect	-179	-421	-87
Unrealized gain on interest rate swap, net of tax	279	655	133
Loss reclassified from accumulated other comprehensive loss to interest expense	496	1,215	1,783
Amount excluded from effectiveness assessment and ineffective portion gain (loss) recognized in other income (expense), net	$0	$0	$0

Rent_Expense_Detail

Rent Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments And Contingencies Disclosure [Abstract]
Rent expense	$16,259	$17,062	$18,543

Future_Commitments_under_Capit

Future Commitments under Capital and Operating Leases (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]
Capital Leases, 2015	$244
Capital Leases, 2016	57
Capital Leases, 2017	0
Capital Leases, 2018	0
Capital Leases, 2019	0
Capital Leases, thereafter	0
Capital Leases, total	301
Capital Leases, less amount representing interest	-17
Capital Leases, future minimum payments, present value of net minimum payments	284
Capital Leases, Current maturities of capital lease obligations	228
Capital lease obligations, net of current maturities	56
Operating Leases, 2015	15,659
Operating Leases, 2016	14,987
Operating Leases, 2017	10,180
Operating Leases, 2018	5,527
Operating Leases, 2019	3,073
Operating Leases, Thereafter	1,248
Operating Leases, Total	$50,674

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Remote hosting service support agreement term (in years)	10 years
Base annual payment obligation for data center and hosting services	$50

Expense_Incurred_Under_Affilia

Expense Incurred Under Affiliated Computer Services Agreement (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Long Term Purchase Commitment [Line Items]
Expenses incurred under Xerox agreement	$204,549	$213,933	$211,308	$202,099	$212,778	$204,644	$208,545	$212,638	$831,889	$838,605	$839,790
Xerox
Long Term Purchase Commitment [Line Items]
Expenses incurred under Xerox agreement									$68,165	$62,259	$55,987

Business_Segments_Additional_I

Business Segments - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2014
	Segment	Segment
Segment Reporting [Abstract]
Number of reportable segments	3
Number of operating segments		9

Revenues_and_Income_from_Opera

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenue	$340,903	$345,389	$351,296	$340,285	$350,977	$330,191	$344,827	$347,066	$1,377,873	$1,373,061	$1,446,325
Gross Profit	136,354	131,456	139,988	138,186	138,199	125,547	136,282	134,428	545,984	534,456	606,535
Income (Loss) from operations	656	-18,840	-9,093	-11,911	-27,545	-43,452	-28,321	-28,283	-39,188	-127,601	13,271
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue									13,160	21,146	23,292
Gross Profit									-61,772	-69,213	-44,794
Income (Loss) from operations									-346,775	-423,288	-363,290
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue									827,926	871,819	947,011
Gross Profit									398,774	407,624	458,930
Income (Loss) from operations									175,318	166,500	239,712
Population Health [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue									284,836	257,738	244,153
Gross Profit									192,445	175,591	157,007
Income (Loss) from operations									115,732	108,733	101,457
Managed Services [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue									251,951	222,358	231,869
Gross Profit									16,537	20,454	35,392
Income (Loss) from operations									$16,537	$20,454	$35,392

Supplemental_Disclosures_Detai

Supplemental Disclosures (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Supplemental Cash Flow Elements [Abstract]
Interest	$15,585	$12,997	$11,218
Income taxes paid, net of tax refunds	7,104	7,944	7,040
Obligations incurred to purchase capitalized software	$4,800	$0	$0

Accrued_Expenses_Detail

Accrued Expenses (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]
Royalties, certain third party product costs and licenses	$23,946	$30,997
Other	55,021	65,502
Total accrued expenses	$78,967	$96,499

Supplemental_Disclosures_Addit

Supplemental Disclosures - Additional Information (Detail)	Dec. 31, 2014
Payables And Accruals [Abstract]
Maximum percentage accounted by individual expenses of total current liabilities	5.00%

Revenues_by_Geographic_Area_De

Revenues by Geographic Area (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Revenues From External Customers [Line Items]
Total revenue	$340,903	$345,389	$351,296	$340,285	$350,977	$330,191	$344,827	$347,066	$1,377,873	$1,373,061	$1,446,325
United States [Member]
Schedule Of Revenues From External Customers [Line Items]
Total revenue									1,327,840	1,321,779	1,387,304
Canada [Member]
Schedule Of Revenues From External Customers [Line Items]
Total revenue									20,727	24,999	23,909
Other International [Member]
Schedule Of Revenues From External Customers [Line Items]
Total revenue									$29,306	$26,283	$35,112

LongLived_Assets_by_Geographic

Long-Lived Assets by Geographic Area (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	$145,830	$174,013
United States [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	133,485	160,237
India [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	8,044	9,652
Israeli [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	2,142	2,180
Canada [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	935	1,295
Other International [Member]
Long-Lived Assets by Geographical Areas [Line Items]
Long lived assets	$1,224	$649

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	1-May-12
Loss Contingencies [Line Items]
Contingency allegations		Counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation.
Amount paid in connection with resolution of claims	$4	$14
Physicians Healthsource Inc [Member]
Loss Contingencies [Line Items]
Damages sought per alleged violation of the TCPA			500

North_American_Site_Consolidat1

North American Site Consolidation Plan - Additional Information (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 18, 2013
												Office
												Warehouse
Restructuring Cost And Reserve [Line Items]
Research and development	$41,538,000	$45,962,000	$53,016,000	$52,305,000	$47,870,000	$49,400,000	$51,822,000	$50,659,000	$192,821,000	$199,751,000	$162,158,000
North American Site Consolidation Plan [Member]
Restructuring Cost And Reserve [Line Items]
Number of offices closed under the Site Consolidation Plan												12
Number of Warehouse closed under the Site Consolidation Plan												1
Severance costs (benefits)									-2,200,000	20,100,000
Research and development										3,900,000
Accrued severance costs					4,200,000			11,200,000		4,200,000
Payments of severance costs									$2,000,000

Quarterly_Financial_Informatio2

Quarterly Financial Information (Unaudited) (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Revenue	$340,903	$345,389	$351,296	$340,285	$350,977	$330,191	$344,827	$347,066	$1,377,873	$1,373,061	$1,446,325
Expenses incurred under Xerox agreement	204,549	213,933	211,308	202,099	212,778	204,644	208,545	212,638	831,889	838,605	839,790
Gross Profit	136,354	131,456	139,988	138,186	138,199	125,547	136,282	134,428	545,984	534,456	606,535
Selling, general and administrative expenses	85,038	97,034	86,663	89,946	109,273	104,506	101,588	104,232	358,681	419,599	384,370
Research and development	41,538	45,962	53,016	52,305	47,870	49,400	51,822	50,659	192,821	199,751	162,158
Asset impairment charges	256	188	1,751	195	950	7,371	2,814	319	2,390	11,454	11,101
Amortization of intangible and acquisition-related assets	8,866	7,112	7,651	7,651	7,651	7,722	8,379	7,501	31,280	31,253	35,635
Income (Loss) from operations	656	-18,840	-9,093	-11,911	-27,545	-43,452	-28,321	-28,283	-39,188	-127,601	13,271
Interest expense	-7,292	-7,542	-7,230	-7,233	-7,024	-6,895	-9,499	-4,637	-29,297	-28,055	-16,187
Other income (expense), net	-1	171	230	-32	-213	-826	218	8,131	368	7,310	-14,544
Loss before income taxes	-6,637	-26,211	-16,093	-19,176	-34,782	-51,173	-37,602	-24,789	-68,117	-148,346	-17,460
Income tax benefit	4,459	448	-1,677	-1,566	14,164	2,233	14,726	13,197	1,664	44,320	16,307
Net loss	($2,178)	($25,763)	($17,770)	($20,742)	($20,618)	($48,940)	($22,876)	($11,592)	($66,453)	($104,026)	($1,153)
Loss per share - basic and diluted	($0.01)	($0.15)	($0.09)	($0.12)	($0.12)	($0.27)	($0.13)	($0.07)	($0.37)	($0.59)	($0.01)

Quarterly_Financial_Informatio3

Quarterly Financial Information (Unaudited) (Parenthetical) (Detail) (USD $)	3 Months Ended			12 Months Ended			3 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2013	Dec. 31, 2014
Quarterly Financial Information Disclosure [Line Items]
Tax Credit Carryforward, Valuation Allowance	$5,200,000	($2,700,000)	$16,300,000	$25,800,000	$13,600,000
Deferred debt issuance cost written off with previous credit facility				0	3,901,000	0
Interest Expense
Quarterly Financial Information Disclosure [Line Items]
Deferred debt issuance cost written off with previous credit facility							3,900,000
Other Nonoperating Income (Expense)
Quarterly Financial Information Disclosure [Line Items]
Gain on sale of investment in Humedica, Inc.								4,700,000
Gain from the remeasurement of interest in dbMotion in connection with the acquisition								$3,300,000

Schedule_II_Valuation_And_Qual

Schedule II - Valuation And Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Valuation And Qualifying Accounts [Abstract]
Beginning Balance	$54,252	$45,320	$27,627
Charged to Expenses/Against Revenue	9,592	20,095	37,447
Deferred Revenue Reclassification	-5,340	1,116	-7,640
Write-Offs, Net of Recoveries	-22,457	-12,279	-12,114
Ending Balance	$36,047	$54,252	$45,320